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Antibody-based therapeutics continue to be a fast growing field in pharmaceutics due to 
their increased selectivity for a specific target over small molecule drugs. Antibody solutions are 
often formulated at high protein concentrations in order to achieve low injection volumes, 
especially for subcutaneous administration, which can cause many challenging problems when it 
comes to stabilization. The instability of antibodies can often lead to aggregation which can 
occur during many parts of the manufacturing process including purification, fill-finish, shipping 
and storage. Aggregation of antibodies can cause many problems such as not injecting the proper 
dose, due to a decrease in the protein’s concentration, or causing immunogenic responses that 
may affect the safety or efficacy of the drug potentially causing harm to patients. Therefore, the 
aggregation pathway(s) of antibody drug candidates need to be characterized in great detail and 
well understood before they reach the market.  Currently, several common analytical techniques 
are being used to distinguish the amount and size of aggregation impurities produced when an 
antibody undergoes accelerated stresses during formulation development. However, more novel 
techniques are needed to get a better, more in-depth understanding of the types of aggregates 
formed along of the aggregation pathway. The development of novel techniques to screen 
antibody stability and aggregation propensities can not only elucidate degradation mechanisms 
that proteins undergo throughout the lifetime of the drug, it can also allow us to better understand 
effective ways to increase the shelf-life and maintain product safety. In this study, various 
monoclonal antibodies (mAb) and bispecific antibodies (biAb) were examined under varying 
stress conditions and their physical stability monitored using conventional and novel techniques. 
New techniques examined include a high throughput GroEL-based BLI (Biolayer interferometry) 





conditions (temperatures) by being able to detect pre-aggregate species forming prior to more 
established techniques show the formation of larger sized aggregates (methods such as size 
exclusion chromatography and micro-flow digital imaging). Another novel technique examined 
in these studies is the use of hydrogen-deuterium exchange mass spectrometry, which is used to 
identify problematic portions of the antibody molecule, by monitoring changes in local flexibility 
or rigidity, when exposed to different excipients and pH levels.  Finally, the use of Langmuir 
trough to examine interfacial and intermolecular interaction properties of various antibodies and 
formulation conditions was evaluated. Understanding antibody molecules tendencies to drive to 
the air-water interface or have intermolecular interactions can predict physical instability 
problems throughout the purification process and during long term storage conditions. This type 
of aggregation risk assessment during early formulation development can decrease the resources 
spent on protein drug candidates that will be problematic. Each of these novel analytical 
techniques can increase the understanding of antibody instability issues in solution, and 
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1.1 Monoclonal Antibodies Structure and Function 
Antibodies are an important part of the human immune system. There are many roles 
antibodies can play in a protective immune response including neutralization of the infectious 
agent, phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-mediated 
lysis of infected cells or pathogens.1,2  There are five classes of antibodies which consist of IgG, 
IgA, IgM, IgD, and IgE3 with IgG being the most prevalent at 75% of the total. These classes are 
highly conserved structurally but can differ not only in their variable binding regions, but also in 
their constant regions and therefore have different effector functions and therefore differ in 
physicochemical and behavior.4 IgG’s can further be broken down into subclasses of IgG1, IgG2, 
IgG3, and IgG4, with IgG1 being the most abundant in human serum at ~65% of the total IgG 
amount.  
The structure of an IgG antibody is made up of a homodimer containing two heavy chains 
and two light chains connected by intra and intermolecular disulfide bonds and has a size of ~150 
kDa. The homodimer is folded in a Y-shaped structure to form two fragment antigen-binding (Fab) 
domains and a fragment crystallizable (Fc) domain. The Fab domains contain a light chain linked 
to a heavy chain while the Fc domain is made up of two heavy chains (Figure 1). The light chain 
has two domains, VL and CL. The heavy chain has four domains VH and three CH regions that 
consist of CH1, CH2, and CH3 (or Cγ1, Cγ2, and Cγ3). Within the CH2 domain of all γ chains there 
is an N-linked glycosylation site (N297) in which is attached oligosaccharides of varying 
carbohydrate group(s) that helps determine the overall quaternary structure of the antibody. The 
Fab region contains three complementarity-determining regions (CDRs) each that are about 10 





Depending on the amino acid sequence, the shape and local ionic strength can change greatly and 
are highly specific for a specific antibody.  
The subclasses of IgGs have 90-95% conservation compared to one another in the constant 
region.  The subclasses of IgG differ in their constant regions, mainly around the hinges and upper 
portion of the CH2 domain.4 These regions are involved in binding to receptors which results in 
them having various effector functions, such as triggering phagocytosis or antibody-dependent cell 
mediated cytotoxicity and activating complement. In addition, IgGs, IgAs, and IgDs have 
segmental flexibility where the Fab portions can move relative to each other bending at the hinge 
region which is located between CH1 and CH2. IgMs and IgAs antibodies form multimeric 
molecules and have a polypeptide called the joining (J) chain to stabilize the structure.  
IgG1 is the most common IgG subclass and are involved in biological activities including 
opsonization, agglutination, placental transfer, ADCC, and neutralization of toxins.2 The IgG4 
subclass is the least common of the IgGs and is unique in its structure and function properties. 
IgG4 antibodies are induced by repeat exposure to antigen in a non-infectious setting.4 The main 
structural difference is that IgG4 antibodies can also undergo changes between the disulfide bonds 
in the hinge region. These changes can form either inter-chain or intra-chain which also allows it 
to undergo ‘half-antibody’ exchange in vivo that result in recombination of antibodies domains 
that result in two different binding specificities.5 This is due to the presence of a serine residue at 
position 228 rather than the lysine found in an IgG1. This also makes it so IgG4 cannot crosslink 
the target antigen. Overall, the average conformation stability(e.g. Tm  values) of an IgG4 is about 
10°C less stable than that of an IgG1.6 This reduction in structural stability can cause an increase 





1.2 Bispecific Antibodies Structure and Function 
Bispecific antibodies (biAb) comprise of two individual binding entities instead of just one 
seen in the monoclonal antibodies (mAb). This allows biAbs  to bind simultaneously to two 
different epitopes on the same antigen or onto two separate antigens.7 BiAbs can potentially 
achieve numerous more clinical applications compared to mAbs. This includes recruitment of T-
cells to tumor cells, increasing binding specificity and affinity, and by addressing the binding of 
two different antigens. Currently, there are two biAb based drugs  (catumxomab and 
blinatumomab) approved for therapy.8  
There are over 50 different formats for biAb combinations that have been developed.9 This 
diversity allows for the design and development of antibodies with more desirable specific 
attributes such as size, flexibility, half-life, and bio-distribution. BiAbs can be divided into two 
main structural categories and classified as either whole-IgG that comprises an Fc-portion or Fc-
less which has a small fragment. Whole -IgG biAb have two different heavy chains and light 
chains. In contrast, Fc-less are able to penetrate tissues more readily but have the disadvantage of 
not having Fc-mediated functions like ADCC. This type of BiAb also has a shorter half-life in 
vivo. They consist of different Fab fragments from different antibodies and are chained together 
by a linker.  
1.3 Protein Folding and Stability 
Protein molecules can follow different pathways for folding, unfolding, and aggregating 
due to competition between various interactions.10 To reach its properly folded, three 
dimensional native state, a protein can go through several transition barriers (intermediate states) 





can be determined by intrinsic factors, the protein molecule itself, and extrinsic factors like the 
environment around the molecule.12 Intrinsic factors include the protein’s amino acid sequence 
while extrinsic factors include the solution conditions (e.g., formulation additives, temperature, 
pH, ionic strength). Both intrinsic and extrinsic factors can play a role in the proper folding and 
resulting conformational stability of the protein molecule.  
One of the major driving forces for protein folding into its native, three-dimensional 
structure is the polar and apolar surfaces. Apolar surfaces or regions of a protein, containing 
more dense concentration of hydrophobic amino acid residues, tend to bury into the center of the 
folded protein to be excluded from the presence of water. The folding of a protein molecule 
requires the removal of water from the core.13 This process has an energy cost as well as entropic 
cost of organization in order for this to be a favorable reaction.  This protein folding process is 
described by Gibbs free energy in the equation that follows:  
(1) G=H-TS 
Where G is the change Gibbs free energy, H is the change in enthalpy, T is the temperature in 
Kelvin, and S is the change in entropy in the system. The folding and removal of water will 
spontaneously occur if the end result is lower in energy (smaller Gibbs free energy). Lower 
overall energy of the protein in the folded state can be driven by many of the intrinsic properties 
of the protein such as the hydrophobicity, electrostatic interactions, steric considerations, 
hydrogen bonding, and more.11  
 Protein folding due to hydrophobicity effects has shown to be a driving force due to the 
large change in heat capacity.13 Aromatic residues can contribute to the hydrophobicity and also 





of the protein molecules three-dimensional structure.15 Steric constraint limits the possible 
conformations the protein can pack into. Due to the inherent secondary structure based on the 
protein’s amino acid sequence,16 Ramachandran plots of proteins allow the prediction of protein 
folding based on the possible secondary structures elements from the dihedral angles.17  
Electrostatic interactions through charged residues like Arg, Asp, Lys, and Glu can not only play 
a major role in the inner core of the folded protein molecule through the formation of salt 
bridges, but can also stabilize the protein on the surface due to their favorable interaction with 
polar solvents like water.18,19  Secondary structural elements also play a major role in the three 
dimensional folding of proteins. Alpha helix structures rely on interactions formed from the CO 
and the NH components of the polypeptide chain from amino acids four residues away11, while 
beta sheets can form due to hydrogen bonding between amino acid residues distant in the protein 
molecule’s primary sequence.20 
1.4 Protein Aggregation 
Aggregation of proteins can occur due to numerous factors. These can be categorized into 
intrinsic properties of the protein, which consist of the primary, secondary, tertiary, and 
quaternary structure, or extrinsic factors such as the solution conditions, environment stresses or 
various processing conditions.21 Many problems during clinical development can be attributed to 
protein aggregation such as reduced biological activity, increased immunogenicity, or other side 
effects for the patients. While protein-based drug products can be formulated at the optimal 
conditions based on the proteins stability profile, several steps, such as purification, can also 
present the protein to unfavorable environments during manufacturing.  





Aggregates can be classified by several categories and defined in several terms. Four 
common ways to group different types of protein aggregates are by conformation, linkage, 
reversibility, and size.11 Conformation can be broken down into native or non-native states 
depending on if the higher-order secondary and tertiary structure of the protein within the 
aggregate is significantly altered. Linkage can be defined by covalent or non-covalent. Covalent 
linkages are a result of chemical bonds such as disulfide bonds.22 Non-covalent bonds are often 
dissociable and are formed due to forces like hydrophobic and electrostatic interactions.23 
Reversibility is defined as returning to the native state upon returning to the stable environmental 
condition such as a change in temperature or concentration. Irreversible aggregates stay in the 
non-native form even with the removal of the stress and return to ambient conditions. Size of the 
aggregates are categorized into soluble, subvisible, and visible aggregates. Soluble aggregates 
are in the form of oligomers such as dimers and trimers that are soluble in solution.24 Subvisible 
particles are typically in the size range from 100 nm to 100 µm.25 Differences in the morphology 
can be seen with the formation of subvisible aggregates.26 Visible aggregates can be seen by the 
naked eye and classified as 100 µm or greater in size.  
Overall, when protein aggregation occurs in vivo it can take the form of misfolded 
aggregates, inclusion bodies, or amyloid fibers.27 Some aggregates observed are in  in  the form 
of amyloid fibers, which that have an increased amount of -sheet content and reduced amount 
of alpha helicity compared to the native state, which can be due to the increase of intermolecular 
contacts.28  Inclusion bodies are another form where monomeric aggregates self-assemble into 
growing polymers typically during overexpression within host cells during production of 
recombinant proteins.29 





The aggregation of proteins can happen through numerous different pathways that are 
kinetically available. It is a complex pathway and can have several intermediate states before 
reaching one of many possible end states (Figure 3).30 A protein molecule can go from the native 
folded state to another stable intermediate state readily due to the small energy barrier and 
because proteins are in constant flux.31 The energy from a stable protein to an unfolded protein 
can be as little as 5-20 kcal/mol which is equivalent to two or four hydrogen bonds which 
demonstrates that the native, folded state of a protein molecule is only marginally stable.32 
 The aggregation process  can start by the local unfolding within a protein molecule that 
can allow for the aggregation prone “hot spots” to be exposed and available.33  Native, globular 
proteins in solution are in equilibrium with this partially unfolded state and the folded.34 The 
local unfolding event allows there to be an interaction between monomers by the exposure of 
amino acid residues that were previously sterically unavailable.35 These partially unfolded 
intermediates are also in equilibrium with the unfolded state25,27 and therefore  proteins can 
unfold in a reversible fashion and obey a two-step kinetic model.36 This process suggests that the 
population of partially unfolded intermediates can lead to an increase in larger amounts and sizes 
of irreversible aggregation.37  This effect can be due to the exposure of hydrophobic sites that 
have been shown to have an increase in flexibility of the intermediate state compared to the 
native state.38 Exposure of hydrophobic sites and their ability to come in contact with others, 
could stabilize the aggregation state, just as such contacts can stabilize the native state.39 If the 
aggregation kinetics depend on the rate of unfolding, and even if the unfolding is not the rate 
limiting step, the levels of this intermediate can have a significant impact on the overall 





It is also possible for protein aggregation to occur without going through these 
structurally altered intermediate states.41 This is possible by the direct association of native state 
proteins to one another by electrostatic or hydrophobic interactions under the right experimental 
conditions including protein concentration.42 This association can be reversible and can depend 
on the second virial coefficient (B22), where a positive value indicates repulsion between the 
proteins and a negative value indicates attraction.12 Thus, when the protein aggregation process 
is controlled by the self-association step of multiple protein molecules coming together then it is 
primarily linked to the protein molecule’s colloidal stability, while when aggregate formation 
process is controlled by the formation of structurally altered, unfolded intermediates,  this 
process is linked to the protein molecule’s conformational stability.11  
The initially formed protein aggregates start as small and soluble and grow into larger 
insoluble particles as they grow in size. The insoluble aggregates can form into different types 
such as amorphous precipitates or fibrils.43 The type of aggregate formed will depend on the 
intrinsic and extrinsic conditions that are present as described above. Another possible rate 
limiting step in the aggregation pathway can be the process of nucleation.40 That is, one 
aggregate that causes the formation of others to aggregate and increase in size and number and 
even polymerization.44 This nucleation process often follows first-order kinetics due to the rate 
limiting step by a monomer addition. This can be seen by a lag time before aggregation is seen.  
Depending on the environmental conditions, multiple different aggregation pathways can 
occur for any given protein molecule, since the environment around the protein can affect its 
conformational and colloidal stability properties, and these different aggregation pathways can 





Some proteins, such as IgG4 antibodies can swap domains and has been suggested that this can 
be an intermediate on the pathway of formation of IgG4 antibody aggregation.45 
1.4.3 Causes of Protein Aggregates 
Proteins may contain aggregation-prone regions (APR), and in antibodies these APRs are 
usually located in the CDR region.11 The APR has been shown to be one of the largest driving 
factors to the physical instability of antibodies.46 Environmental stresses during the 
manufacturing process like cell culture, purification, formulation, filling/packaging, and shipping 
can all potentially cause proteins to aggregate.47 Such stresses include temperature, pH, high 
concentrations, shear, air-liquid interfaces, light, and much more. All these stresses and solution 
conditions can cause  a specific protein molecule to go through several different aggregation 
pathways.48 Due to protein molecules being dynamic in nature, the slightest of change in 
environment towards the non-native state can initiate the process that can cause aggregation.49,50 
1.4.3.1 Temperature 
Temperature is a major factor that can impact protein stability and aggregation rates. The 
thermal stability of a protein can be measured by the free energy of unfolding (Gunfolding). The 
higher the Gunfolding the more resistant the protein is to unfold at increased temperatures. The 
maximum free energy is usually found in a narrow temperature range. Increasing and decreasing 
the temperature can cause the protein to be less stable.51 Protein molecule’s thermal stability is 
often measured by their thermal melting temperature (Tm) which is a relative measure that can be 
compared across other various conditions.52 Proteins are unfolded at their Tm values and can start 
to aggregate53 but higher Tm values does not necessarily mean the protein is less likely to 





as well. Lower temperatures can decrease the strength and number of hydrophobic interactions55 
within a protein molecule.  In addition, excipients can crystalize, which can lead to phase 
separation and decrease their protection effects on protein stability.56,57 The diffusion coefficient 
is also related to the temperature. When the temperature of the solution is increased, protein 
molecules move more rapidly and are able to collide more frequently with one another.38,58 The 
increase in collision frequency can increase unfavorable interactions that allow protein 
aggregation to occur along with faster diffusion to and from the interface.59 A change from the 
optimal temperature range can also play a role in increasing the chemical degradation rate of 
proteins that in turn can lead to aggregation by the change in molecular motion. 
1.4.3.2 Solution pH 
Solution pH is another important factor that can dictate the aggregation of a protein. Changes 
in the pH value can change the type and distribution of the charges on the surface of a protein 
molecule.60 This change can affect the folding interaction within the protein as well as the 
interactions between proteins. Protein’s have a minimal solubility at their isoelectric point (pI) 
where the net charge is zero because the charge repulsion of the protein is at its lowest.61 
Changing the charge on the surface of a protein can also change the way it interacts with the 
excipients in solution, which can also affect the likeliness of a protein to aggregate.62 Another 
way solution pH affects protein aggregation is by altering the chemical degradation rates the 
protein will undergo creating chemically altered proteins with increased propensity to 
aggregate.63  
 





Ionic strength is dependent on the concentration of ions in the solution and can have many 
effects in the protein aggregation pathway.64 When the ionic strength is increased, it allows for 
better neutralization of the charges seen on the surface of the protein.61 This can decrease the 
amount of charge interaction by electrostatic screening. The salt type can also play an important 
role in how it stabilizes or destabilizes the protein including effects on protein solubility as well 
as protein structural integrity.65 
1.4.3.4 Excipients  
Excipients added to the solution can change the stability of a protein in many different ways. 
There are many different categories of excipients used in pharmaceutical drug products such as 
sugars, amino acids, polymers, and surfactants, and many different types of excipients within 
each category.  
Sugars are small, often neutral compounds that can have a stabilizing effect on the protein’s 
stability.66 Sugars commonly used in formulations are sucrose, lactose, and trehalose. Sugars 
help stabilize proteins by maintaining their correct conformation and this effect usually increases 
with increasing concentrations of additive.67 Although sugars usually have a stabilizing effect on 
proteins, there are some cases that shows an increase in aggregation as a result of their addition.68 
This could be due to a chemical reaction with the protein’s lysine residues and the reducing end 
of a sugar molecule.69 Sugar alcohols such as sorbitol and mannitol can have similar stabilizing 
effects without the potential for chemical degradation byproducts. 
Amino acids can have several effects on the stabilization or destabilization of protein.70 





aggregation by decreasing protein interactions.71,72 Arginine is also another common charged 
amino acid used for it beneficial effects with protein refolding assistance.71 
Polymers have many different way of decrease protein aggregation such as surface activity 
and viscosity effects which decrease diffusion of the proteins in solutions.73 There are many 
types of polymers used in protein formulation such as neutral, amphoteric, polycationic, and 
polyanionic. A couple of ways polymers can increase the stability of proteins is increase the 
distance between them or cover the hydrophobic regions of both the unfolded and folded state.74  
Surfactants used in protein formulation work come in two general classes, ionic and 
nonionic. The ionic surfactants have been shown to have a large effect on protein aggregation 
due to their ability to form a stronger bond with the protein.75 Nonionic surfactants have 
hydrophobic tails that can interact with the hydrophobic areas on the protein.76 Surfactants have 
been shown to be very effective against agitation stresses like shaking and stirring by 
outcompeting the protein molecules for the air-water interface.  
1.4.3.5 Protein Concentration 
Increasing the concentration of protein can have several results on protein aggregation. One 
of the limitations of high concentrations of proteins is an increase in aggregation rates due to the 
increase in colloidal interactions.41,42 Another common problem with high concentrations of 
proteins is the limited solubility of a protein. If the concentration of the protein is higher than the 
limit, precipitation can occur. A high protein concentration, however, can also stabilize proteins 






Agitation is a common stress that is seen throughout the manufacturing and shipping process 
and can cause protein aggregation through a number of different mechanisms. Shaking and 
stirring are common types of agitation that increase the colloidal interaction propensities of 
protein.77 These agitations can also increase interaction at the air-water interface which can lower 
the energy barrier of unfolding and thus allowing the hydrophobic surfaces of a protein molecule 
to be exposed and increasing aggregation.78,79 Stirring can then increase the transfer of these 
unfolded proteins at the surface into the bulk solution and nucleate further protein aggregation.80 
Agitation stresses can also enable certain chemical degradation reactions that in turn increase 
protein aggregation.81 
1.4.3.7 Tangential Flow Filtration  
Tangential flow filtration (TFF) is a commonly used unit operation used for diafiltration and 
ultrafiltration during protein purification and formulation, but TFF processing can lead to many 
different stresses on protein molecules such as shear, cavitation, exposure to air-liquid interfaces, 
and protein-membrane surface interactions.82 These stresses can cause many problems with the 
protein during processing including structural alterations and aggregation.  
1.4.3.8 Light 
Light exposure can cause proteins to have  a wide variety of chemical degradation 
reactions.83 UV light can cause cross-linking between cysteine and tryptophan residues as well as 
the cleavage and formation of disulfide bonds.84 Changes within the protein primary structure 
due to chemical degradation reactions can also shift the protein away from its native structure to 
an aggregated state. This can be seen by mutations in the amino acid sequence or chemical 





crosslinking and has been seen to be involved in amyloid plaques that has been associated with 
protein misfolding diseases.11  
1.4.4 Predicting Protein Aggregation 
Prediction of rate and extent of aggregation of proteins would be an extremely useful 
tool. Although there is no model that is able to predict all proteins likeliness to aggregate, there 
are several approaches used to give an initial evaluation.  One common approach is the use of 
computer models, such as TANGO, to simulate the dynamics based on the hydrophobicity, 
aggregation prone sequences, and other indicators.86  The amino acid sequence and structural 
features are another indication of the likeliness of aggregation to occur.87 
1.4.5 Controlling Protein Aggregation  
Controlling protein aggregation is challenging and a large amount of information and 
experimental data need to be gathered to best formulate a candidate protein drug product. 
Common strategies to decrease protein aggregation are to control solvent and temperature 
conditions or to identify and remove the “hot spots” by altering the sequence.33 Engineering and 
altering the aggregation prone areas can cause problems of its own, however, such as disrupting 
the proper folding of the protein or affecting biological activity.88 Other ways to control protein 
aggregation include identification of proper formulation and storage conditions.  
1.5 Analytical Tools to Monitor Protein Aggregation 
There are many commonly used analytical tools used to monitor protein aggregation across 
size ranges 1 nm to 1 mm (Figure 4). These techniques are robust and can provide large amounts 
of information to characterize the protein aggregate’s physical and chemical properties. These 





light scattering, microflow digital imaging for aggregate size analysis, and Fourier transform 
infrared spectroscopy for structural information about the protein molecules within an 
aggregate.40  
1.5.1 Size exclusion chromatography 
Size exclusion chromatography (SEC) is perhaps the most common technique used to 
quantify the amount and size of soluble aggregates and can be routinely adopted for 
characterization of biopharmceutics.89 It has relatively high resolution and accuracy. This 
technique works by separation of macromolecule by a silica-based microparticles of the size 
range from 5-10 µm.90 The sample flows through the column and the smaller molecule weight 
species diffuse inside the pores of the microparticles resulting in a later elution time. The larger 
molecular weight species cannot enter the micropores and therefore elute at an earlier time. The 
concentration of each species can be seen by spectrophotometric detector. Standard molecule 
weight species are injected and can be compared to the elution times of the protein sample under 
the same experimental conditions. The column size and microparticles and their pore sizes can 
be optimized to detect aggregates from 5-103 kDa in size. SEC has some limitations such as a 
dilution effect when the sample is injected. This dilution effect can cause aggregates to 
dissociate.91 Another downfall is the possibility of the protein and the aggregates to interact with 
the column material causing a misrepresentation of the elution peaks.92 The mobile phase can be 
altered to decrease this effect, but this can cause the modification of aggregates. 
1.5.2 Dynamic light scattering 
Dynamic light scattering (DLS) is the measure of the fluctuation of light scattering 
intensity due to the random motion of the molecules over a period of time.93 This provides 





and no interactions, D can be correlated to the hydrodynamic radius (RH) by the Stokes-Einstein 
equation. This technique is used to measure the size of aggregates from the size range of 1 nm to 
1 µm.94 In a heterogeneous mixture of protein aggregates, various size distributions can be 
detected. The light scattering information obtained is intensity weighted and can be converted to 
number based, volume based, or weight based, but these numbers are based on assumptions of 
the particle shape.94 The light scattering from the DLS measurements are typically collected at a 
90° angle, but newer instruments can now collect back-scattering data as well which allows for 
higher sample concentration to measure without secondary scattering effects.95 Some drawbacks 
to the DLS method is that since the data is intensity weighted, larger aggregation can have a 
large effect of the size distribution obtained. Another limitation is that the method assumes the 
protein molecules being measured are spherical in shape.  
1.5.3 Static light scattering 
Static light scattering (SLS) is the measure of time and average intensity of scattered 
monochromatic light from particles at various angles. This depends on the molecular weight, 
concentration, shape, virial coefficient (B), wavelength, and angle of detection and is analyzed 
by the Zimm plot.96 The light scattering from multiple angles (MALS) can be collected and 
provides accurate information about higher molecular weight aggregates. SLS can measure 
aggregates with the molecular weight greater than 5 kDa. SLS is commonly combined with SEC 
along with UV and refractive index detection.97  This separates the aggregates and allows the 
SLS detectors to be more accurate in determination the molecular weights. Due to high 
background scatter, the readouts of low concentration of smaller molecular weight aggregates are 
not as accurate or reproducible.  





Microflow digital imaging (MFI) is used to detect subvisible particles that are important 
to characterize in a protein solution. These particles fall into the size range of ~1-100 µm. The 
lower end is hard to detect by SEC and the higher end can be seen by the naked eye. MFI is 
based on digital images being taken from the flow of the sample solution through a flow cell and 
images are collected by microscopy.98 The particle count, size, transparency, and morphology of 
the particles can be analyzed. Some limitations with MFI occurs with the resolution of particles 
at high concentrations and how many particle images are captured per frame, which can lead to 
over or under estimations.  
1.5.5 Fourier Transform Infrared Spectroscopy and Circular Dichroism 
Fourier transformation infrared spectroscopy (FTIR) and circular dichroism (CD) as 
essential to obtaining information about the overall secondary structure of proteins. This 
information is important for understanding the mechanism that aggregates form through the 
detection of conformational changes.99 FTIR is used to obtain information about the overall 
secondary structure content of the protein. CD can be used in the far-UV (180-260 nm) providing 
information on the secondary structure and it can also be used in the near-UV (240-340 nm) 
which provides information on the tertiary structure. A limitation of these techniques is that low 
concentration of aggregated species can be masked by the native protein, therefore, aggregates 
may need to be separated to be analyzed properly.  
1.5.6 Transmission electron microscopy  
Transmission electron microscopy (TEM) is used to provide images of protein aggregates 
to gain information about their morphology, size and shape.90 An electron beam is used and 
focused on the sample. The contrast from the surrounding and the sample produces a high 





limitation of TEM is that it cannot be used for quantifying the number of aggregates. Sample 
preparation, such as staining, can also affect the state the aggregation is in. Finally, small subsets 
of the sample are viewed and may not represent the entire sample distribution.  
1.6 Novel Tools used to Detect Protein Aggregation 
There are many other approaches that can give a deeper understanding of the aggregation 
of proteins. In order to dive deeper into this, more novel applications can be used. The novel 
techniques come with many limitations such as low throughput and increased optimization steps. 
But overall, a larger amount of information can be gained to understand exactly what is 
happening when a protein is aggregating and/or forming particulates.  
1.6.1 GroEL-Biolayer interferometry  
GroEL-Biolayer interferometry (GroEL-BLI) has been used to study the pre-aggregate 
species of several proteins.  Pre-aggregate species are defined as partial unfolded proteins and 
cannot be detected by other pharmaceutical methods such as SEC or DLS. Biotinylated-GroEL, a 
chaperonin, is coupled to a streptavidin biosensor and is able to capture the pre-aggregate 
species.  Association of the protein to the GroEL is detected using BLI. This method was 
developed using several proteins including monoclonal antibodies, polyclonal antibodies, and 
FGF.100 Further optimization allowed for a high-throughput screening on several antibodies 
under various stress and buffer conditions resulting in the detection of pre-aggregates prior to 
soluble aggregates detected by SEC or subvisible detected by MFI as described in this thesis 
work. 101 This method can help screen different excipients and can potentially be correlated to 
longer term storage stability.  





Hydrogen-deuterium exchange mass spectrometry (HX-MS) is a technique to observe 
flexibility and rigidness of a protein by the rate of hydrogen exchange.  A detailed map of the 
proteins local structural flexibility can be analyzed.102 Certain segments of the protein can be 
identified as being stabilized or destabilized depending on the extrinsic conditions such as 
excipients. Areas of the proteins seen to increase in flexibility under certain conditions can point 
to areas of the protein that are problematic and can lead to aggregation.  
1.6.3 Langmuir trough 
The Langmuir trough is a valuable technique that can provide a large amount of 
information about interfacial properties of a protein molecule.103 The air-water interface can 
cause proteins to increase the exposure of otherwise buried hydrophobic patches. The likeliness 
of a protein to go to the interface can help predict its ability to aggregate under agitation stresses. 
The more a protein tends to go and stay at the air-water interface can be correlated to the initial 
unfolding event (as well as nucleating further aggregation when it returns to the bulk). Langmuir 
trough measures the surface pressure of the solution. When a higher surface pressure is observed, 
an increased amount of protein is presented at the air-water interface.  
1.6.4 Small-angle X-ray scattering  
Small-angle X-ray scattering (SAXS) is a novel method that is used to study structural 
properties at a nanoscale.104 This method can be used to build 3D models of macromolecular 
complexes and study equilibria and kinetic along with flexible components. SAXS work 
provides information about the elastic scattering of photons. SAXS has been used to correlate the 
structure information to the protein stability information obtained by SEC and protein thermal 
shifts.105 It was able to show important differences between an IgG1 and an IgG4 such as the 





envelopes. SAXS can also provide more accurate atomic-level information of molecules in 
solution, which is an advantage over crystallization techniques which allows the detection of 
conformational flexibility.106 The use of this technique allows for important information such as 
flexibility, dynamic conformational changes, and is not affected by rotation of the molecules, 
that provide a more in-depth understanding of the interaction and aggregation properties of 
macromolecules.  
1.7 Chapter Reviews 
1.7.1 The Use of a GroEL-BLI Biosensor to Rapidly Assess Preaggregate Populations for 
Antibody Solutions Exhibiting Different Stability Profiles. (Chapter 2) 
An automated method using biotinylated GroEL-streptavidin biosensors with Bio-Layer 
Interferometry (GroEL-BLI) was evaluated to detect the formation of transiently formed, pre-
aggregate species in various pharmaceutically relevant monoclonal antibody (mAb) samples.  The 
relative aggregation propensity of various IgG1 and IgG4 mAbs was rank-ordered using the 
GroEL-BLI biosensor method, and the least stable IgG4 mAb was subjected to different stresses 
including elevated temperatures, acidic pH, and addition of guanidine-HCl.  The GroEL-BLI 
biosensor detects mAb pre-aggregate formation mostly prior to, or sometimes concomitantly with, 
observing soluble aggregates and subvisible particles using size exclusion chromatography (SEC) 
and microflow imaging (MFI), respectively.  A relatively unstable bispecific antibody (Bis-3) was 
shown to bind the GroEL-biosensor even at low temperatures (25oC).  During thermal stress (50°C, 
one hour), increased Bis-3 binding to GroEL-biosensors was observed prior to aggregation by SEC 
or MFI.  Transmission electron microscopy (TEM) analysis of Bis-3 pre-aggregate-GroEL 
complexes revealed, in some cases, potential hydrophobic interaction sites between the Fc domain 





detection of transiently formed pre-aggregate species that initiate protein aggregation pathways, 
but also permits rapid mAb formulation stability assessments at low volumes and low protein 
concentrations.   
 
1.7.2 Evaluation of Hydrogen Exchange Mass Spectrometry as a Stability-Indicating 
Method for Formulation Excipient Screening for an IgG4 Monoclonal Antibody. 
(Chapter 3) 
Antibodies are molecules that exhibit diverse conformational changes on different 
timescales, and there is ongoing interest to better understand the relationship between antibody 
conformational dynamics and storage stability. Physical stability data for an IgG4 monoclonal 
antibody (mAb-D) were gathered through traditional forced degradation (temperature and 
stirring stresses) and accelerated stability studies, in the presence of different additives and 
solution conditions, as measured by differential scanning calorimetry, size exclusion 
chromatography, and microflow imaging. The results were correlated with hydrogen exchange 
mass spectrometry (HX-MS) data gathered for mAb-D in the same formulations. Certain 
parameters of the HX-MS data, including hydrogen exchange in specific peptide segments in the 
CH2 domain, were found to correlate with stabilization and destabilization of additives on mAb-
D during thermal stress. No such correlations between mAb physical stability and HX-MS 
readouts were observed under agitation stress. These results demonstrate that HX-MS can be set 
up as a streamlined methodology (using minimal material and focusing on key peptide segments 
at key time points) to screen excipients for their ability to physically stabilize mAbs. However, 
useful correlations between HX-MS and either accelerated or real-time stability studies will be 





1.7.3  A Formulation Development Approach to Identify and Select Stable Ultra-High-
Concentration Monoclonal Antibody Formulations With Reduced Viscosities. 
(Chapter 4) 
High protein concentration formulations are required for low-volume administration of 
therapeutic antibodies targeted for subcutaneous, self-administration by patients. Ultra-high 
concentrations (150 mg/mL) can lead to dramatically increased solution viscosities, which in 
turn can lead to stability, manufacturing, and delivery challenges. In this study, various 
categories and individual types of pharmaceutical excipients and other additives (56 in total) 
were screened for their viscosity reducing effects on 2 different mAbs. The physicochemical 
stability profile, as well as viscosity ranges, of several candidate antibody formulations, 
identified and designed based on the results of the excipient screening, were evaluated over a 6-
month time period under accelerated and real-time storage conditions. In addition to reducing the 
solution viscosities to acceptable levels for parenteral administration (using currently available 
and acceptable delivery devices), the candidate formulations did not result in notable losses of 
physicochemical stability of the 2 antibodies on storage for 6 months at 25°C. The experiments 
described here demonstrate the feasibility of a formulation development and selection approach 
to identify candidate high-concentration antibody formulations with viscosities within 
pharmaceutically acceptable ranges that do not adversely affect their physicochemical storage 
stability. 
1.7.4 Development of Scale-Down Assays for Assessment of Mechanism(s) of Tangential 
Flow Filtration Instability of Proteins. (Chapter 5) 
During the formulation process of drug product development, many proteins have to go 





common ways to do this. Due to the high shear rate, contact with the membrane, pump strain, 
and pressure, this process is can cause major stress of the protein and induce aggregation. This 
instability has a great effect on some molecules compared to others. This is the case with 
molecules 8 and 9 compared to the more stable molecules 1 and 2. The four antibodies were 
studied by their biophysical components, colloidal stability, and interfacial properties. The 
information was used to look at trends between these studies and their aggregation propensities 
when using TFF.  
1.7.5 Conclusions and Future Work. (Chapter 6) 
Protein aggregation can cause many pharmaceutical issues when developing a protein 
drug product. When proteins aggregate, they can have a reduced or even no biological activity.107 
Another problem is the immunogenicity effects aggregation can cause when administered.44,108 
Therefore, aggregation needs to be monitored and controlled throughout the manufacturing 
process and during long terms storage as well as during patient administration. Newer techniques 
are needed in order to better predict and understand how and why protein therapeutic candidates 
aggregate. With the development of these techniques, more can be done to create more stable 







Figure 1.1: Schematic of the primary structure of an IgG1 antibody.109 
A representation of an IgG1 antibody consisting of two heavy chains and two light chains that 
are connected by disulfide bonds. Each heavy chain has 3 constant domains (purple) and 1 
variable domain (teal). Each light chain has one constant domain (pink) and one variable domain 
(yellow). The constant domain controls the Fc effector function biological activity and the 















Figure 1.3: Overview of protein aggregation pathway.110,111  
The native state (F) can take multiple pathways when aggregating that initiates with a common 
intermediate. R and Rx represent reversible intermediates followed by irreversible formation of 
small soluble aggregates (A) that may grow through several mechanisms to reach the size of 
soluble higher molecule weight (HMW) aggregates and eventually the formation of insoluble 
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Patients worldwide depend on therapeutic protein drugs to treat a wide number of diseases 
such as diabetes, cancer, immune disorders and infections.1 The number of protein-based medical 
drug products on the market is increasing rapidly, especially with the expanded use of monoclonal 
antibodies (mAbs).2 The complexity of biopharmaceutical drug candidates is also increasing to 
now include bispecific antibodies, antibody-drug conjugates, single chain fragments variable 
(scFv) and modified natural enzymes.3 To ensure safety and efficacy of protein therapeutic drugs 
across their shelf-life, key biological and structural characteristics that lead to product degradation 
need to be well understood and controlled when formulating a new biopharmaceutical candidate.  
To this end, critical quality attributes4, such as potency, solubility and physicochemical stability, 
are used to define the overall stability profile of the protein drug candidate across the entire shelf-
life.  Numerous strategies now exist where directed engineering methods are implemented to 
rationally mutate suspect surface residues that decrease aggregation while not impacting biological 
activity (e.g., maintaining target affinity of mAbs while improving stability).5  In other instances, 
purposeful engineering and improvement of antigen binding or Fc receptor binding sites, can have 
the undesired effect of increasing aggregation5 or altering the conformational dynamics and 
physical stability6, of the engineered antibodies.  
Protein-based drugs can be exposed to many types of environmental stresses (e.g., 
temperature, agitation, light, etc.) during manufacturing, long-term storage, distribution and 
administration7. These stresses can cause proteins to aggregate to varying extents, depending on 
the specific protein and formulation conditions, thereby reducing potency and/or increasing 
immunogenicity risk upon patient administration.  Aggregation is a complex multistep pathway in 





the formation of reversible and nonreversible intermediates or small aggregate clusters.8 
Elucidation of the exact steps of the aggregation pathway for a particular protein, formulation and 
stress can be experimentally and theoretically challenging.  One important analytical challenge is 
the ability to monitor and capture any initially formed, structurally altered intermediates (i.e., pre-
aggregates), which are transiently present and reversible in nature. Since commonly used 
analytical methods to characterize protein therapeutics are unable to specifically detect this initial 
step, it is difficult to prevent or limit its occurrence during formulation development or even during 
initial production since an effective analytical assay that detects these transient states and reports 
on early stage stabilization by excipients is lacking.  
A recent strategy has been developed where a chaperone GroEL biolayer interferometry 
(BLI) biosensor is constructed to detect dynamic hydrophobic transients that occur prior to the 
formation of larger scale aggregation.9 This detection scheme is based on the observation that 
chaperone proteins in cells capture and prevent or reverse misfolding of cellular proteins  and are 
important in maintaining protein homeostasis within the cell.10  The GroEL (hsp60) chaperonin is 
made up of 14 identical subunits with a molecular mass of 58K each that assemble into two stacked 
heptameric rings.  Within the center of these tail to tail assembled rings, a central hydrophobic, 45 
Å wide, protein-binding cavity is present that can easily accommodate aggregation prone 
hydrophobic regions of dynamically fluctuating, partially folded or misfolded proteins. Upon ATP 
binding, the GroEL binding cavity switches to a hydrophilic interior allowing the bound partially 
folded or even fully folded protein to be released into solution.  The hydrolysis of ATP resets the 
system back to its higher affinity protein capture state.11 The form of the chaperonin that is used 
to construct the biolayer interferometry biosensors is the nucleotide free form of GroEL since its 





antibody affinities.11 Previous work in our laboratories has shown that a biotinylated GroEL-
streptavidin-BLI biosensor is able to capture and detect pre-aggregate species during stress with 
several pharmaceutically relevant protein molecules (polyclonal Ab, IgG1 mAb and a heparin 
binding growth factor, FGF-1) before irreversible aggregation could be detected by size exclusion 
chromatography (SEC).9 In addition to increased binding during various stress conditions, the 
protein molecules also showed some binding under unstressed temperature conditions (25oC). This 
detection/binding of pre-aggregates was verified to be specific for the chaperonin binding site 
because the binding was most often reversed by adding ATP to the GroEL-protein substrate 
complex that was immobilized on the BLI biosensor.  In addition, preliminary TEM data of 
released GroEL complexes from the biosensor surface exposed to stressed mAb solution distinctly 
showed the presence of bound densities attributed to captured antibody proteins.9   
In this work, we further explore and develop the utility of this analytical technology9 by 
using GroEL-BLI biosensors linked to an automated BLI technology platform (the Octet® 96 well 
system). The automated method was used to detect the formation of the pre-aggregate species for 
larger sets of various mAbs (both IgG1 and IgG4), as well as a bispecific antibody, to assess 
aggregation propensity of multiple samples simultaneously. This series of pharmaceutically 
relevant mAbs showed variable rates of aggregation when exposed to a variety of different stresses 
(e.g., acidic pH, Gdn-HCl, temperature cycling), conditions shown previously to generate pre-
aggregate species with other mAbs.12-14 The GroEL biosensor results were compared with the rate 
and extent of soluble aggregates and sub-visible particulates formation as measured by SEC and 
MFI, respectively. TEM analysis was also used as an orthogonal method to structurally detect pre-





the biosensor surface) with the goal of specifically pinpointing particular hydrophobic regions on 
the Ab structure that leads to aggregation and product degradation.   
  
2.2 Materials and Methods 
2.2.1 Materials 
Two IgG1 monoclonal antibodies (mAb-E & mAb-J), an IgG4 monoclonal antibody 
(mAb-D), and a bispecific antibody (Bis-3) were provided by MedImmune (Gaithersburg, 
Maryland). The mAb-E was provided as a 100 mg/mL protein solution in 25 mM Histidine, 8% 
Trehalose pH 6.0, mAb-J as a 150 mg/mL protein solution in 25 mM Histidine, 100 mM Arginine-
HCl, 90 mM Sucrose, pH 6.5, mAb-D as a 50 mg/mL protein solution in 50 mM Acetate, 100 mM 
NaCl, pH 5.5, and Bis-3 as a 4.2 mg/mL protein solution in 20 mM Sodium Phosphate, 235 mM 
Sucrose, pH 7.2. The concentration of the various Abs and GroEL was measured after dialysis 
(into 5 mM citrate-phosphate buffer (CP) containing either 150 or 500 mM NaCl at pH 7.4 as 
described below) with an Agilent 8453 UV-visible spectrophotometer (Palo Alto, California).  The 
absorption values at 280 nm were averaged for triplicate analysis and extinction coefficients of 
1.42 (mAb-E), 1.56 (mAb-J), 1.68 (mAb-D), and 1.54 (mg/mL)-1 cm-1 (Bis-3) were used to 
calculate the protein concentration. FGF-1, used as an assay control in this work, was provided by 
Professor Mike Blaber at Florida State University. 
 Streptavidin (SA) biosensors were purchased from Fortébio (Menlo Park, California). 
Ninety six well black polypropylene plates were purchased from Greiner (Monroe, North 
Carolina). An XL25 dual channel pH meter, sodium chloride, guanidine hydrochloride, potassium 
chloride, EDTA, and LC-MS grade water were obtained from Fisher Scientific (Fair Lawn, New 





were purchased from Acros Organics (Fair Lawn, New Jersey). Glycerol, Trizma base, ATP, and 
BSA were obtained from Sigma Aldrich (St. Louis, Missouri). 
2.2.2 Methods 
2.2.2.1 Biolayer Interferometry 
Samples were analyzed by biolayer interferometry using an Octet RED96 system 
(Fortebio, Menlo Park, CA) with the sample holder set at 25oC, even for cases where samples were 
initially subjected to thermal stress (as described below). Biotinylated GroEL-Streptavidin 
biosensors were used to monitor the presence of pre-aggregates in antibody solutions using 9 steps 
to produce a sensogram as described below. Before a sensogram is obtained, each streptavidin 
biosensor is first hydrated for 10 min in GroEL buffer (50 mM Tris, 50 mM KCl, 10 mM MgCl2, 
and 0.5 mM EDTA, pH 7.5) prior to start of the study.  The automated nine step procedure is as 
follows:  (1) an initial reference baseline of 30 sec is performed with GroEL buffer alone, (2) 
Biotinylated GroEL (b-GroEL-1mg/ml – 1 to 3 biotin adducts per GroEL oligomer 8) is loaded 
onto the streptavidin biosensor for 170 sec followed by a (3) baseline determination that is 
performed in PBS.  Once loaded, (4) a 220 sec blocking step was implemented to further diminish 
non-specific binding using BSA (1 mg/ml) as the blocking agent.  This blocking step was followed 
by a 30 sec baseline wash that is performed with buffer identical to that used for the mAb (5).  In 
the testing phase, (6) the association of stressed or unstressed antibody sample (concentration 
ranges from 0.2 to 5.0 mg/ml) with the GroEL biosensor is performed for 5 min, (7) followed by 
monitoring the dissociation phase for 220 sec using a buffer identical to that used for the antibody 
sample. To reverse the specific binding of the stressed antibody from the GroEL biosensor, (8) 
three pulses of 20 mM ATP in an osmolyte mixture of 4M Urea, 4M glycerol is used to remove 





is acquired for 60 sec using a buffer identical to that employed for the antibody and compared with 
the starting amplitude from step 5 (further described in Figure 1 in the Results section).  As was 
shown previously, biotinylated GroEL remains tetradecameric and is fully functional under these 
solution conditions.15  
2.2.2.2  GroEL-BLI Method Optimization 
GroEL-BLI biosensor tips are pretreated with BSA to decrease possible nonspecific 
binding of mAb to any bare streptavidin biosensor surfaces. To insure that non-specific binding 
does not occur, the response of 1 mg/ml BSA binding to the streptavidin tip was examined with 
increasing concentration of GroEL loading. During step 2, concentrations of 0, 2.5, 5 ,10, 25, 100, 
500, 1000 µg/mL GroEL were loaded onto individual biosensors in the automated OCTETRed96 
system to evaluate loading capacity. Although BSA binding diminishes as GroEL binding 
increases (see Figure 2 in Naik et al., 2014)9, as a precautionary step, during automated step 4, 1 
mg/mL BSA was included in the buffer to block any nonspecific binding sites on the biosensor 
surface (Blocking step Figure 3A). The BSA blocking step may seem redundant when GroEL 
loading has been optimized (see also Figure 2 in reference 9), but in cases where GroEL loading 
has not been optimized (lower GroEL binding on the Biosensor), inclusion of the BSA blocking 
step simply insures that nonspecific binding of the test antibody sample does not occur.  In fact, 
BSA loading onto bare streptavidin tips also leads to diminished non-specific Ab binding 
(Supplemental Figure S1).  As a control, Step 6 was performed using a stable nonstressed antibody 
to evalute the amount of nonspecific/background binding occuring for each mAb prior to exposure 
of antibody solutions to stress conditions. A final concentration of 500 µg/mL GroEL was used 





2.2.2.3 Size Exclusion Chromatography (SEC) 
The monomer, aggregate and fragment content of stressed antibody samples was assessed 
using a 7.8 x 30 cm2 TOSOH TSK-Gel BioAssist G3SWXL column and 6.0 mm ID x 4.0 cm TSK-
Gel SWXL guard column (TOSOH Biosciences, King of Prussia, Pennsylvania).  Prior to analysis, 
the column was pre-equilibrated with 7-column volumes of mobile phase composed of 0.2 M 
sodium phosphate, pH 6.8.  Removal of insoluble aggregates from the stressed samples was 
accomplished by centrifugation at 14,000 x g for five min before injection onto the column.  
Elution of the various species from the column was assessed by monitoring the UV absorbance at 
214 and 280 nm (as described previously)16 using a Shimadzu high-performance liquid 
chromatography system equipped with a photodiode array detector.  Molecular weight standards 
(Biorad Laboratories, Hercules, California) were used to assess the efficiency of separation.  
Injection of antibody stored in the formulation buffer was also completed on the day of each time-
point to assess day-to-day variability and column lifespan.  Peaks corresponding to aggregates, 
monomer, and fragments were selected and the area under each peak was quantified using the LC 
Solutions data analysis package. 
2.2.2.4 Microflow Imaging (MFI) 
A DPA-4200 microflow imaging system (Protein Simple, Santa Clara, California) was 
used to count an image micron-sized subvisible particles in the size range of 2-100 μm.  Stressed 
and control samples were added directly to the MFI without any prior dilution as described in 
detail elsewhere.17  Buffer controls containing no protein, were also analyzed and subtracted from 






2.2.2.5 Transmission electron microscopy (TEM) 
A JEOL JEM-1400 TEM operating at 100KV equipped with an AMT digital camera 
system was used to visualize the GroEL and GroEL-complexes. To form the GroEL-mAb 
complexes, mAb-D and Bis3 samples were heated at 50°C for 60 min in solution with a selected 
molar ratio of GroEL. To analyze biosensor released GroEL-Ab complexes, the Biosensor was 
loaded with the 60 min stress Ab sample and the complex was released onto EM grids by reducing 
the S-S biotinylated GroEL-Ab complexes with 50 mM dithiothreitol (DTT).9  To assess 
complexes that form on the GroEL biosensor, S-S biotinylated GroEL was used since the complex 
is easily removed from the biosensor surface using 50 mM containing DTT solution. Two μL of 
the sample was placed on carbon coated Cu 300 square mesh copper grids (Electron Microscopy 
Sciences) that were glow discharged prior to use. The samples were incubated on the grids for 10 
min, followed by a 3X wash with deionized water. The grids were then negatively stained with 
filtered (0.02 micron Whatman filters) 0.75% uranyl formate and imaged. 
2.2.2.6 Sample preparation and temperature stress treatment of mAbs 
To determine potential candidates for further analysis, long term thermal stress 
experiments were performed.  Stock solutions of various mAbs that were initially stored at -80°C 
were dialyzed into 5 mM citrate-phosphate buffer (CP) containing either 150 mM or 500 mM NaCl 
at pH 7.4. The mAbs were then diluted using the CP buffer to achieve a protein concentration of 
5 mg/mL (mAb-E, D, and J). The samples were filtered using 0.22 μm syringe filters in a laminar 
flow hood (Millipore, Billerica, Massachusetts).  Aliquots of 1.5 mL were placed into 3 mL 
borosilicate glass type I vials and capped with rubber stoppers (West Pharmaceutical Services, 
Exton, Pennsylvania).  Samples of all three mAbs were stored at 4, 50, 55, and 60 °C for various 





2.2.2.7 Sample preparation and stress treatment by pH shift with mAb-D 
The mAb-D stock solution was diluted using the CP buffer with 150mM NaCl to achieve 
a protein concentration of 5 mg/mL. The samples were then stressed by shifting the pH to 4.0 for 
1 minute using 0.5 M HCl and then increasing the pH back to 7.4 by titrating with a 1 M Na 
phosphate stock solution.  Using a concentrated stock solution allows one to adjust the pH of the 
solution with minimal dilution.  A second set of samples were generated by shifting the pH to 5.0 
and back to 7.4 after 1 min incubation. Once the pH reached 7.4, the samples were analyzed 
immediately using the GroEL-BLI, SEC and MFI.     
2.2.2.8 Sample preparation and stress treatment by thermal cycling of mAb-D 
The mAb-D stock solution was diluted using the CP buffer with 150 mM NaCl to achieve 
a protein concentration of 5 mg/mL. mAb-D was stressed by thermal cycling from 25 to 45°C and 
back to 25°C at 3°C per sec resulting in ~68 complete thermal ramps in 15 min and ~ 540 complete 
thermal ramps over a two 2 h period. The samples were then analyzed using GroEL-BLI, SEC, 
and MFI. 
2.2.2.9 Sample preparation and stress treatment by addition of Guanidine HCl of mAb-D 
A stock solution of 5 M guanidine was prepared in 5 mM CP, 150 mM NaCl at pH 7.4.  
The stock mAb-D was diluted using the corresponding CP buffer and the guanidine hydrochloride 
stock solution to achieve a protein concentration of 5 mg/mL and 0.5 M guanidine HCl.  The mAb-
D control samples were also prepared using only CP buffer with 150 mM NaCl.  The samples were 
filtered using 0.22 μm syringe filters (Millipore, Billerica, Massachusetts).  Aliquots of 1.5 mL 
were placed into 3 mL borosilicate glass type I vials and capped with rubber stoppers (West 
Pharmaceutical Services, Exton, Pennsylvania).  Triplicates of the perturbed samples were 





2.2.2.10 Sample preparation and stress treatment by 50°C incubation of Bis-3 and of mAb-D 
The mAb-D stock solution (50 mg/mL) was diluted using the CP buffer with 150 mM NaCl 
to achieve a protein concentration of 5 mg/mL. The stock solution of Bis-3 (4.2 mg/mL) was 
diluted to a final concentration of 0.2 mg/mL using 20 mM sodium phosphate, 235 mM sucrose at 
pH 7.2. mAb-D and Bis-3 solutions were stressed over 1 h at 50°C. At time points of 0, 5, 10, 20, 
30, and 60 min (mAb-D) and 0, 10, 20, 30, 45, 60 min (Bis-3), the samples were analyzed using 
GroEL-BLI, SEC, and MFI. 
2.2.2.11 P-value calculation 
p-values were calculated using the t-Test: paired two sample for means data analysis 
function from Excel software (Microsoft, Redmond WA). The alpha value was 0.05 with N=3 for 
all sample sets. 
2.3 Results and Discussion 
2.3.1 Automated GroEL-BLI assay optimization and initial assessment of aggregation 
propensity of three mAbs 
In this work, the utility and pharmaceutical applicability of a previously reported GroEL-
BLI biosensor assay9 to monitor the formation of pre-aggregate species found in various 
therapeutic mAb candidates exposed to different environmental stresses were evaluated.  A key 
analytical advancement in this work was the development and implementation of an automated 
BLI platform (OctetRed96 system).  By moving from the single channel BLI system described 
previously9 to an automated, multichannel platform (96 well plate), this work demonstrates the  
use of the GroEL biosensor as a part of formulation development of mAbs and other therapeutic 
protein candidates.  Other improvements in the assay described in this work include the addition 





surface even with variable GroEL loading, and more routine implementation of various controls 
(including a relatively unstable control protein, FGF-1, and non-stressed mAbs as positive and 
negative controls).  Moreover, by using an automated platform, many more replicates can be run 
for each sample to further ensure the reproducibility of each set of experiments.  The automated 
GroEL-BLI system was then examined with 4 different therapeutic mAb candidates (two IgG1 
molecules, one IgG4 molecule and one bispecific mAb) exposed to different environmental 
stresses previously shown to induce formation of aggregates using various mAbs.12-14 
As an initial step to optimize the assay and minimize any potential nonspecific binding to 
the biosensor, concentrations of 0-1 mg/mL of b-GroEL (0, 2.5, 5 ,10, 25, 100, 500, 1000 µg/mL) 
were loaded onto the biosensor. This step was followed by a blocking step with concentrations of 
0-1 mg/mL bovine serum albumin (BSA). A non-stressed mAb sample was then exposed to the 
biosensor. The conditions with the least amount of non-specific binding during the association 
phase were chosen for future studies and consisted of loading with 0.5 mg/mL GroEL and 1 mg/mL 
BSA (See Supplemental Figure S2). 
Following adaptation to the Octet multichannel system and assay optimization, a screening 
of three pharmaceutically relevant mAbs (mAb-D, E, and J) was performed. Thermal stresses were 
used to probe each mAb at temperatures approaching their Tonset  values, at the Tonset, and above 
the Tonset (mAb-D: 58.9°C ± 0.5; mAb-E: 56.3°C ± 0.08; mAb-J: 55.3°C ± 0.2 as obtained by 
differential scanning calorimetry, data not shown). All three mAbs were stressed at temperatures 
of 50, 55, and 60°C (along with a 4°C control) for 14 days in solutions containing different salt 
concentrations (150 mM and 500 mM NaCl). Figure 1 represents the average binding amplitude 
of the different samples (each mAb at 5.0 mg/ml) from the GroEL-BLI biosensor. In general, it 





the three elevated temperatures. In addition, increasing the NaCl concentration from 150 to 500 
mM did not have any major effect on the IgG binding amplitudes. The slight decrease in binding 
amplitude seen from 50°C to 60°C can be due to the smaller pre-aggregate species forming larger 
sized aggregates in solution (from the increase heat stress) and these larger aggregates cannot be 
captured by the GroEL as effectively. This decrease in GroEL biosensor capture efficiency could 
be due to the diminished exposure of hydrophobic patches upon aggregation or the decreased 
collisional frequency with the biosensor due to a decrease in diffusion or a combination of both 
these aggregate properties.  These results show that different mAbs can be compared for their 
aggregation propensity in different solutions using this GroEL-BLI biosensor method in an 
automated platform. 
2.3.2 GroEL-BLI, SEC, and MFI analysis of mAb-D aggregation under various stress 
conditions 
To further evaluate the utility of this approach, mAb-D was further exposed to four other 
environmental stresses involving acidic pH exposure, thermal cycling, Gdn-HCl perturbation, and 
50°C incubation as outlined by the flowchart illustrated in Figure 2 (conditions 1, 2, 3, 4, 
respectively). These experimental conditions were selected based on previous reports for their 
ability to initiate formation of early intermediates in the mAb aggregation pathways12-14.   Figure 
3A shows a representative GroEL-BLI biosensor sensogram of mAb-D stressed under one of the 
four conditions (condition 4, 50°C for 60 min).  The association step shows triplicate runs of mAb-
D stressed solution with the dissociation step conducted in mAb-D formulation buffer alone.  The 
final baseline determination was performed after using the mAb-D formulation buffer with added 
ATP to induce release of bound mAb-D from the GroEL.  The sensogram trace returns at or near 





baseline buffer return in Figure 3A), indicating specific binding to the GroEL biosensor.  Figure 
3B is an enlargement of the association and dissociation phases of the same sample after a 60 min 
thermal stress treatment. Similar GroEL-BLI experiments were then performed with mAb-D 
exposed to each of the four stress conditions (Figure 2) and the results are described below and 
summarized in Figure 3C. The GroEL-BLI results were compared to analysis of the same mAb-D 
samples by SEC and MFI as summarized in Figure 4A and 4B, respectively. 
For condition 1, a brief decrease in solution pH to acidic conditions has been previously 
shown to cause the formation of a wide range of metastable aggregate species with various mAbs, 
produced by the unfolding of the Fab region12. The mAb-D solution was subjected to a brief 
exposure (1 min pH jump) by rapidly dropping to pH 4.0 followed by the pH return to 7.4 by 
readjusting with concentrated phosphate buffer. This pH pulse and return resulted in a significant 
increase (p-value of 0.0025) in the binding amplitude using the GroEL-BLI assay compared to the 
non-stressed mAb-D control (Figure 3C).  This change in binding amplitude was also observed 
during a pH 5.0 pulse, but the BLI binding signal was diminished compared with the pH 4.0 pulse 
amplitude (p-value of 0.0037), thereby indicating that pH 4.0 pulse created a larger population of 
aggregates compared to the pH 5.0 pulse.  When these samples were examined using size exclusion 
chromatography (SEC), a substantial increase in percent aggregation (soluble and insoluble) of 
~18% for the pH 4.0 pulse samples and ~ 15% for the pH 5.0 samples was observed compared to 
the control sample that contained ~0.2% aggregate (Figure 4A). An increase in formation of both 
soluble and insoluble aggregates (loss of total area in the SEC chromatogram) with a concomitant 
decrease in the monomer peak was observed. The samples were assessed for formation of 
subvisible particles by Microflow Imaging (MFI), with both pH pulsed samples showing an 





The particle size distribution of the control and stressed mAb-D samples showed the majority of 
particles to be in the size range of 2-10 µm (data not shown). 
For condition 2, mAb-D was exposed to multiple thermal cycles from 25 to 45°C and back 
to 25°C.  The heating phase during thermal cycling has been shown previously to partially unfold 
the Fab domain of an antibody while the cooling phase minimizes protein aggregation14. To 
determine if these conditions could lead to the formation of pre-aggregate species with mAb-D, 
the thermal cycling was performed from 25°C to 45°C and back to 25°C at 3°C per second over 
the course of 15 min and 2 h and resulted in an increase in the binding amplitude using the GroEL-
BLI assay compared to the mAb-D non-stressed control (Figure 3C). When the samples were 
examined using SEC, a relatively small increase in total aggregation was seen. There was ~0.5% 
increase in aggregation seen for the 15 min thermal cycled samples and ~1% increase for the 2 h 
cycled samples compared to the non-stressed mAb with ~ 0.2% total aggregation (Figure 4A). This 
was also accompanied by a loss in total peak area, indicating the formation of insoluble aggregates 
that did not pass through the column matrix.  The samples were assessed by MFI with both 15 min 
and 2 h samples showing an increase in subvisible particle concentration compared to the non-
stressed mAb-D control (Figure 4B).  The particle size distribution of the control and stressed 
mAb-D samples showed the majority of particles to be in the size range of 2-10 µm (data not 
shown). 
Exposing mAb-D to conditions 1 and 2 (Figure 2) showed concomitant formation of pre-
aggregate species (GroEL-BLI biosensor), aggregates (SEC) and subvisible particles (MFI).  
These results with mAb-D can be compared to previous work done on other mAbs12 12.  For 
example, a brief low pH shift12 resulted in polydisperse mAb aggregates from dimers to aggregates 





mAb-D with aggregates of varying size (from dimer to subvisible particles of 2-10 µm). For the 
thermal cycling method14, however, the heating pulse was reported to lead to partial unfolding of 
the Fab region allowing Fab-Fab interactions to occur. The cooling period caused the refolding 
and minimization of detectable aggregation for the examined mAb. Thermal cycling led to an 
increase in the amount of fragments with a concomitant decrease in the presence of dimers 
observed by SEC. In contrast, in this study, mAb-D showed a steady increase in the level of 
insoluble aggregates and increased amounts of subvisible particles after multiple thermal cycling 
events. These contrasting results could be due to differences in the inherent stability or dynamics 
of the two mAbs, or possibly differences in experimental solution conditions.  
In summary for conditions 1 and 2, mAb-D formed irreversible aggregates under the 
conditions of acidic pH exposure and temperature cycling as measured by SEC and MFI. 
Concomitantly, an increase in binding amplitude was observed using the GroEL biosensor. Thus, 
the GroEL biosensor was detecting either formation of the pre-aggregate species and/or formation 
of the irreversible aggregates.  It was difficult to distinguish these two possibilities under these two 
experimental conditions because of the formation of multiple types of aggregates during these 
stresses. Indeed previous results indicate that the GroEL-BLI biosensor binds to stable IgG 
dimers8.  Thus, the biosensor results correlate with SEC and MFI data indicate that the GroEL 
biosensor method can potentially be used as a rapid general assessment of protein aggregation 
propensities which bodes well implementation of a routine  automated assay setup (8 or 16 channel 
Octet systems and other higher HDXOctet 96 channel BLI throughput systems).   
In contrast to the mAb-D aggregation profile observed with conditions 1 and 2, conditions 
3 and 4 (see Figure 2) showed a different profile in which the GroEL-BLI biosensor detects 





formation as measured by SEC and MFI.  For example, Condition 3 consisted of perturbing mAb-
D with 0.5 M guanidine HCl for various times. Exposure to intermediate concentrations of Gdn-
HCl has previously been shown to partially unfold the CH2 domains of a mAb and lead to 
aggregate formation13.  Therefore, perturbation of mAb-D with 0.5 M Gdn-HCl was performed to 
evaluate the ability of these conditions to generate aggregate and/or pre-aggregate species. A 
significant increase in the binding amplitude using the GroEL-BLI assay (compared to the mAb-
D non-stressed control) was observed (Figure 3C).  The association phase during the GroEL-BLI 
study show a slight increase in binding at the 24 h time point compared to earlier times, which 
showed no significant differences (p-value=0.059).  Based on SEC, the mAb-D samples produced 
less than 1.5% total aggregation (approx. equivalent to the amount observed in the unstressed 
mAb-D control where no significant GroEL biosensor binding was observed, Figure 4A).  
Similarly, when the samples were also analyzed by MFI, no notable increase in total subvisible 
particle concentration (compared to the non-stressed mAb-D control) at the early time points (8 
and 68 min, and 2 h) were observed, although the longer time points under these same conditions 
(5 h and 24 h) showed a small increase in subvisible particle concentration compared to the control 
(Figure 4B).   
Under the final stress condition examined (Condition 4, see Figure 2), mAb-D was 
incubated at 50°C for various times up to an hour. For the GroEL-BLI results, Figure 3C shows 
increasing binding amplitudes for the stressed mAb-D samples at 50°C for up to one hour.  The 
stressed mAb-D samples were also evaluated for the presence of aggregates using SEC as well as 
for the formation of larger, subvisible particles by MFI.  Figure 4A displays the percent total 
aggregate formation as determined by SEC for mAb-D samples for various times along with an 





shows the concentration of subvisible particles in the same samples as measured by MFI. Results 
indicate that no increase in particle formation is observed between 10 and 60 min of incubation at 
50°C. The particle size distribution of the control and stressed mAb-D samples showed the 
majority of particles in the range of 2-10 µm (data not shown). 
TEM analysis was used to visualize the GroEL-mAb-D complexes that were formed after 
exposing the mAb-D sample to heating at 50°C for 60 min (Condition 4).  Figure 5 shows TEM 
images of the different preparations, including 0.05 µM GroEL in the solution as a control (Figure 
5A), solution based interaction of the stressed 0.05 µM mAb-D with 0.05 µM GroEL (Figure 5B), 
dissociation of –S-S- biotinylated-GroEL (SS-b-GroEL) from the streptavidin biosensor with a 
DTT control (Figure 5C), and dissociation of the mAb-D-GroEL complex from the streptavidin 
biosensor surface using DTT (Figure 5D). Complexes between the GroEL and mAb-D (or 
potentially fragments of mAb-D), after temperature exposure, can be seen using both approaches 
(Figure 5B and 5D) indicating the binding of structurally altered forms of mAb-D species to GroEL 
upon exposure of the mAb-D to elevated temperature. This is manifested as extra density bound 
to the GroEL binding site.    
Exposing mAb-D to conditions 3 and 4 (Figure 2) showed formation of pre-aggregate 
species (GroEL-BLI biosensor) prior to formation of aggregates (SEC) and subvisible particles 
(MFI).  These results with mAb-D can be compared to the previous work reported on other mAbs13 
18.  Mehta et. al. 201413 showed unfolding of the CH2 domain was the interaction site for 
aggregation of this particular mAb when exposed to 1.2-1.6 M Gdn-HCl. At lower denaturant 
concentrations, the mAb remained in its native state. In the case of mAb-D in our study, when 
exposed to 0.5 M Gdn-HCl, SEC and MFI showed no increased amounts of aggregation compared 





pre-aggregates.  For thermal stress, Hawe et. al. (2009)18 showed that thermal incubation of a mAb 
solution (at a few degrees below its visible aggregation temperature) resulted in formation of small 
aggregates around 30 nm and subvisible particles below 25 μm. During the thermal stress of mAb-
D in this work, performed at ~9 degrees below its Tonset value, no increase in aggregates was 
detected using SEC and nor MFI, yet the GroEL-BLI system does detect early structurally altered 
forms of mAb-D.  These results demonstrate that the different environmental stresses lead to the 
formation of differing levels of mAb-D pre-aggregate, soluble aggregate and subvisible particle 
species which can be elucidated using a combination of the GroEL-BLI biosensor, SEC and MFI 
analyses.  
 
2.3.3 Automated GroEL-BLI, SEC, and MFI analysis of Bis-3 bispecific antibody under 
thermal stress conditions 
To further examine the ability of the automated, optimized GroEL-BLI biosensor to detect 
formation of pre-aggregate species, solutions of a pharmaceutically relevant bispecific Ab (Bis-3) 
were examined, before and after thermal stress, by a combination of the GroEL-BLI biosensor 
assay, SEC and MFI. Bis-3 solutions at a low protein concentration (0.2 mg/ml) were incubated at 
50°C (for up to 60 min), a temperature well below the Tonset of the bispecific antibody (as 
determined by differential scanning calorimetry where Bis-3 exhibited a multiphasic DSC 
thermogram with a Tm1 value of ~64°C). Figure 6A shows representative GroEL-BLI biosensor 
sensograms of the association and dissociation phase of Bis-3 samples before and after an exposure 
to elevated temperature (50°C, 10 min) followed by a return to 25oC prior to measurement.  Figure 
6B shows the association and dissociation phase of Bis-3 samples after 60 min at 50°C. The 





containing solution (with elevated values due to high refractive index of solution due to the 
glycerol) released the captured Bis-3 specifically bound to the GroEL as evidenced by the return 
to the original GroEL loaded baseline. For each of the time points, the average binding amplitude 
(from three replicates) for the association, dissociation, and final baseline were plotted as a bar 
graph in Figure 6C. An increase in binding amplitude of the unstressed Bis-3 sample (at room 
temperature) over the buffer control (no Bis-3) is observed indicating the Bis-3 molecule has an 
exposed hydrophobic GroEL binding interaction site even at room temperature.  In contrast, 
neither the IgG1 nor the IgG4 mAbs showed any such GroEL-BLI binding signal at room 
temperature. Interestingly, the Bis3 sample concentration tested (0.2 mg/ml) was significantly 
lower than the mAb-D sample tested (5 mg/ml), yet showed a larger binding amplitude during the 
association phase. 
When the same temperature stressed Bis-3 samples were examined for irreversible 
aggregate formation using SEC, no substantial increase in percent aggregation was observed (both 
for soluble aggregates in the chromatogram and insoluble aggregates as indicated by total area 
recovered), compared to the control Bis-3 sample (both contained ~0.45% aggregate) (Figure 7A).  
The Bis-3 thermally stressed samples also showed no increase in the levels of subvisible particles 
as assessed by MFI measurements over the unstressed Bis-3 control (Figure 7B).  For both the 
unstressed and thermally stressed samples, the particle size distribution within the 2-10 µm size 
range remained the same (data not shown). These results indicate that these thermally stressed Bis-
3 samples contained an easily detectable amount of pre-aggregate species by the GroEL-BLI 
biosensor prior to any detectable formation of irreversible aggregates as determined by SEC and 





TEM was used to visualize the GroEL-Bis-3 complexes. Figure 8 shows representative 
TEM fields of Bis-3 GroEL complexes generated from both solution formed and biosensor 
released complexes.  The first two image fields represent the complexes that were formed in 
solution with the GroEL alone (Figure 8A) and GroEL-Bis-3 complexes (Figure 8B) which were 
heated at 50°C for 60 min.  The field in Figure 8B represents a solution containing equal molar 
amounts of Bis-3 and GroEL; see methods section).  In Figure 8C and D, the images were 
generated  by performing the GroEL-BLI assay on streptavidin biosensors loaded with S-S 
biotinylated GroEL, and then dissociating GroEL alone (Figure 8C) and GroEL-Bis3 complexes 
(Figure 8D) by reducing the S-S linkage with DTT from three separate biosensors (to enhance 
complex concentrations, see methods section).  In Figure 8D, the released GroEL-Bis-3 complex 
was formed by heating the Bis-3 sample at 50oC for 60 min followed by an immersion of the 
GroEL biosensor into this solution for 5 min.  After this immersion phase, the complex was then 
released from the biosensor with DTT and visualized using negative staining TEM.  For both 
approaches to form the GroEL-Bis 3 complexes, the TEM images clearly show that the GroEL 
binding site is occupied by extra protein density with prominent extensions.  In Figure 8B, some 
GroEL complexes show clear interactions between the GroEL binding site and the Fc portion of 
the bispecific mAb with the Fab domains pointing away from the GroEL binding site (Figure 8B). 
In Figure 8D, the biosensor released complexes also show clear extensions but the complexes are 
not as resolved as in the GroEL-Bis-3 solution complexes (Figure 8B).  
Bispecific antibodies are designed by recombinant DNA technologies to recognize two 
different antigens to increase effectiveness of the therapeutic protein for certain targets19. Due to 
their asymmetrical, multi-domain nature, such engineered antibody molecules can have very 





stability19. When examining Bis-3 using the GroEL-BLI assay, it was first noted that there was an 
increase in binding amplitude of unstressed Bis-3 sample (at room temperature) that was not seen 
with the three other IgG mAbs. Importantly, this GroEL-BLI detection signal with Bis-3 occurred 
at a ~25-fold lower protein concentration than with the mAb-D samples. This result indicates the 
Bis-3 molecule has a structurally altered, enhanced hydrophobic nature at room temperature 
compared to the mAbs.   In addition, the Bis-3 samples were also inherently less stable than the 
IgG1 and IgG4 mAbs when the Bis-3 samples were exposed to limited thermal stresses (i.e., 10 
min at 50°C) and the binding amplitudes remained relatively constant over the 60 min sampling 
period. This constant signal may indicate that the population of pre-aggregate species reaches an 
equilibrium state after thermal stress that does not diminish even after the samples are returned to 
ambient temperatures for the GroEL BLI biosensor measurements.  This enhanced signal with the 
GroEL biosensor for both unstressed and thermally stressed Bis3 samples was obtained without 
any appreciable increase in the formation of irreversible aggregate species as measured by SEC 
and MFI. One additional difference between the Bis-3 and mAb-D is that Bis-3 had a significantly 
higher binding amplitude in the GroEL-BLI assay, probably indicating a higher population of the 
pre-aggregate species. This is also consistent with the increased population of complexes seen with 
TEM.  
Previous results by Naik et al. (2014) 9 showed that the GroEL-BLI biosensor could detect 
the existing and thermally stressed formation of hydrophobic patches on polyclonal-IgG and mAb 
samples, with binding amplitudes seen to increase with the time of thermal stress. Likewise, the 
mAb-D examined in this work also showed time dependent increases in GroEL binding and hence 
detection as the thermal stress times increased.  In contrast, this trend was not observed for the Bis-





over the 60 min sampling period but rather manifested a steady, consistent binding response. In the 
samples examined in this work, the GroEL binding hydrophobic species (pre-aggregates) remained 
in solution even after the temperature is returned to ambient temperatures prior to analysis.  This 
is another unexpected advantage of this method because this enhanced detection scheme could be 
useful in determining conditions that can inhibit the formation of or alternatively reverse the 
accumulation of these potentially metastable, kinetically trapped, partially unfolded, hydrophobic 
states.   
2.4 Conclusions 
In this work, a previously described GroEL-BLI based method9 was further optimized and 
automated (using an Octet system, 96 well plate format) to bind and detect partially structurally 
altered intermediates (pre-aggregates) formed in stressed solutions of several different therapeutic 
Ab candidates including IgG1, IgG4 and bispecific antibodies. Transmission electron microscope 
(TEM) images of stressed Ab samples bound to the GroEL showed the formation of Ab pre-
aggregate-GroEL complexes.  The utility of this approach for use in protein formulation 
development was explored with various mAbs (IgG1 and IgG4) exposed to various stress 
conditions as well as by using a relatively less stable bispecific antibody (Bis-3).  For the latter, 
significant binding amplitudes were observed with the GroEL-BLI biosensor at room temperature 
at significantly lower protein concentrations (i.e., unstressed conditions), compared to the other 
mAbs, indicating its relatively enhanced hydrophobic nature, and by correlation, aggregation 
propensity. When Bis-3 was incubated at 50°C, increases in GroEL-BLI binding amplitude were 
observed before any increases were seen for irreversible aggregate/particle formation as measured 
by SEC and MFI.  When examining the more stable mAb-D (IgG4), upon exposure to different 





BLI biosensor could detect pre-aggregate formation before, or in some cases concomitantly with, 
irreversible aggregate formation as measured by SEC and MFI.  Thus in this case, the GroEL-BLI 
biosensor can supplement information gained from more traditional aggregation detection methods 
to better detect pre-aggregate species that may be involved in the formation of longer term 
deleterious protein aggregates.  
The GroEL biosensor technology provides protein specific information about the presence 
of potentially aggregation prone species. In some instances, this technology reports the formation 
of pre-aggregate transient species (GroEL binders) before larger scale aggregation is even 
detected. The specificity of this GroEL-Ab interaction can be confirmed by ATP induced reversal 
of Ab binding and the GroEL-Ab complexes can be easily visualized by TEM analysis.  This 
method can rapidly assess solution stability and pre-aggregate formation within the relatively short 
time window of minutes.  This rapid detection of pre-aggregate species using an automated 
platform can be particularly useful for protein formulation development.  This early BLI detection 
method can be used to identify stabilizing conditions and excipients that diminish pre-aggregate 







Figure 2.1: Screening of the aggregation propensity of mAb-D (red), mAb-E (blue), and mAb-J 
(green) performed using the optimized, automated GroEL-BLI biosensor assay.  
The mAb solutions were incubated at temperatures of 4, 50, 55, and 60°C for 2 wk.  The average 
binding amplitude of the different samples are shown with mAb-D showing the highest amplitude 
at both salt concentrations and at each of the three elevated temperatures. Error bars represent one 
standard deviation (N=3). The mAbs were formulated at 5 mg/mL in 5 mM citrate-phosphate 






Figure 2.2: Flow chart of the various stresses performed on mAb-D to assess aggregation 
propensity by a variety of analytical methods (GroEL-BLI, SEC and MFI).   
Condition 1 was performed by rapidly dropping the pH of the solution from 7.4 to pH 4.0 or 5.0, 
holding for 1 min and then returning to pH 7.4 with the addition of 1 M phosphate buffer. For 
condition 2, thermal cycling was performed from 25°C to 45°C back to 25°C for times between 
15 min to 2 h at 25°C. Condition 3 consisted of addition of 0.5 M GdnHCl and incubation from 8 
min to 24 h.  Condition 4 was a 50°C incubation at various time points over 60 min. The 
aggregation of mAb-D solutions after exposure to each of the four conditions was examined using 
the GroEL-BLI biosensor, SEC, and MFI.  The mAbs were formulated at 5 mg/mL in 5 mM citrate-












Figure 2.3: GroEL-BLI biosensor analysis of mAb-D after exposure to different stresses a 50°C 
for 60 min.  
(A) Representative sensogram of mAb-D stressed at 50°C for 60 min in the GroEL-BLI assay 
showing association and dissociation phases, followed the addition of ATP and subsequent return 
to baseline (indicating specific GroEL binding; see text). B) Expanded view of the association and 
dissociation phases of the sensograms, and (C) Comparison of the binding amplitudes at the 
association phase of each of the mAb-D samples. Error bars represent one standard deviation 
(N=3).  The mAbs were formulated at 5 mg/mL in 5 mM citrate-phosphate buffer (CP) containing 






Figure 2.4: Effect of various stress conditions on mAb-D aggregation and particle formation as 
measured by SEC and MFI, respectively. 
 (A) Percent total aggregation (soluble and insoluble) of mAb-D before and after various stresses 
as measured by SEC, and (B) concentration of subvisible particles of mAb-D samples before and 
after various stresses as measured by MFI. Error bars represent one standard deviations (N=3). 
The mAbs were formulated at 5 mg/mL in 5 mM citrate-phosphate buffer (CP) containing 150 






Figure 2.5: Representative TEM images of GroEL alone and GroEL complexed with mAb-D 
stressed at 50°C for 60 min.  
Enlarged images of GroEL molecule (blue boxs) are shown to the right.  (A) GroEL alone in 
solution, (B) GroEL-mAb-D complexes formed in solution, (C) GroEL released from the BLI 
biosensor surface with 50 mM DTT, and (D) GroEL-stressed mAb-D complexes released from the 












Figure 2.6: GroEL-BLI biosensor analysis of a bispecific Ab (Bis-3) during exposure to 50°C over 
60 min.  
(A) An expanded association and dissociation phase of the sensograms of 50°C stressed Bis-3 
sample for 10 min in triplicates (green, red, and teal) and the unstressed sample (Blue) (B) An 
expanded association and dissociation phase of the sensograms of 50°C stressed Bis-3 sample for 
60 min in triplicate (green, red, and teal) and buffer (Blue), and (C) comparison of binding 
amplitudes in the GroEL-BLI assay of each of the Bis-3 samples at the association, dissociation, 
and final baseline return after ATP. The baseline binding amplitude returning to near zero values 
after ATP exposure indicates specific binding to GroEL. Error bars represent one standard 
deviation (N=3).  The Bis-3 was formulated at 0.2 mg/mL in a 20 mM sodium phosphate buffer 






Figure 2.7: Effect of elevated temperature (50°C) on aggregation and subvisible particle formation 
of the bispecific antibody Bis3 as measured by SEC and MFI, respectively.  
(A) Percent total aggregation (soluble and insoluble) of Bis-3 before and after temperature stress 
as measured by SEC, and (B) concentration of subvisible particles of Bis3 samples before and after 
thermal stress as measured by MFI from ≥2 <100 . Error bars represent one standard deviation 
(N=3). The Bis-3 was formulated at 0.2 mg/mL in a 20 mM sodium phosphate buffer containing 













Figure 2.8: Representative TEM images of GroEL alone and GroEL complexed to the bispecific 
antibody Bis-3 stressed at 50°C for 60 min.  
Representative enlarged images of GroEL from each TEM images (blue boxs) are shown to the 
right.  (A) GroEL alone in solution, (B) GroEL-stressed Bis-3 complexes formed in solution, (C) 
GroEL released from the BLI biosensor surface with 50 mM DTT, and (D) GroEL-stressed Bis-3 
























Supplementary Figure 2.1: Optimization of the GroEL-BLI biosensor method.  
The binding amplitudes of the different concentrations of b-GroEL was plotted vs BSA (1 mg/mL). 
Unstressed mAb-D was exposed to the GroEL loaded tip with 150 mM NaCl and the binding 








Supplementary Figure 2.2: Optimization of the GroEL-biosensor method.  
The binding amplitudes of the different concentrations of b-GroEL and BSA (1 mg/mL) were 
summed together for total binding onto streptavidin tips. Unstressed mAb-D was exposed to the 
GroEL loaded tip with 150 and 500 mM NaCl and the binding amplitude was measured. (n=2-4, 
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3.1 Introduction 
Monoclonal antibodies (mAbs) are an important class of therapeutic biomolecules and 
represent the majority of protein-based drug candidates currently in development.1,2 They are 
molecules that exhibit diverse conformational changes on a variety of timescales, and it is 
important from a pharmaceutical perspective to better understand the relationship between mAb 
conformational stability, conformational dynamics, and storage stability.3,4 A monoclonal 
antibody consists of 4 polypeptide chains connected by disulfide bonds, 2 heavy chains, and 2 light 
chains. The heavy chains form the tertiary structural domains CH1, CH2, CH3, and VH, whereas 
the light chains form the tertiary structural domains CL and VL.5 The higher order structure of a 
mAb consists of 2 antigen-binding domains (Fab) and 1 crystalizable domain (Fc). These structural 
elements are arranged in a “Y-shaped” structure, with the linkages between domains being highly 
flexible.6-8 Owing to the flexible linker, mAbs are highly dynamic molecules in solution, capable 
of movements ranging from small-scale fluctuations to large-scale rearrangements of the 
domains.7-9 
The physicochemical stability of mAbs is a critical factor to consider in the effort to develop 
high-quality efficacious drug candidates. A common strategy to improve long-term storage 
stability and to help protect protein pharmaceuticals from environmental stresses is to add one or 
more excipients to the formulation. Some commonly used excipients are salts, amino acids, 
carboxylic acids, carbohydrates, detergents, sugars, and polyols.10 Stabilizing excipients are 
generally identified through excipient screening, an empirical approach where physicochemical 
stability of the protein of interest is assessed in a large number of test formulations containing 
excipients of interest. Owing to the large numbers of test formulations, such physical stability 
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profiles are often measured rapidly by taking advantage of high-throughput screening methods 
employing multiple monitoring techniques.11-13  
Previous studies in our laboratory have explored the interrelationships between mAb 
conformational dynamics as measured by hydrogen exchange mass spectrometry (HX-MS), mAb 
aggregation propensity and conformational stability, and the influence of various pharmaceutical 
excipients and other additives on each of these parameters. Similarly, the potential and utility for 
HXMS to probe for mAb conformational dynamics in pharmaceutical formulations was recently 
reviewed.4 It has been shown that backbone dynamics can be significantly altered in specific 
regions of different mAbs due to varying solution conditions, site-directed mutations, and chemical 
modifications. In addition, other studies have successfully used HX-MS to characterize 
aggregation pathways14 and propensity,15 and to characterize higher order structural differences 
resulting from point mutations16 or between biophysically similar molecules.17 It has been shown 
that increased conformational stability and reduced aggregation propensity correlate with small 
decreases globally in relative local flexibility. In addition, large increases in relative local 
flexibility in the CH2 domain, HC 241-251, correlated with decreased conformational stability and 
increased aggregation across several different IgG1mAbs. The ability of HX-MS to monitor 
backbone dynamics in differing formulations has thus been proposed to be a potential analytical 
tool for formulation scientists. As opposed to conducting accelerated and real-time stability studies 
where results take months to years to generate, HXMS could potentially be used to rapidly assess 
(using minimal material) rigidifications or perturbations in protein structure in the presence of 




   
To further expand this idea using a case study, HX-MS was used in this work to monitor 
conformational dynamics of an IgG4 mAb (mAb-D) in the presence of various additives, including 
pharmaceutical excipients as well as known protein destabilizers (used as controls), and the results 
were correlated with traditional biophysical techniques. To the best of our knowledge, this report 
is the first-time HX-MS with an IgG4 mAb that has been performed in the context of formulation 
development. In addition, although HX-MS has the potential to be an important tool for excipient 
screening, one barrier to implementing this approach is that differing excipient solutions can alter 
chemical exchange rates in hydrogen exchange (HX) experiments, rendering HX results from 
differing formulations difficult to interpret due to combined effects of additives on the protein's 
conformational flexibility as well as the inherent chemical exchange rate. Recently, we have 
validated a procedure to correct HX-MS data for these differences with minimal additional 
experimentation.18 To more extensively evaluate the potential applicability of HX-MS for 
excipient screening as part of the formulation development of therapeutic mAb candidates, the 
effect of various additives on an IgG4 mAb (mAb-D) was evaluated using traditional approaches 
with standard biophysical techniques: forced degradation study using DSC (conformational 
stability), and accelerated stability studies using size exclusion chromatography (SEC) and 
microflow imaging (MFI; to monitor aggregation and particle formation, respectively). The results 
from the biophysical measurements are compared with those obtained from HX-MS (using a 
streamlined version of the methodology) to determine if correlations can be drawn between the 
effects of the additives on mAb-D stability as detected by the different approaches/methods. 
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3.2 Materials and Methods 
3.2.1 Materials 
The IgG4 (mAb-D, ~145,000 Da, calculated pI 7.07) was provided by MedImmune 
(Gaithersburg, MD) at a concentration of 50 mg/mL in 50-mM acetate, 100-mM NaCl, pH 5.5. 
After dialysis, the mAb concentration was quantified with an Agilent 8453 UV-visible 
spectrophotometer (Palo Alto, CA). Triplicate samples were prepared by diluting the stock mAb 
solution 1:50 into buffer. The intensity at 280 nm was averaged for over triplicate analyses. An 
extinction coefficient of1.68 (mg/mL)1 cm1 was used to calculate the protein concentration. 
Trehalose dihydrate was purchased from Pfanstiehl (Waukegan, IL). Arginine 
monohydrochloride, deuterium oxide (99 + %D), D-methionine, D-mannitol, porcine pepsin, 
sodium sulfate, TWEEN® 20, and liquid chromatography grade acetic acid and phosphoric acid 
were purchased from Sigma-Aldrich (St. Louis, MO). Premiumgrade tris (2-carboxyethyl) 
phosphine hydrochloride and liquid chromatography-mass spectrometry (LC-MS) grade formic 
acid (+99%) were purchased from Thermo Scientific (Rockford, IL). Sodium phosphate dibasic 
(anhydrous), citric acid (anhydrous), and sodium thiocyanate were purchased from Acros Organics 
(Fair Lawn, NJ). Sodium chloride, guanidine hydrochloride (Gdn-HCl), LC-MS grade water, 
acetonitrile, and isopropanol were purchased from Fisher Scientific (Fair Lawn, NJ). For stability 
studies, glass vials used were from West Pharmaceuticals, (3-mLVial, Fiolax Clear, Item#6800-




   
3.2.2 Methods 
3.2.2.1 Sample Preparation 
Stock solutions of mAb-D were dialyzed into 5-mM citratephosphate (CP) buffer at pH 6.5 
or 7.4, with or without 150-mM NaCl. Dialysis was performed using Slide-A-Lyzer cassettes 
(30,000 MWCO; Thermo Fisher Scientific, Waltham, MA) with a ratio of sample to dialysate at 
least 1:500, 3 times with at least 4 h between buffer changes. A stock solution of each additive was 
also prepared in 5-mM CP at pH 6.5 or 7.4, with or without NaCl, at a higher concentration than 
desired in the final sample. The mAb-D stock solution was diluted using the corresponding CP 
buffer and the appropriate additive stock solution to achieve a protein concentration of 5 mg/mL 
and the desired additive concentration (e.g., 0.3-M arginine, 0.3-M guanidine, 0.3-M sodium 
thiocyanate, 0.3-M sodium sulfate, 0.2-M methionine, 0.4-M trehalose, 0.8-M mannitol, or 0.05% 
polysorbate 20 [PS20]). Control samples of mAb-D were prepared using only CP buffer at the 
appropriate pH, with or without NaCl. After addition ofmAb-D and the additive, the pH value of 
the samples was adjusted (using acid and base) to be within 0.1 pH unit of the desired pH. Buffer 
controls were also prepared in the same manner without addition of mAb-D. Both mAb-D and 
buffer control samples were placed in a laminar flow hood and sterile filtered using 0.22-mm 
syringe filters (Millipore, Billerica, MA). Aliquots, 1.5 mL, were placed into 3-mL type I 
borosilicate glass vials and capped with rubber stoppers and an aluminum overseal (West 
Pharmaceutical Services, Exton, PA). Before use, glass vials were autoclaved in a large beaker 
and allowed to cool overnight.  
For accelerated stability studies, samples of mAb-D were stored at 4°C and 50°C. 
Triplicate samples from 3 separate vials were analyzed by SEC and MFI at time 0 and after storage 
for 2 weeks at 4°C and after 1 and 2 weeks at 50°C. Triplicate buffer samples were prepared and 
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analyzed at time 0 by MFI. For stirring stress studies, mAb-D and buffer control samples were 
stressed by placing a small pivot-ring-free stir bar (7 x 2mm flea micro; Bel-ArteSP Scienceware, 
Wayne, NJ) inside each 3-mL vial prepared as described above and stirring on setting 5 at 25°C 
for 30 min using a ReactiTherm III (Thermo Scientific). No vortex was observed under these 
conditions.  
For the HX-MS studies, additives which contain exchangeable hydrogens were fully 
deuterated before sample preparation. Each additive was prepared in D2O at a slightly higher than 
final concentration (to account for dilution effects) and allowed to incubate for 30 min. The 
additive solution was vacuum dried at 30°C for 48 h. Two additional cycles of dissolution in D2O 
followed by evaporation were performed. The final powder was dissolved in the appropriate 
volume of CP buffer prepared using D2O. The pD was adjusted 6.5 or 7.4 with deuterium chloride 
or deuterium oxide. To account for the offset associated with measuring pD with a pH meter, 
solutions were adjusted to a pH 0.4 units lower than the desired value.19 
3.2.2.2 Size Exclusion Chromatography 
SEC was performed on all samples using a 7.8 mm x 30 cm TOSOH TSK-Gel BioAssist 
G3SWXL column and 6.0 mm ID x 4.0 cm TSK-Gel SWXL guard column (TOSOH Biosciences, 
King of Prussia, PA), with UV detection at 214 and 280 nm using a prominence high performance 
liquid chromatography system (Shimadzu, Tokyo, Japan) equipped with a photodiode array 
detector. Before analysis, the column was pre-equilibrated with 90 mL of mobile phase, composed 
of 0.2-M sodium phosphate, pH 6.8. Removal of insoluble aggregates from the stressed samples 
was accomplished by centrifugation at 14,000 x g for 5 min before injection onto the column. 
Molecular weight standards (Biorad Laboratories, Hercules, CA) were used to assess the efficiency 
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of separation. Peaks corresponding to aggregates, monomer, and fragments were selected and 
quantified using the LC Solutions data analysis package (Shimadzu). 
3.2.2.3 Microflow Imaging 
A DPA-4200 MFI system (Protein Simple, Santa Clara, CA) was used to count and 
image subvisible particles in the size range of 2-100 mm. The instrument was calibrated using 
10-mm polystyrene particle standards (Duke Standards; Thermo Fisher Scientific, Waltham, 
MA) before measurements. Measurements were made in triplicate at ambient temperature for all 
samples with no centrifugation before analysis. The cell was flushed with particle free water and 
illumination was optimized using particle-free water before all measurements. The samples were 
carefully drawn up in a low protein binding, filter-tip pipette (Neptune Scientific) and analyzed 
using a flow rate of 0.2 mL/min. The purge volume for each measurement was 0.4 and 0.6 mL of 
sample was analyzed. Particles with circularity greater than 0.95 were filtered out before analysis 
to avoid counting air bubbles as protein particles. 
3.2.2.4 Differential Scanning Calorimetry 
Differential scanning calorimetry was performed using a Microcal VP-Capillary DSC 
equipped withanautosampler (MicroCal, Northampton, MA). Samples were heated from 15°C to 
85°C using a scan rate of 1°C/min. Reference thermograms of buffer containing the respective 
additives were subtracted from the thermograms of mAb-D in the presence of the additive. Each 
mAb-D sample was analyzed in triplicate, except mAb-D prepared in Mannitol without NaCl at 
pH 7.4 in which only 1 and 2 thermograms were used for analysis, respectively. The data were 
fitted to a multistate model with 2 transitions using the MicroCal LLC DSC plug-in for the Origin 
7.0 software. The onset temperature (Tonset) was determined using the temperature at which the 
heat capacity (Cp) reached 500 cal mol-1 C-1 for the first thermal transition. 
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3.2.2.5 Hydrogen Exchange Mass Spectrometry 
HX-MS experiments were performed using a QTOF mass spectrometer (Agilent 6530, 
Santa Clara, CA) as described previously.20 Three microliters of mAb-D prepared at 40 mg/mL 
were labeled with deuterium at 25°C using 21 mL of deuterated buffer. The pD of all labeling 
buffers was adjusted to 6.5 or 7.4 with deuterium chloride or deuterium oxide, using the offset 
associated with measuring pD with a pH meter, solutions were adjusted to a pH 0.4 units lower 
than the desired value.19 Samples of mAb-D were subjected to the exchange conditions for either 
1000 s (pH 6.5) or 125 s (pH 7.4). Incubation at each time point was completed in triplicate. After 
incubation, the HX reaction was quenched using a 1:1 dilution into quench buffer (4-M Gdn-HCl, 
0.2-M phosphate, 0.5-M tris (2-carboxyethyl) phosphine hydrochloride, pH 2.5) at 1°C for 60 s. 
Twenty-five microliters of quenched mAb-D was injected into the sample loop of a refrigerated 
compartment (maintained at 0°C) containing a pepsin column (50 X 2.1 mm, pepsin was 
immobilized and packed as described previously4), reversed phase trap (Poroshell 120 EC-C8, 2.1 
X 5 mm, 2.7 micron particle diameter; Agilent), and reversed phase column (Zorbax 300SB-C18 
2.1 X 50 mm, 1.8 micron particle diameter; Agilent).  
MS/MS analysis was used to generate a peptide map of mAb-D consisting of 360 peptides 
with 97% sequence coverage of the light chain and 98% sequence coverage of the heavy chain. 
Comprehensive analysis of all of the HX-MS data from all peptides in all formulations would 
substantially diminish throughput without necessarily adding additional value for this application. 
As such, from this set of 360 peptides, a subset of 40 peptides was chosen for analysis. To generate 
this subset of peptides, a similar number of peptides were chosen from each domain of mAb-D, 
with some peptides exhibiting differences in deuterium accessibility in the presence of additives 
(based on screening studies) and others showing no differences in deuterium uptake. Peptides 
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crossing domain boundaries were assigned to the domain belonging to the majority of its residues. 
The HX data were processed using HDExaminer software (Sierra Analytics, Modesto, CA). 
Difference plots for each peptide were generated by subtracting the mass of each peptide after 
labeling in CP control buffer from that of the peptide when labeled in the additive containing 
buffer. For some figures, the y axis is displayed as “fractional uptake,” here defined as the uptake 
in Da divided by the number of residues in the peptide.  
While HX-MS has the potential to be a useful tool for screening of additives for mAb 
stability effects, a barrier to this type of work is the propensity of differing excipient solutions to 
alter chemical exchange rates in HX experiments, rendering varying results from differing 
formulations. Recently, we have outlined a procedure to correct HX-MS data for these potential 
differences with minimal additional experimentation,18 briefly, differences in chemical exchange 
rates in different formulations are determined using a short reporter peptide having the sequence 
YPI. Then a correction from the YPI data is determined that is used to empirically correct the HX 
data for differences in the intrinsic HX rate caused by the excipients, ensuring that any differences 
remaining are a function of protein dynamics.  
3.3 Results 
3.3.1 Screening of mAb-D for Stabilizing Additives by DSC, SEC, and MFI 
Eight different additives were selected for evaluation in this work: trehalose, mannitol, 
methionine, arginine hydrochloride, sodium sulfate, sodium thiocyanate, and Gdn-HCl. The 
additives cover different classes of pharmaceutical excipients including salts, amino acids, sugars, 
polyols, and detergents, or have wellestablished effects including both destabilization and 
stabilization of proteins.10 As an initial step in better understanding the effect of these 8 different 
additives on the stability ofan IgG4 mAb (mAb-D), differential scanning calorimetry was 
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performed to evaluate their effects on the overall conformational stability of the mAb-D. Figure 
1a shows representative DSC thermograms of mAb-D at pH 6.5 with 150-mM NaCl in the control 
buffer and with the control buffer containing a stabilizing and a destabilizing additive. The DSC 
thermograms were fitted to 2 thermal transitions (Tm1 and Tm2) as well as a thermal onset value 
(Tonset) as shown in Figure 1b. The Tm1, corresponds to the CH2 domain, and is likely to be 
important for the initiation of destabilization and aggregation as its unfolding occurs at the lowest 
temperature. Figure 2 shows the effect of the 8 additives on the thermal transitions of mAb-D at 
different solution pH values in the presence and absence of NaCl. It can be seen that thermal 
transition values of mAb-D trend somewhat higher at pH 7.4 compared with pH 6.5 and that the 
addition of NaCl had a minimal effect. In contrast, thiocyanate, guanidine, and arginine had a 
notable destabilizing effect, whereas mannitol and trehalose had a stabilizing effect. Methionine, 
PS20, and sodium sulfate had no major effects compared with the control mAb-D solution. 
The effect of the same formulations on the aggregation propensity of mAb-D during 
storage at elevated temperatures was then evaluated by a combination of SEC and MFI analysis. 
SEC was performed on each of the mAb-D samples with and without various additives before and 
after incubation for 14 days at 50°C. Figure 3 shows the effect of the additives on the total 
aggregate formation (soluble and insoluble aggregation) of mAb-D following heat stress. As 
shown in Figure 3a for mAb-D in control buffer alone, on heat stress, the formation of aggregate 
and fragment species occurs, as well as the loss of total area. The total amount of aggregation is 
defined as the sum of aggregate peaks (soluble aggregates) and the loss of total area (referred to 
here as insoluble aggregates; caused either by formation of aggregates too large to enter the column 
or nonspecific binding to the column which may be related to conformational changes). Also 
shown in Figure 3a is that additives in the control buffer can either alleviate or promote the 
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formation of aggregates. Figure 3b shows the additives ranked by their propensity to promote 
aggregation. It can be seen that aggregation trends higher at pH 7.4 compared with pH 6.5, and 
that the absence of NaCl led to increased aggregation of mAb-D. The addition of thiocyanate, 
guanidine, and arginine had a notable destabilizing effect with large increases in aggregate 
formation. Mannitol had a stabilizing effect. Methionine, PS20, sodium sulfate, and trehalose had 
no major effects compared with the control mAb-D solution. 
The same samples were also analyzed by MFI for formation of subvisible particles before 
and after incubation for 14 days at 50°C and after stirring stress. For both stresses, the total 
subvisible particle concentration before stress for each of the additive solutions was below 2500 
particles/mL (Supplemental Fig. S1a). For conditions with 150-mM salt, the total particle 
concentrations of the mAb-D samples before stress were below 16,000 particles/mL for all 
additives, except sulfate, where total particle concentration before stress was higher, 
approximately 105 particles/mL (see Supplemental Fig. S1b). For samples without salt, the total 
particle concentrations before stress were higher but were still below 35,000 particles/mL for all 
samples (Supplemental Fig. S1b). Particle size distributions in mAb-D samples before stress, in 
general, have the highest concentration of particles in the smallest size bin and concentrations 
decrease with particle size (Supplemental Fig. S2). Figure 4a shows the effects of the additives on 
the total subvisible particle formation by mAb-D following heat stress. Under these conditions, 
solution pH and NaCl had a complex effect on mAb-D subvisible particle formation with both 
stabilizing and destabilizing effects caused by the different additives. Thiocyanate, guanidine, 
arginine, and to a lesser extent sodium sulfate, had destabilizing effects leading to increases in 
subvisible particle formation. In contrast, methionine, trehalose, mannitol, and PS20 had no major 
effects compared with the control mAb-D solution with low concentrations of subvisible particles 
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after stress. For most samples, although total particle concentrations increased on heat stress, the 
distribution ofparticles among the different size bins did not change (see Supplemental Fig. S3). 
Exceptions are the additives arginine and Gdn-HCl at pH 6.5 + NaCl, where the concentration of 
particles in the 5-10 mm size bin increased relative to other bins (when compared to time 0) and 
guanidine at pH 7.4 without NaCl, where particle concentrations in the 5-10, 10-15, 15-25, and 
25-40 µm size bin increased relative to other bins when compared with time 0. 
The effect of the same set of the 8 additives on the physical stability of mAb-D after stir 
stress was then evaluated. The results of MFI analysis of the number and size range of subvisible 
particles formed because of stirring are shown in Figure 4b. Under stir stress conditions, solution 
pH and NaCl also had a complex effect on mAbD subvisible particle formation with both 
stabilizing and destabilizing effects caused by different additives. Gdn-HCl had an effect on the 
stressed mAb-D samples leading to increases in subvisible particle formation. In contrast, sulfate 
and methionine had no notable effects compared with mAb-D control buffer. In addition, mAb-D 
solutions containing thiocyanate, arginine, trehalose, mannitol, and PS20 all displayed low 
concentrations of subvisible particles. For all samples, the particle size distributions on stir stress 
were altered compared with time 0, with particle concentrations in the smallest (2-5 µm) size bin 
increasing relative to other size bins. 
3.3.2 Screening of Additives for Effects on mAb-D Local Flexibility by HX-MS 
A peptide map was developed for mAb-D consisting of 360 peptides with 97% sequence 
coverage of the light chain and 98% sequence coverage of the heavy chain. To reduce analysis 
load, a subset of 40 peptides were chosen for analysis such that a similar number of peptides 
covered each domain of mAb-D. HX was then measured for mAb-D in 5-mM CP and mAb-D in 
5-mM CP with each 1 of the 8 additives, at the salt and pH conditions described previously. After 
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the reaction was quenched at different exchange times, peptic peptides were generated and 
analyzed by LC-MS to determine deuterium uptake. A chemical exchange correction factor was 
established for all solution conditions as described in methods.18 Figure 5a-5c show plots of the 
difference (following additive correction) between HX by mAb-D with additives minus mAb-D 
in control buffers.  
Figure 5 demonstrates that additives can have a substantial effect on HX results with mAb-
D. For example, the additives arginine, guanidine, sulfate, and thiocyanate caused substantial 
increases in HX in many peptide segments, relative to mAb-D in the corresponding control buffer, 
indicating increases in backbone flexibility. Concurrent with these substantial increases in 
flexibility for specific peptide segments was a trend of small increases in flexibility in the majority 
of peptide segments for those same additives except thiocyanate. Mannitol, methionine (for pD 
7.4 with NaCl), and PS20 (for pD 6.5 + NaCl pD 7.4 + NaCl) caused slight global increases in 
flexibility without the substantial localized increases that were observed in the presence of 
arginine, guanidine, sulfate, and thiocyanate. The opposite effect was also noted for some 
additives, with a global decrease in flexibility for methionine (pD 6.5 + NaCl and pD 7.4) and 
trehalose. In general, increased pH (comparing left column to middle column) had no notable effect 
on flexibility with the exception of methionine where increased pH caused a slight global increase 
in flexibility and thiocyanate where increased pH caused a slight global decrease in flexibility. 
Addition of salt (comparing right column to middle column) had no notable effect for arginine, 
guanidine, mannitol, and sulfate, while resulting in a slight increase in flexibility for methionine, 
PS20, and thiocyanate, and a slight decrease in flexibility for trehalose. For visualization of these 
HX observations, the most substantial additive effects on local flexibility of mAb-D were mapped 
onto a homology model of the antibody (based on PDB 5DK321) displayed in Figure 6. 
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3.4 Discussion 
The main goal of this study was to correlate the HX data collected with mAb-D in the 
presence of various additives with both conformational stability data (DSC) and the propensity of 
mAb-D to form aggregates and particulates over time (as measured by an accelerated stability 
study combined with SEC and MFI analysis). We aimed to determine what aspects of mAb-D 
stability (from a pharmaceutical perspective) can be most directly reported on by local flexibility 
analysis from HX-MS, and to evaluate whether a streamlined version of HX-MS can serve as a 
useful screening technique to identify stabilizing excipients. If adequate correlates can be found, 
HX-MS may serve as a useful technique to predict aspects of mAb storage stability in different 
solutions and thus has the potential (given additional correlations with more comprehensive 
stability data sets as part of future work) to be used as an alternative to accelerated stability 
studies.22 To this end, as a first step, we focused on various approaches to analyze the HX-MS data 
generated with mAb-D in the presence of various additives (e.g., commonly used pharmaceutical 
excipients as well as control additives known to destabilize proteins) to provide an overall 
description of the trends (in terms of excipient effects) that can be more easily compared with 
mAb-D stability data collected by more traditional approaches, as outlined below. 
3.4.1 Traditional Additive Screening Studies With mAb-D Using DSC, SEC, and MFI 
Results from DSC studies (Fig. 2) reveal that mAb-D is conformationally destabilized in the 
presence of guanidine, thiocyanate, and arginine, listed from greatest to least destabilizer. In 
addition, trehalose proved to be the most notable conformational stabilizer of mAb-D. In general, 
increased pH (comparing blue through orange bars) resulted in a trend (although within error) 
toward an increase in thermal stability for mAb-D in all additive solutions, with the exception of 
thiocyanate and guanidine, where increased pH slightly decreased thermal stability (also within 
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error). Addition of salt (comparing black and gray bars) in general caused a slight decrease in 
thermal stability for mAb-D in all additive solutions (within error) with the exception of arginine, 
where thermal stability slightly increased (within error) on addition of salt. 
Results from SEC studies of aggregation after heat stress (Fig. 3) reveal the same trend, with 
mAb-D exhibiting the greatest increase in percent aggregation in the presence of guanidine, 
thiocyanate, and arginine, listed from greatest aggregation to least. In addition, results on 
subvisible particle formation from MFI studies (Fig. 4) following heat stress further confirm this 
trend, with mAb-D in the presence of guanidine, thiocyanate, and arginine showing the greatest 
total particle concentrations, listed in order from greatest total particle concentration to least. 
Trehalose was not a significant stabilizer in aggregation due to heat stress studies. Results from 
SEC and MFI studies of aggregation after heat stress reveal that increased solution pH values 
(comparing blue to gray bars, Figs. 3b and 4a) resulted in a substantial increase in aggregation for 
destabilizing additives, yet values were within error for stabilizing additives. Addition of salt 
(comparing black and gray bars) resulted in a substantial decrease in mAb-D aggregation due to 
heat stress for all additive solutions, both stabilizing and destabilizing. These results indicate that 
mAb-D is less colloidally stable at pH values above the pI ofmAb-D (~7.07, estimated based on 
sequence) where mAb-D is net negatively charged, and that addition ofsalt alleviates this colloidal 
instability, perhaps by screening of electrostatic interactions. 
In summary, the results from heat stress of mAb-D in the presence of the 8 additives indicate 
that conformational destabilization is likely an important step in the pathway to aggregation due 
to heat stress for mAb-D. In the first step of one of the main aggregation pathways of mAbs 
proposed by Roberts et al.,23,24 and confirmed by others,25 the native monomers become partially 
unfolded and begin to associate into loose clusters. In the second step, within these clusters the 
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now exposed aggregation hotspots can align and lead to the formation of irreversible aggregates. 
It is likely that the DSC results report on this first conformational destabilization step thus its 
apparent correlation with aggregation due to heat stress. 
In general, the results of aggregation due to stir stress (Fig. 4b) do not correlate with DSC 
results (in contrast to the results described above for heat stress). Most notably, the additives 
thiocyanate and arginine, while significant destabilizers in DSC (Fig. 2) and aggregation due to 
heat stress (Figs. 3b and 4a) studies, are significant stabilizers for aggregation due to stir stress. 
These results indicate that aggregation due to stir stress does not follow the same pathway as 
aggregation due to heat stress. It is likely that the pathway responsible for aggregation due to 
stir stress instead involves unfolding and nucleation on the liquid-solid or liquid-air interfaces,26 
thus the ability of surfactants such as PS20 and zwitterions such as arginine to act as stabilizers. 
3.4.2 Additive Screening Studies With mAb-D Using HX-MS 
To correlate these results with the HX data, we must also treat the HX data to obtain an 
overall trend. Here we do so by reducing the dimensionality of the HX data in several ways. 
First, we restrict our view to a CH2 aggregation hotspot region identified previously in our 
laboratory in IgG1 mAbs27 (Fig. 7). This region covers residues 241-251 in the heavy chain and 
contains several hydrophobic residues that pack against glycans in the structure of IgG1 mAbs. 
This region corresponds to residues 250-260 for mAb-D. In general, the CH2 peptide was 
significantly more flexible in the presence of thiocyanate, guanidine, arginine, and sulfate than 
in control buffer, listed in that order from greatest to least increase. In comparison to the control 
buffer alone, PS20, mannitol, and methionine had no effect within experimental error. Finally, 
the CH2 peptide was significantly more rigid in the presence of trehalose. This additive trend 
most closely matches that of the conformational stability of mAb-D as measured by DSC, 
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suggesting that HX in this case is reporting most directly on conformational stability. This trend 
also matches that of mAb-D aggregation due to heat stress, and likely this correlation exists for 
the reason mentioned previously, that conformational destabilization is an important step in the 
pathway to aggregation due to heat stress for mAb-D, a common aggregation pathway for 
mAbs.24,28 
We also averaged the HX data over the 5 peptides from each domain with the greatest 
magnitude (absolute value) of fractional exchange difference, chosen from among the 40 
peptides seen in Figure 5 (Fig. 8). No trends were found in the effects of additives matching 
those seen in conformational stability and aggregation due to heat stress, with the exception of 
the CH2 domain. The trend in the CH2 domain explicable by the influence of the CH2 
aggregation hotspot peptide discussed previously. 
In addition, we restricted our view of the HX data to one peptide (chosen from the subset 
of 40) spanning each complementarity-determining region (CDR) region (Fig. 9), as well as to 
the average HX difference over the whole protein (Fig. 10). No correlations were found when 
examining the HX data from the CDR regions of mAb-D (Fig. 9) or when examining the HX 
data averaged over the whole protein (Fig. 10). This result may seem at odds with studies where 
the nature of the CDR loops are found to be important in the aggregation pathway of a mAb29; 
however, it is possible that for mAb-D, the composition of the CDR loops are not prone to induce 
aggregation, and thus the observed CH2 destabilization (observed by HX within an aggregation 
“hotspot”, residues 250-260 for mAb-D) is the rate-limiting step in the aggregation pathway for 
this particular mAb. The effects of additives on the whole protein's average flexibility can be 
seen in Figure 10, showing fractional uptake averaged among all peptides. The overall trends in 
the HX are that guanidine, sulfate, arginine, mannitol, and PS20 caused an increase in average 
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global hydrogen exchange across the entire protein. Both thiocyanate and methionine had no 
effect on the average global exchange, whereas trehalose caused a decrease in average global 
exchange. 
In contrast to heat stress, where a good correlation was observed between HX of the 
aggregation hotspot (and entire CH2 domain) and mAb-D physical stability, no such correlation 
was found between HX and aggregation due to stir stress. Likely this is because the aggregation 
pathway for stir stress is an interfacial phenomenon that does not involve steps that HX-MS can 
report on directly. It has been established that mAbs often follow differing aggregation pathways 
depending on the stress applied.28 Here, an apparent trend is that amphipathic molecules capable 
of acting as surfactants (e.g., PS20) tend to be stabilizers in aggregation due to stir stress, 
indicating that the pathway for aggregation due to stir stress likely involves accumulation of 
protein at the air/water interface, another common pathway.28 
Results from averaged HX-MS results and biophysical studies, as a function of heat and stir 
stresses, are summarized in Figure 11, where additives are colored based on HX-MS results for 
the CH2 aggregation hotspot peptides. In general, additives that promote flexibility in a hotspot 
peptide (yellow) of mAb-D tend to be destabilizing in terms of conformation (measured by DSC) 
and aggregation propensity during storage at elevated temperatures (as measured by SEC). The 
exception to this trend is sulfate, which caused increased flexibility in HX-MS studies in the 
hotspot region of mAb-D, but was not observed to be a destabilizer in the physical stability 
studies. In the HX-MS studies, sulfate increased flexibility to a lesser extent than guanidine, 
thiocyanate, or arginine. It is possible that the smaller increase in flexibility is not sufficient to 
destabilize mAb-D during storage, or that the destabilization effect would be revealed only with 
longer incubation times. It is also possible that the destabilization by sulfate is more complex 
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phenomena given that sulfate is a divalent anion (e.g., charge shielding effects). In contrast, no 
such consistent trend between additive effects on mAb-D as measured by HX-MS, DSC, and 
SEC studies were observed when stirring is the stress. 
 
Table 3.1: Percent monomer content by SEC analysis  
Mixture Average Monomer Percent 
HM-Fc control 99.7±0.0 
Man5-Fc Control 99.7±0.1 
GlcNAc-Fc Control 99.8±0.1 
N297Q-Fc Control 97.8±0.0 
Mixture 1 99.7±0.0 
Mixture 2 99.6±0.1 
Mixture 3 98.9±0.1 
Mixture 4 99.6±0.1 
Mixture 5 99.6±0.0 
Mixture 6 99.4±0.1 







   
 
 
Figure 3.1: Differential scanning calorimetry studies show that additives affect conformational 
stability of mAb-D.  
(a) Representative DSC thermograms of mAb-D in CP buffer, pH 6.0 alone (control) and in the 
same buffer in the presence of thiocyanate and trehalose. (b) DSC data were fitted to a multistate 
model with 2 transitions, with the midpoints of each transition, Tm1 and Tm2, identified. Also 




   
 
Figure 3.2: Effect of additives on the thermal transition values of mAb-D (Tonset, Tm1, and Tm2) 
as measured by DSC: (a) Tonset, (b) Tm1, and (c) Tm2 values are shown.  
Additives are ordered from lowest to highest transition temperature of mAb-D, sorted by the 
average of the 3 different solution conditions. Samples were prepared in CP buffer at indicated 
pH values in the presence or absence of NaCl (pH 7.4) and different additives (see Materials and 




   
 
 
Figure 3.3: Effect of additives on total aggregate formation of mAb-D following incubation at 
50°C for 14 days as measured by SEC. 
(a) Representative SEC profiles of mAb-D before and after accelerated stability study. (b) Rank 
ordering of additives from the highest to lowest percent aggregation of mAb-D in 3 different 
solution conditions. Samples were prepared in CP buffer at indicated pH values in the presence or 
absence of NaCl (pH 7.4) and different additives (see Materials and Methods section for 
concentrations). Error bars represent the sample standard deviation for triplicate measurements. 
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Figure 3.4: Effect of additives on subvisible particle formation by mAb-D as measured by MFI 
following incubation (a) at 50°C for 14 days, and (b) after stirring stress.  
Subvisible particles are defined as particle sized between 1 and 100 μm in diameter. Additives are 
ordered from the highest to the lowest total particle concentration for mAb-D in 3 different 
solutions. Samples were prepared in CP buffer at indicated pH values in the presence or absence 
of NaCl (pH 7.4) and different additives (see Materials and Methods section for concentrations). 
Error bars represent the sample standard deviation for triplicate measurements. 
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Figure 3.5: Difference plots exhibiting the differential fractional exchange by mAb-D in the 
presence of additives (vs. control buffer) 
in (a) CP buffer pH 6.5 with 150-mM NaCl, (b) CP buffer at pH 7.4 with 150-mM NaCl, and (c) 
CP buffer at pH 7.4 in the absence of salt, following correction for differences in chemical 
exchange rates (see Materials and Methods section). Fractional uptake is shown for all peptides; 
positive values indicate additive addition caused in increase in hydrogen exchange by the peptide 
segments, whereas negative values indicates decreased hydrogen exchange. Difference plots are 
shown for arginine, guanidine, mannitol, methionine, PS20, sulfate, thiocyanate, and trehalose. 
 
Figure 3.6: Homology model of mAb-D showing effects of selected additives on the local 
flexibility of mAb-D as measured by HX-MS.  
Regions shown in yellow (peptides 6, 13, 14, and 28; residues HC 112-115, HC 243-260, and LC 
37-47) exhibited substantial increases in hydrogen exchange in the presence of thiocyanate, 
arginine, and guanidine. Regions in blue (peptide 1, HC 30-35) exhibited substantial decreases in 
hydrogen exchange in the presence of thiocyanate and sulfate. The mAb homology model is based 
on PDB 5DK3.21  
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Figure 3.7: Fractional exchange differences in the mAb-D CH2 aggregation hotspot peptide (heavy 
chain residues 250-260) in the presence of the indicated additives.  
Data are shown for mAb-D at pH 6.5 with 150-mM NaCl and pH 7.4 with and without 150-mM 
NaCl following correction for differences in chemical exchange rates (see Materials and 
Methods section). Additives are ordered by the average differential deuterium uptake averaged 
among the 3 conditions from greatest to least. Error bars represent the sample standard deviation 
for triplicate measurements propagated over the differences. 
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Figure 3.8: The effect of additives on the domain-averaged fractional exchange differences in 
mAb-D domains.  
Data are shown for the (a) VH, (b) CH1, (c) CH2, (d) CH3, (e) VL, and (f) CL domains of mAb-D in 
the presence of the indicated additive (vs. control buffer) at pH 6.5 with 150-mM NaCl and pH 7.4 
with and without 150-mM NaCl following correction for differences in chemical exchange rates 
(see Materials and Methods section). Fractional uptake difference was averaged over the 5 
peptides (peptides 1-4 and 6 for VH, 8-12 for CH1, 13, 14, and 16-18 for CH2, 21-25 for CH3, 
27-31 for VL, and 34, 35, and 38-40 for CL) showing the greatest magnitude of effect in the data 
set (the same group of 5 for all additives and conditions). Additives are ordered by the average 
differential deuterium uptake averaged among the 3 conditions from greatest to least. Error bars 
represent the sample standard deviation for triplicate measurements propagated over the average 
of the differences. 
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Figure 3.9: Fractional exchange differences in the CDR regions of mAb-D in presence of various 
additives.  
Data are shown for (a, peptide 1) CDR-H1, (b, peptide 3) CDR-H2, (c, peptide 6) CDR-H3, (d, 
peptide 27) CDR-L1, (e, peptide 29) CDR-L2, and (f, peptide 31) CDR-L3 in the presence of the 
indicated additive (vs. control buffer) at pH 6.5 with 150-mM NaCl and pH 7.4 with and without 
150-mM NaCl following correction for differences in chemical exchange rates (see Materials and 
Methods section). Additives are ordered by the average differential deuterium uptake averaged 
among the 3 conditions from greatest to least. Error bars represent the sample standard deviation 




   
 
Figure 3.10: The effect of additives on the fractional exchange difference averaged across all 
peptides in mAb-D.  
Data are shown for mAb-D in the presence of the indicated additive (vs. control buffer) at pH 6.5 
with 150-mM NaCl and pH 7.4 with and without 150-mM NaCl following correction for 
differences in chemical exchange rates (see Materials and Methods section). Additives are ordered 
by the average fractional exchange difference averaged among the 3 conditions from greatest to 
least. Error bars represent the sample standard deviation for triplicate measurements, propagated 
over the average of the differences. 
109 
  
   
 
Figure 3.11: Generalized conclusions from biophysical and HX-MS studies of the effect of 
additives on mAb-D physical stability profile and local flexibility in presence of different 
additives.  
(a) In the first section, additives are placed in 1 of 3 categories based on conclusions from HX-MS 
data; increased flexibility, within error of control, and reduced flexibility. (b, c) In subsequent 
sections, additives are placed in 1 of 3 categories based on conclusions from biophysical data; 
destabilizing, within error or control, and stabilizing. Additives are colored based on HX-MS 
results for hotspot peptide (first column) and retained in other columns to highlight commonalities 
(e.g., guanidine ranking highly in all studies). 
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Supplementary Figure 3.1: Total subvisible particle concentrations for additive and control 
buffers and mAb-D samples in the corresponding buffers at time zero (before stress).  
Total particle concentrations were measured by MFI (A) before any stress was applied for 
additive and control buffers alone (with no protein added), and (B) mAb-D protein samples 




   
 
Supplementary Figure 3.2: Particle size distributions for mAb-D + additives prior to heat or stir 
stress as measured by MFI.  
Each vertex of the polygon represents a particle diameter size range (in microns), and the radius 
of the polygon at each vertex represents the concentration of particles in that size range (in number 
of particles per mL). Distributions are shown for pH 6.5 + NaCl (A, B), pH 7.4 + NaCl (C, D, E), 
and pH 7.4 (F, G). Within each row, conditions are the same but samples are separated based to 
the maximum vertex for sake of visibility. Each vertex has an associated error that is not 
represented in these charts. 
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Supplementary Figure 3.3: Particle size distributions for mAb-D + additives after heat stress as 
measured by MFI.  
Each vertex of the polygon represents a particle diameter size range (in microns), and the radius 
of the polygon at each vertex represents the concentration of particles in that size range (in number 
per mL). Distributions are shown for pH 6.5 + NaCl (A, B), pH 7.4 + NaCl (C, D, E), and pH 7.4 
(F, G, H). Within each row, conditions are the same but samples are separated based to the 
maximum vertex for sake of visibility. Each vertex has an associated error that is not represented 
in these charts. 
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Supplementary Figure 3.4: Particle size distributions for mAb-D + additives after stirring stress as 
measured by MFI.  
Each vertex of the polygon represents a particle diameter size range (in microns), and the radius 
of the polygon at each vertex represents the concentration of particles in that size range (in number 
per mL). Distributions are shown for pH 6.5 + NaCl (A, B), pH 7.4 + NaCl (C, D, E), and pH 7.4 
(F, G, H). Within each row, conditions are the same but samples are separated based to the 
maximum vertex for sake of visibility. Each vertex has an associated error that is not represented 
in these charts.  
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Chapter 4 A Formulation Development Approach to Identify and Select 
Stable Ultra-High-Concentration Monoclonal Antibody Formulations 
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4.1 Introduction 
Due to their high specificity and adaptability, mAbs have become the most rapidly 
growing class of therapeutic proteins in the pharmaceutical industry.1,2 Because mAbs are 
typically relatively low potency drugs, they usually must be administered in relatively high 
doses.3 For certain disease treatments, the preferred delivery for many therapeutic mAb 
candidates is subcutaneous injection administered by the patient, which limits the volume of the 
drug dose to typically under 1.5 mL,4 thus necessitating the requirement for highly concentrated 
mAb formulations. In addition to the physical instability issues commonly associated with 
concentrated protein formulations, concentrated mAb solutions are at times, depending on the 
individual mAb candidates, highly viscous that often leads to increased tissue back-pressure and 
injection pain.5 Pharmaceutical manufacturing challenges, such as elevated levels of shear stress 
during pumping, high back-pressure, and clogging of membranes, are also exacerbated by high 
viscosity solutions.6 Despite these difficulties, several commercial protein formulations reaching 
concentrations >150 mg/mL have been developed including, for example, Actemra (180 mg/mL) 
from Genentech, Cosentyx (150 mg/mL) from Novartis, and Alirocumab (150 mg/mL) from 
Sanofi-Regeneron.7 
  Protein-protein interactions (PPI) can occur in solutions of monoclonal antibodies. 
Undesirable PPI can result in concentration-dependent elevated viscosities in highly concentrated 
mAb solutions arising from a crowded environment of antibodies forming reversible PPI leading 
to nonideal behavior.8,9 Additionally, PPI can contribute to issues such as protein aggregation, 
undesirable levels of solution opalescence, and in some cases, liquid-liquid phase separation.10 
This association of mAb molecules has been attributed to several transient interactions, such as 
electrostatic, hydrophobic, dipole-dipole, hydrogen bonding, and van der Waals interactions8,9,11-
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13 via FabeFab,8 and in some cases Fab-Fc interactions,14 between immunoglobulin G (IgG) 
mAbs. 
PPI of mAbs in high-concentration mAb solutions can be sequence specific, sometimes 
depending on single amino acids.15,16 The variable nature of these interactions has led to reports of 
a wide variety of excipients with viscosity-reducing effects. Common inorganic salts have been 
reported by several studies to reduce mAb viscosity,17-19 suggesting that electrostatic interactions 
strongly contribute to PPI in many antibodies. However, this is not universally observed.20 The 
viscosity-reducing effects of amino acids, especially arginine, have also been reported in multiple 
studies.11,21,22 Hydrophobic salts have been evaluated in at least 2 studies that reported significant 
viscosity-reducing properties of bulky, aliphatic, ionic constituents.20,23 Polar solvents including 
dimethyl sulfoxide (DMSO) and dimethylacetamide (DMA) have also been shown to reduce 
viscosities of concentrated mAbs formulations.24 Although some studies have examined the 
relationship between PPI of mAbs and viscosity mechanistically,8,9 development of relatively low-
viscosity, stable high-concentration mAb formulations remains largely an empirical process. 
Because PPI are mAb concentration dependent, they are often referred to as reversible self-
association. Such reversible self-association behavior can potentially contribute to physical and 
conformational instability of mAbs, including the formation of aggregates.17 In this study, 2 
monoclonal antibodies (1 IgG1 and 1 IgG4) that were previously formulated to be stable during 
storage, but are problematically viscous at high concentrations, were evaluated. We sought to add 
an additional 1-3 excipients to the established formulations of these mAbs that reduced solution 
viscosity, and at the same time, did not adversely affect their storage stability at ultra-high protein 
(>150 mg/mL) concentrations. To this end, we screened 56 different pharmaceutical excipients 
and other additives for their ability to reduce/mitigate solution viscosity and maintain/improve the 
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2 mAb's physicochemical stability profile. Stability studies of candidate high concentration 
formulations with each of the 2 mAbs, which were designed and developed based on previous 
formulation development work and the results from this work, were set up to monitor viscosity 
and stability changes over time under accelerated and real-time storage conditions. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Frozen mAb A (an IgG4) and mAb C (an IgG1) stocks were supplied by Janssen Biotech 
(Malvern, PA); mAb Awas supplied at a concentration of 115 mg/mL in 10 mM histidine, 8.5% 
sucrose, at pH 5.75. mAb C was supplied at a concentration of50 mg/mL in 10mM histidine, 4% 
sucrose, at pH 5.75. Sucrose and trehalose were purchased from Pfanstiehl Laboratories 
(Waukegan, IL). Sodium chloride, polysorbate 80, polysorbate 20, Triton X-100, and urea were 
purchased from Fisher Scientific (Hampton, NH). Ethanol, sodium camphorsulfonate, and 
triethylphenylammonium iodide were purchased from Acros Organics (Hampton, NH). 
Poloxamer 188was purchased from Spectrum Chemical Manufacturing (New Brunswick, NJ). 
Human serum albumin was purchased from Octapharma (Lachen, Switzerland). Sulfobutyl-b-
cyclodextrin was purchased from Ligand (San Diego, CA). All other chemicals were purchased 
from Sigma Aldrich (St. Louis, MO). 
4.2.2 Methods 
4.2.2.1 Sample Preparation, Concentration Determination, and Osmolality Measurements 
Antibody samples were exhaustively dialyzed into 10 mM histidine buffer at the desired 
pH at 4°C. Samples were then concentrated to >200 mg/mL by spin filtration using Amicon 
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Ultra 15 mL Centrifugal Filters (30K MW cutoff) (Millipore, Billerica, MS). Concentrated 
stocks of the excipients were made in 10 mM histidine buffer at the pH values desired in the 
antibody samples. Excipients were then added from stocks to aliquots of mAb A and mAb C, 
which were further diluted, if necessary, to the desired concentrations of protein by addition of 
buffer containing the desired concentration of excipient. Sample pH values were checked to 
ensure that they did change during the concentration procedure. Protein concentrations were 
determined by measuring absorbance at 280 nm with either a Thermo Scientific NanoDrop 2000 
spectrophotometer (Thermo, Wilmington, DE) or a Solo VPE Cary 50 Bio variable path length 
spectrophotometer (C Technologies, Bridgewater, NJ) using an extinction coefficient of 1.37 
(mg/mL) 1 cm-1. The osmolality of samples were determined using an OSMETTE II osmometer 
(Precision Systems Inc., Natick, MA). Measurements were made in triplicate. 
4.2.2.2 Accelerated and Long-Term Stability Studies 
  Stability studies were performed at 4°C, 25°C, and 40°C in the formulations and 
concentrations described. Samples were stored in sealed 2-mL glass vials with 13 mm rubber 
serum stoppers (West Pharmaceutical Services, Exton, PA). At the indicated time points, samples 
were moved to -80°C for storage until analyzed. 
4.2.2.3 Viscosity Measurements 
Solution viscosities were measured at 25C with an m-VROC viscometer (Rheosense, 
San Ramon, CA). Samples of mAb A and mAb C were injected at a rate of100 mL/min at a 
shear rate of1935.6 1/s for a duration of 100 s using a 1-mL glass syringe (Hamilton Co, Reno, 




   
4.2.2.4 Differential Scanning Calorimetry 
DSC measurements were performed using a VP-Capillary DSC System (Microcal, 
acquired by Malvern Instruments Ltd). Protein concentrations were adjusted to 5 mg/mL before 
the measurement. The corresponding formulation buffer was used as a reference for each sample. 
The samples were heated from 10°C to 90°C at a rate of 60°C/h. Resulting thermograms were 
corrected by subtraction of buffer-only scans and then normalized to the molar concentration of 
the protein and were analyzed using Origin 7.0 software (OriginLab Corporation, Northampton, 
MA). 
4.2.2.5 Size-Exclusion Chromatography 
HPLC-size-exclusion chromatography (SEC) was performed in triplicate with a Shimadzu 
HPLC System (Shimadzu, Columbia, MD) with simultaneous UV absorbance detection at 214 and 
280 nm using a Tosoh TSK-Gel BioAssist G3SWXL (PEEK column) (Tosoh Bioscience, King of 
Prussia, PA) and a corresponding guard column with a Shimadzu HPLC System. Experiments 
were performed at 25°C with a mobile phase containing 0.2 M sodium phosphate (pH 6.8) at a 
flow rate of 0.7 mL/min. Samples were diluted to 1 mg/mL and centrifuged at 14,000 x g for 5 
min before injection. Resulting data were analyzed as described previously using a dual-
wavelength size exclusion high-performance liquid chromatography method.25 
4.2.2.6 SDS-PAGE 
Samples were mixed with 4 NuPAGE LDS sample buffer (Thermo Fisher Scientific, 
Waltham, MA) with and without 5 mM dithiothreitol (Thermo Scientific, Rockford, IL) and 
incubated at 95C for 5 min. Samples were then treated with 10 mM iodoacetamide (Thermo 
Scientific) at 25°C in the dark for 30 min. Each sample (10 mg) was separated on 10-20% Tris-
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glycine gels using NuPAGE MES SDS Running Buffer (Thermo Fisher Scientific). SeeBlue 
Plus2 Pre-stained Protein Standard (Thermo Fisher Scientific) was used as a molecular weight 
ladder. Protein bands were visualized by staining the gels with Bio-safe Coomassie Blue G250 
stain (BioRad Laboratories, Hercules, CA), followed by destaining in destaining buffer (50% 
methanol, 10% acetic acid). 
4.2.2.7 Capillary Isoelectric Focusing 
Capillary isoelectric focusing (cIEF) experiments were performed on an iCE3 instrument 
from Protein-Simple (San Jose, CA). Samples were run in triplicate at 4C using a 
temperaturecontrolled autosampler. The mAb samples (final concentration of 0.15 mg/mL) were 
mixed with Pharmalyte® 3.0-10.0 (GE Healthcare, final concentration of 4%), acidic and basic 
isoelectric point (pI) markers of 6.14 and 9.46 (Protein-Simple), 0.1% 
tetramethylethylenediamine, and methyl cellulose (final concentration of 0.35%; Protein-
Simple). Samples were separated in 2 focusing periods, one at 1500 V for 1 min and a second at 
3000 V for 4.3 min. 
4.2.2.8 Microflow Imaging 
Using a microflow imaging (MFI) DPA 4200 instrument (Protein Simple, Santa Clara, CA), 
subvisible particle formation data were collected by MFI methods described previously.26 The 
instrument was primed with purified water before each run to obtain a particle-free baseline. 
Samples were either diluted to a protein concentration of 1 mg/mL (in the case of samples stored 
at 40°C) or 50-fold (all other measurements) in the corresponding formulation buffer before being 
passed through the instrument at a flow rate of 0.1 mL/min. Subvisible particle concentration 
values were not corrected for dilution factor because counting accuracy vs. dilution factor has been 
reported (and observed in our laboratories as well) to deviate from linearity in similar 
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experiments.27 Rather, data are evaluated in terms of the change in total particle counts compared 
with previous time points in the stability study. Measurements were made in duplicate. 
4.3 Results 
4.3.1 Excipient Screening to Reduce Viscosity of mAb A and mAb C Solutions 
A total of 56 additives, most of them pharmaceutical excipients used in approved 
products for parenteral injection (i.e., listed in the FDA inactive ingredient guide28), were 
screened. These additives were grouped into known categories including salts, polyols, alcohols, 
sugars, detergents, proteins, amino acids, and polymers.29 The classes and individual types of 
excipients were screened for their viscosity-reducing effects on mAb A and mAb C solutions 
prepared at high concentrations between 130 and 165 mg/mL protein (Fig. 1). DMSO, DMA, 
sodium (þ)-10camphorsulfonate, and trimethylphenyl-ammonium iodide were included in this 
list based on recent studies reporting reduced viscosities of mAbs formulated at ultra-high (>150 
mg/mL) concentrations with polar solvents and hydrophobic salts.20,23,24 Initial screening was 
performed at relatively high concentrations of excipients to aid in identification of potential 
“hits.” The measured dynamic viscosities of the mAb formulations were grouped into 3 
categories: (1) “preferred” viscosities of 10 cP or lower, (2) “acceptable” viscosities between 10 
and 20 cP, and (3) “unacceptable” viscosities of >20 cP. These values were selected based on 
available internal experience and knowledge of the capabilities of delivery devices, such as pre-
filled syringes, auto-injectors, and patch pumps. For example, the SmartDose® system from 
West Pharmaceutical Services claims to accommodate viscosities as high as 20 cP.30 Excipients 
that were observed to reduce viscosities of the mAb formulations <15 cP were identified as 
“hits” and were down selected for further study (Table 1). The value of 15 cP was used (instead 
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of 20 cP) to avoid values too close to the viscosity cutoff and to further reduce the number of 
excipients (and their combinations) to be evaluated in subsequent experiments.  
Next, we examined the effects of the lead excipients on the 2 mAbs at different protein 
concentrations. Due to reversible mAb self-association, ultra-high concentration solutions (150 
mg/mL mAb) typically display sharp, exponential increases in solution viscosity.12 We observed 
this phenomenon with solutions of both mAb A and mAb C, with dynamic viscosities 
dramatically increasing at concentrations above about 150 mg/mL (Fig. 2). For example, at 200 
mg/mL, differences as high as ~145 and ~85 cP in viscosities were observed in formulations of 
mAb A and mAb C, respectively. 
Because excipient concentrations in these initial excipient screening experiments were 
comparatively high, the next phase of the study was to work toward developing more isotonic 
formulations, which are desired for subcutaneous parenteral administration. To this end, 
titrations of the best-performing classes and types of excipients from Figure 2 were evaluated 
(see Fig. 3). The promising additives were grouped in the following excipient classes: amino 
acids, buffer agents, and salts (including divalent, monovalent, and hydrophobic salts). Among 
the amino acids tested, arginine and lysine had the most pronounced effect on solution viscosity, 
with arginine outperforming lysine for mAb A and the reverse being observed for mAb C. In 
both these cases, the viscosity-reducing effects appeared to plateau at an additive concentration 
of about 50 mM. Among the buffer systems compared, histidine outperformed the other 
compounds examined in viscosity reduction for mAb A. In the case ofmAb C, each of the 
buffering agents examined were found to reduce solution viscosity to approximately the same 
degree. The divalent salts CaCl2 and MgCl2 both reduced the viscosity to a greater extent than 
NaCl at the same concentrations for both mAbs, possibly due to the ionic strength of the solution 
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being greater in the case ofthe divalent salts.31 Further reduction of solution viscosity appeared to 
diminish at salt concentrations >150 mM (the DebyeeHückel charge shielding limit). The 
plateauing effect observed with the amino acids in Figure 3 could be attributed to this 
phenomenon as well but could also potentially be caused by arginine's and lysine's ability to also 
interact with apolar and aromatic amino acid residues in proteins or a mixture of both effects 
(also see Discussion).14 
Formulations comprised combinations of the best-performing excipients (in terms of 
viscosity reduction) were then designed and evaluated (Table 2). In selecting these formulations, 
we considered not only viscosity effects but also known protein stabilization effects of certain 
additives29 and previously obtained stability data with these 2 mAbs (data not shown). The sugar 
sucrose was included in these formulations for its known stabilizing effect on monoclonal 
antibodies, especially during freeze-thaw.32 Although the same preferential exclusion of sucrose 
molecules from protein surfaces that leads to this stabilizing effect can potentially also lead to 
increased intermolecular interactions of proteins at high concentrations and, therefore, can 
contribute to increased viscosity,14 no notable effects on dynamic viscosity from 5% sucrose was 
observed for either mAb A or mAb C when formulated with 75 mM NaCl and 50 mM arginine 
or lysine, respectively. The storage stability of these 2 mAbs in their original formulations (mAb 
A in 10 mM histidine, 8.5% sucrose, at pH 5.75, and mAb C in 10 mM histidine, 4% sucrose, at 
pH 5.75) was previously established before initiation of this work (data not shown). However, 
because pH can affect the viscosity of protein solutions, we evaluated its effect at pH values at, 
above, and below the pI range of mAb A and mAb C (Supplementary Fig. S1). None of the 
alternative pH values (range 5.0 to 8.0) resulted in mAb A or mAb C solution viscosities lower 
than that observed at pH 5.75. 
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Based on the results from the excipient screening experiments described earlier, 3 
candidate formulations were designed for further evaluation with both mAb A and mAb C (Table 
3) at protein concentrations of 50, 150, and 175 mg/mL. For these studies, protein concentrations 
exceeding 175 mg/mL were not considered due to theoretical limits to the extent viscosity could 
be reduced due to the impact of the excluded volume effect as described by the Ross-Minton 
equation.33 A “base” buffer, formulations F1 and F4 (10 mM histidine, 5% sucrose, 0.02% 
polysorbate 20, pH 5.3), were used as controls for mAb A and C, respectively. This buffer was 
selected based on previously determined storage stability data (data not shown). Formulations F2 
(base buffer þ 75 mM NaCl and 50 mM arginine) and F5 (base buffer þ 75 mM NaCl and 50 mM 
lysine) were selected based on their viscosity-reducing properties revealed in the excipient 
screening studies. Formulation F3 (88 mM histidine, 5% sucrose, 50 mM arginine, 0.02% 
polysorbate 20, pH 5.3) was included at a single concentration of 175 mg/mL mAb A to compare 
with formulation F2, which had the same ionic strength. We also included formulation F6 (base 
buffer þ 75mM sodium camphorsulfonate, 50 mM lysine) at a single concentration of 175 
mg/mL mAb C to evaluate the effect of hydrophobic salts (sodium camphorsulfonate) on storage 
stability of mAb C. Sodium camphorsulfonate was selected over trimethyl-phenylammonium 
iodide because it has been used more often in pharmaceutical formulations.34 The experimentally 
determined osmolality values for each of these formulations are also listed in Table 3. 
4.3.2 Evaluation of mAb A and mAb C Stability in Candidate Low-Viscosity, High, and 
Ultra-High Concentration Formulations 
The conformational stability of the antibodies in the candidate formulations was first 
evaluated by DSC before accelerated and real-time stability studies were performed to assess 
whether the excipients in the candidate formulations affected the inherent structural stability of 
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the mAbs (Fig. 4). Both mAb A and mAb C displayed 1 minor and 1 major transition. No 
notable effect was observed for the mAb C formulations (F4, F5, and F6) when comparing the 3 
candidate formulations. In contrast, for mAb A, additional histidine, NaCl, and arginine in 
formulations F2 and F3 did lower the thermal-onset temperature of the first transition of mAb A 
(Tonset1) by ~5°C. To determine if the increased ionic strength or the presence of arginine was 
the cause of this effect, formulations containing the “base buffer” plus 75 mM NaCl or 50 mM 
Arginine were evaluated (Supplementary Fig. S2). Both excipients seem to have an 
approximately equal and cumulative effect on lowering the Tonset values ofmAb A at the 
concentrations used. Although this destabilizing effect was observed, the effect of a relatively 
small lowering of the Tonset value for mAb A in the candidate formulations F2 and F3 on the 
actual longer term storage stability of mAb A at much lower temperatures in F2 and F3 was not 
predicable and was, therefore, subsequently evaluated experimentally as described subsequently. 
Both accelerated and real-time storage stability profiles of mAb A and mAb C in newly 
designed, lower viscosity, high (50 and 150 mg/ mL), and ultra-high (175mg/mL) protein 
concentration formulations were then evaluated at 3 different temperatures (4°C, 25°C, and 
40°C) for 6months. The physicochemical stability of the 2mAbs was monitored by protein 
concentration using UV spectroscopy, aggregation and fragmentation by SEC and SDS-PAGE, 
subvisible particle formation by MFI, and charge heterogeneity by cIEF. 
Throughout the course of the stability studies, the viscosity of each formulation was also 
monitored (Fig. 5), and no notable change was observed with the exception of a possible increase 
in the case of formulation F4 stored at 40°C (Fig. 5b; values for 50 and 150 mg/mL formulations 
not shown). Similarly, no significant changes in protein concentration were observed by UV 
spectroscopy (data not shown). Protein aggregation and fragmentation were monitored under 
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nondenaturing conditions by SEC and under denaturing conditions by SDS-PAGE. For SEC 
analysis of the 2 proteins at time 0, 0.5%-1.0% soluble aggregates were observed for each of the 
formulations. No fragmentation was observed for any of the formulations at time 0. When the 
formulations were then stored at 4C and 25C, the total concentration of monomer remained 
stable in each of the formulations (Figs. 6b-6d). Small losses of monomer (<1%) over this time 
period indicates that the potential shelf life of both mAbs can be predicted to exceed 2 years 
when stored at 4°C.35 However, when mAb A and C formulations were stored under more 
accelerated stability conditions (40°C), a ~10% reduction in monomer concentration was 
observed after 3 months. Dimer and fragment formation and loss of protein (presumably from 
large aggregates being retained on the guard column) all contribute to this loss of monomer 
content (Fig. 6a, Supplementary Figs S4, S5, and S6). SDS-PAGE analysis (under both reducing 
and nonreducing conditions) did not reveal any notable changes in any formulation at any 
temperature evaluated (Supplementary Fig. S3), indicating no notable formation of fragments or 
covalent aggregates. The fragments observed by SEC (Supplementary Fig. S4, panels C and F) 
were probably not present in high enough concentrations to be observed by Coomassie Blue 
G250 staining. This may also be true for the aggregates observed by SEC and not SDS-PAGE 
(Supplementary Fig. S4, panels A and D), although this more likely could be attributed to 
formation of noncovalently associated protein in these aggregates.  
Subvisible particle formation between 2 and 100 m was monitored by MFI (Fig. 7). At 
time 0, formulations contained 10,000 particles/mL or less, with most having <1000 particles/mL 
after dilution. After storage for 3 months at 40°C, each of the formulations of mAb A contained 
at least an order of magnitude more particles than t ¼ 0 samples. Formulations of mAb C, 
however, did not appear to form particles under the same conditions with the exception of 
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formulation F6. At each of the protein concentrations of mAb A, formulation F1 formed an order 
of magnitude more particles by 6 months when stored at 25°C. In contrast, at lower 
temperatures, no notable particle formation in the 2- to 100-m range was observed for all other 
formulations stored at either 25°C (Fig. 7, panel B) and 4°C (Fig. 7, panel C) over a 6-month 
period. 
The charge heterogeneity profile of mAb A and mAb C was evaluated by cIEF (Fig. 8). 
At time 0, both mAb A and mAb C display 3 peaks in the pI range of7.0-7.5 with a major peak at 
7.2 and 7.1 for mAb A and mAb C, respectively (Fig. 8a). Electropherograms of samples of each 
of the mAb formulations stored at 40C changed notably from T0 to 3M, with significant loss in 
main peak area and new acidic peaks appearing. No notable changes in the cIEF profile was 
observed in the same samples stored at either 25°C (Fig. 8, panel C) and 4°C (Fig. 8, panel D) 
over a 6-month period. 
4.4 Discussion 
The experiments described here were designed to take 2 existing, storage stable, high-
concentration IgG formulations (1 IgG1 and 1 IgG4) and modify them by adding 1-3 
pharmaceutical excipients (ideally already used in FDA-approved products) with the goal of 
reducing their viscosities at high protein concentrations without negatively affecting their 
stability while still maintaining osmolality values compatible with parenteral (subcutaneous) 
administration. It should be noted that the goals of this work differ from early formulation 
development work attempting to simultaneously identify excipients to enhance protein stability 
at high concentrations and to lower solution viscosity (as some excipient combinations may 
contribute to stability but increase viscosity or vice versa). Additionally, by screening a wide 
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variety of excipients, we aimed to obtain a better mechanistic understanding of the nonideal 
behavior of the 2 antibodies evaluated. 
Several factors are well known to contribute to the viscosity of protein solutions. In 
relatively dilute solutions, the electroviscous effect can contribute significantly to solution 
viscosity at pH conditions above or below the protein's pI value.36,37 The viscosity of select 
formulations (F2 and F5) of mAb A and C were evaluated at pH values below (pH 5.0), above 
(pH 8.0), and within the range (pH. 7.4) of their measured range of pI values. The solution pH 
had little effect on the viscosity of these formulations at 175 mg/mL (Supplementary Fig. S1), 
indicating an insignificant contribution of the electroviscous effect in the formulations used in 
these stability studies. Although local electrostatic attractions can be modulated by increasing or 
lowering the solution pH, this effect was apparently masked by ionic screening from the charged 
excipients present in the formulations in our studies as suggested by the observed saturation 
effect at 150 mM concentrations (Fig. 3) where the DebyeeHückel effect is optimal. Viscosity is 
also influenced by excluded volume effects (crowding in solution), particularly at high protein 
concentrations.33,38 The excluded volume effect is in part governed by the size of the molecule 
and limits the degree to which the viscosity of these solutions can be reduced by the addition of 
excipients. At the concentrations of protein and excipients evaluated in this work, nonspecific 
PPI are probably the biggest contributor to solution viscosity.33 These include hydrophobic, 
electrostatic, van der Waals, and dipole-dipole interactions. For both mAbs, the most pronounced 
viscosity reduction was observed in formulations containing amino acids or those at high ionic 
strength (Fig. 3). Hydrophobic interactions likely play a more important role in the PPI of mAb 
A at high concentrations than mAb C based on the observed effects of methionine, tryptophan, 
and isoleucine had on solution viscosity (Table 1). Despite this result, ionic screening from 
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charged excipients (at sufficient concentrations) appears to disrupt PPI in mAb A and mAb C, 
indicating a significant contribution of electrostatic and dipole-dipole interactions in both 
molecules as well. 
Colloidal stability may be related to the same reversible PPI that lead to increased 
viscosity.39,40 We hypothesized that mAb solutions with higher viscosities could also aggregate 
more and form more particles in accelerated and real-time stability studies. This may, indeed, be 
the case in samples of formulation F1 stored at 25C, which did form more subvisible particles 
than the other, lower viscosity, formulations of mAb A at the 6-month time point as observed by 
MFI (Fig. 7). However, this was observed at each of the protein concentrations of formulation F1, 
including the lower viscosity 50 mg/mL and the 150 and 175 mg/mL samples. It should also be 
noted that no similar increase in aggregation for these samples was observed by SEC. Colloidal 
instability at elevated temperature (40C) can most probably be attributed to non-native aggregate 
formation, where aggregates form from proteins that have partially lost their native or folded 
structure,41 and this mechanism may also apply to the observed instability of formulation F1 at 
25C. Clearly, elucidating the actual mechanism of particle formation of mAb A would require 
further study. Finally, the chemical stability of mAb A and C was similar, with only those samples 
stored at elevated temperatures showing loss of the main peak in the cIEF electropherograms (Fig. 
8). From the formation of additional acidic peaks in the samples stored at 40C, we can infer that 
one or more deamination events are also occurring in all the formulations evaluated. 
Previous studies have sought to address the problem of elevated solution viscosities in mAb 
solutions by a variety of different approaches. Similar to the work presented here, some 
approached this by screening excipients for their viscosity-reducing effects. These studies typically 
select a class of excipients (i.e., amino acids, hydrophobic salts, polar solvents, etc.) and screen 
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within a library of select compounds.19,20,23,24,42 Others have taken a more mechanistic approach 
and sought to understand how certain compounds reduce solution viscosities by examining their 
effect on PPI 9,13,14,33 or by seeking to modify the mAb itself to reduce these interactions.16,43 In 
this work, by screening a library of diverse pharmaceutical excipients and additives, our approach 
was able to rapidly screen and select a group of promising compounds for lowering viscosity of 
ultra-high concentration mAb solutions, while not affecting storage stability, without the time-
consuming need of having exact knowledge of the nature of the specific PPI that occur in highly 





   
Table 4.1:  Lead Excipients That Reduce Solution Viscosity to ≤15 cP for Either mAb A or mAb 
C at 150 mg/mL.  
Formulations contain the listed excipients in a base buffer of 10 mm histidine, pH 5.75. Values 
represent the average and SD from triplicate experiments. 
Categories Excipients Viscosity, cP 
mAb A mAb C 
Base buffer 10 mM Histidine, pH 5.75 14.1 ± 1.3 20.1 ± 0.4 
Hydrophobic salts 0.5 M Sodium camphorsulfonate 4.3 ± 0.0 5.8 ± 0.0 
 
0.5 M Trimethylphenylammonium iodide 4.0 ± 0.0 14.2 ± 0.0 
Salts 0.1 M NaCl 8.5 ± 0.0 10.5 ± 0.2 
 
0.5 M NaCl 7.5 ± 0.0 6.4 ± 0.0 
 
1 M NaCl 5.8 ± 0.0 6.2 ± 0.1 
 
0.1 M Sodium succinate 
 
8.9 ± 0.0 
 
10 mM CaCl2 10.5 ± 0.4 13.4 ± 0.1 
 
10 mM MgCl2 10.6 ± 0.1 
 
 
50 mM Sodium phosphate 7.1 ± 0.1 8.8 ± 0.3 
 
50 mM Sodium acetate 12.3 ± 0.1 
 
 
50 mM Sodium citrate 7.3 ± 0.2 13.1 ± 0.3 
 
50 mM Tris(hydroxymethyl)aminomethane 7.7 ± 0.4 13.9 ± 0.3 
Detergents 0.05% Brij 35 14.8 ± 0.2 5.0 ± 0.1 
Reducing agents 1 mM DTT 14.3 ± 0.3 
 
Cyclodextrins 5% Sulfobutyl-β-cyclodextrin 12.2 ± 0.0 
 
 
5% γ-Cyclodextrin 14.1 ± 0.0 
 
Polyols 10% Sorbitol 14.8 ± 0.0 
 
 
10% Glycerol 13.5 ± 0.0 
 
Carboxylic acids 0.1 M Lactic acid 9.1 ± 0.2 7.2 ± 0.1 
 
0.1 M Malic acid 
 
7.0 ± 0.3 
Amino acids 0.1 M Arginine 6.4 ± 0.3 7.7 ± 0.1 
 
0.1 M Aspartate 7.7 ± 0.4 12.8 ± 0.2 
 
0.1 M Glutamate 10.5 ± 0.2 11.1 ± 0.4 
 
50 mM Histidine 5.1 ± 0.1 10.7 ± 0.2 
 




   
Categories Excipients Viscosity, cP 
mAb A mAb C 
 
0.1 M Lysine 3.5 ± 0.0 5.0 ± 0.2 
 
0.02 M Methionine 11.2 ± 0.0 
 
 
50 mM Tryptophan 13.1 ± 0.0 
 
 
0.05 M Arginine + 0.05 M glutamate 8.1 ± 0.0 9.0 ± 0.2 
 
0.045 M Arginine + 0.045 M glutamate + 
0.01 M isoleucine 
6.7 ± 0.0 5.9 ± 0.0 






   
Table 4.2:  The Effect of Combinations of Lead Excipients on the Solution Viscosity and 
Osmolality of 175 mg/mL Solutions of mAb A and mAb C Containing 10 mM Histidine (pH 5.75). 
Values represent the average and SD from triplicate experiments. Arg, arginine; Lys, lysine. 
 
Excipients Viscosity, cP Osmolality, mOsm/kg 
mAb A 
 150 mM NaCl + 50 mM Arg 11.8 ± 0.1 649 ± 11 
 150 mM NaCl + 10 mM MgCl2 20.1 ± 0.0 396 ± 0 
 150 mM NaCl + 10 mM MgCl2 + 50 mM Arg 12.3 ± 0.7 489 ± 10 
 10% sucrose + 50 mM Arg 28.0 ± 0.3 602 ± 9 
 10% sucrose + 10 mM MgCl2 28.8 ± 0.3 442 ± 1 
 10% sucrose + 10 mM MgCl2 + 50 mM Arg 15.2 ± 0.2 642 ± 14 
 5% sucrose + 75 mM NaCl + 50 mM Arg 14.2 ± 0.2 470 ± 3 
 5% sucrose + 75 mM NaCl + 10 mM MgCl2 21.7 ± 0.2 431 ± 4 
 5% sucrose + 75 mM NaCl + 50 mM Arg + 10 mM MgCl2 13.5 ± 0.2 500 ± 1 
mAb C 
 150 mM NaCl + 50 mM Lys 16.1 ± 0.4 500 ± 4 
 150 mM NaCl + 10 mM MgCl2 19.0 ± 0.1 383 ± 3 
 150 mM NaCl + 10 mM MgCl2 + 50 mM Lys 12.1 ± 0.1 512 ± 4 
 10% sucrose + 50 mM Lys 14.1 ± 0.2 375 ± 5 
 10% sucrose + 10 mM MgCl2 39.9 ± 0.3 561 ± 24 
 10% sucrose + 10 mM MgCl2 + 50 mM Lys 15.0 ± 0.2 688 ± 3 
 5% sucrose + 75 mM NaCl + 50 mM Lys 12.3 ± 0.1 530 ± 5 
 5% sucrose + 75 mM NaCl + 10 mM MgCl2 21.6 ± 0.4 476 ± 20 
 5% sucrose + 75 mM NaCl + 50 mM Lys + 10 mM MgCl2 12.8 ± 0.1 603 ± 11 





   
Table 4.3:  Formulation Compositions, Protein Concentrations and Osmolality Values of mAb A 
and mAb C Used in Accelerated and Real-Time Stability Studies. 
Each of the formulations also contained 5% sucrose, 0.02% polysorbate 20 (pH 5.3). Osmolality 
values represent the average and SD from triplicate experiments. 
Formulation Composition Concentration (mg/mL) mOsm/kg 
mAb A 
 F1 10 mM Histidine 50 197 ± 0 
150 289 ± 9 
175 332 ± 2 
 F2 10 mM Histidine + 75 mM NaCl, 50 mM 
arginine 
50 437 ± 12 
150 598 ± 3 
175 640 ± 1 
 F3 88 mM Histidine, 50 mM arginine 175 501 ± 7 
 
mAb C 
 F4 10 mM Histidine 50 194 ± 1 
150 265 ± 0 
175 281 ± 0 
 F5 10 mM Histidine + 75 mM NaCl, 50 mM 
lysine 
50 401 ± 4 
150 483 ± 9 
175 510 ± 4 
 F6 10 mM Histidine + 75 mM sodium 
camphorsulfonate, 50 mM lysine 
175 510 ± 3 
 
 





   
 
Figure 0.1: Screening of 56 pharmaceutical excipients and additives for their viscosity-reducing 
effects on high concentration formulations of (a) mAb A and (b) mAb C.  
Antibody solutions are between ∼135 and ∼160 mg/mL with 10 mM histidine (pH 5.75) and the 
following excipients: (2) no additional excipients, (3) 0.5 M sodium camphorsulfonate, (4) 0.5 M 
triethylphenylammonium, iodide, (5) 1% DMA, (6) 1% DMSO, (7) 0.1 M NaCl, (8) 0.5 M NaCl, 
(9) 1 M NaCl, (10) 0.1 M succinate, (11) 4% lactose, (12) 4% trehalose, (13) 4% sucrose, (14) 5% 
y-cyclodextrin, (15) 5% ethanol, (16) 10% glycerol, (17) 10 mM CaCl2, (18) 1 mM dithiothreitol, 
(19) 1 mM EDTA, (20) 10 mM MgCl2, (21) 0.05% polysorbate 20, (22) 0.05% polysorbate 80, 
(23) 0.05% Triton X-100, (24) 0.05% benzalkonium chloride, (25) 0.05% Brij 35, (26), 
0.05% sodium docusate, (27) 0.05% Poloxamer 188, (28) 50 mM histidine, (29) 50 mM 
Tris(hydroxymethyl)aminomethane, (30) 50 mM sodium acetate, (31) 50 mM sodium citrate, (32) 
50 mM sodium phosphate, (33) 1% hydrolyzed gelatin, (34) 0.2% protamine sulfate, (35) 1% 
human albumin, (36) 10% mannitol, (37) 10% sorbitol, (38) 0.5% chitosan, (39) 0.5% dextran 40, 
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(40) 0.5% PEG 3350, (41) 0.5% hydroxyethyl starch, (42) 0.1 M glycine, (43) 0.1 M arginine, (44) 
0.1 M aspartate, (45) 0.1 M glutamate, (46) 0.02 M isoleucine, (47) 0.1 M lactic acid, (48) 0.1 M 
lysine, (49) 0.1 M malic acid, (50) 0.02 M methionine, (51) 0.02 M proline, (52) 0.1 M urea, (53) 
0.045 M arginine + 0.045 M glutamate + 0.01 M isoleucine, (54) 0.05 M arginine + 0.05 M 
glutamate, (55) 50 mM tryptophan, and (56) 5% propyl-cyclodextrin (57) 5% sulfobutyl-β-
cyclodextrin. The original formulations (1) of mAb A (10 mM histidine, 8.5% sucrose, pH 5.75) 
and mAb C (10 mM histidine, 4% sucrose, pH 5.75) are present as controls (blue bars). Error bars 
are SDs from triplicate measurements. 0.1 M maleic acid, 0.5% carboxymethyl cellulose, 0.5% 
dextran sulfate, 0.5% sodium hyaluronate, and 0.1 M sodium sulfate precipitated both mAb A and 
C. Hydroxyethyl starch precipitated mAb A. “Acceptable” (≤20 cP) and “preferred” (≤10 cP) 
viscosity ranges are indicated by the yellow and green regions, respectively. 
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Figure 0.2: Protein concentration dependence on solution viscosity of (a) mAb A and (b) mAb C 
in the presence of lead excipients.  
Excipients were identified and listed here by the same numbers used in Figure 1. The original 
formulation (1) is listed in Figure 1 and was included as a control at a single protein concentration. 
Error bars are SDs from triplicate measurements. “Acceptable” (≤20 cP) and “preferred” (≤10 cP) 
viscosity ranges are indicated by the yellow and green regions, respectively. 
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Figure 0.3: The effect of the concentration of selected excipients on the solution viscosity of 175 
mg/mL solutions of (a) mAb A and (b) mAb C containing 10 mM histidine at pH 5.75.  
MAb A precipitated in formulations containing sodium citrate concentrations of about 25 mM and 
higher. Values are average and SD from triplicate measurements. 
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Figure 0.4: Conformational stability of mAb A and mAb C in candidate formulations as 
determined by differential scanning calorimetry.  
(a) Representative thermograms of 3 formulations of mAb A. (b) Representative thermograms of 
3 formulations of mAb C. (c) Thermal onset temperatures (Tonset) and thermal melting temperatures 
(Tm) were determined from DSC thermograms. Values are average and SD from triplicate 
measurements. See Table 3 for description of each formulation. 
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Figure 0.5: Solution viscosity of ultra-high concentrations of mAb A and mAb C in candidate 
formulations after 3 months storage at 40°C. 
(a) Viscosity of mAb A at 175 mg/mL and (b) viscosity of mAb C at 175 mg/mL. For 25°C and 




   
 
Figure 0.6: Protein aggregation profile of ultra-high concentrations of mAb A and mAb C in 
candidate formulations during stability as measured by SEC.  
(a) Representative overlay of SEC chromatograms of mAbs before and after storage at 40°C for 3 
months with aggregate, monomer, and fragment peaks indicated. Loss of monomer over time for 
mAbs stored at (b) 40°C, (c) 25°C, and (d) 4°C over 6 months. Formulation composition and 




   
 
Figure 0.7: Subvisible particle formation in mAb A and mAb C over time observed by MFI.  
(a) Particle formation in mAb formulations over time at 40°C, (b) 25°C, and (c) 4°C.Formulation 




   
 
Figure 0.8: Charge heterogeneity profile of mAb A and mAb C as analyzed by cIEF during 
storage. 
(a) Representative overlay of electropherograms of mAbs before and after storage at 40°C for 3 
months. Loss of main peak area over time for mAbs stored at (b) 40°C, (c) 25°C, and (d) 4°C. 
Formulation composition and protein concentrations are listed in Table 3. Values are average and 
SD from triplicate measurements. 
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Chapter 5 Development of Scale-Down Assays for Assessment of 




















   
5.1 Introduction 
Tangential flow filtration (TFF) is the most widely used unit operation in the final stages of 
large scale purification of protein drug candidates during the downstream process.1 TFF is 
commonly used at this final step of the purification to concentrate protein molecules 
(ultrafiltration) and to perform buffer exchanges (diafiltration) into the desired final formulation 
buffer at the target dose.2,3 Ensuring protein stability and minimizing aggregation can be difficult 
to manage at this stage of the manufacturing process, since proteins can go through many different 
environmental stresses during TFF.4 For example, shear stress, cavitation, air-liquid interface, and 
protein-membrane surface interactions5 can all potentially lead to protein structural alterations, 
aggregation and particle formation.  In this study, the impact of various stresses imposed on protein 
molecules during TFF processing on key physicochemical and structural properties of four 
different antibodies (Abs) was examined (i.e., two IgG4 molecules, an IgG1 molecule and a 
bispecific Ab based on IgG4). These four Ab molecules were selected based on different levels of 
instability observed previously during large-scale TFF processing. Two Ab molecules (termed 
“molecule 1” and molecule 2”) were shown to be stable with good protein recovery and low 
amounts of aggregation while the other two Ab molecules (termed “molecule 8” and “molecule 
9”) were shown to be problematic with unacceptable levels of protein loss and aggregation during 
processing with a large scale TFF system.  
To better understand the causes and mechanisms that result in some Ab molecules being 
more susceptible to TFF related instability compared to others, the first step was to establish a 
small-scale TFF method in the laboratory to emulate the observations seen during large scale TFF 
processing. This is a critical practical first step since large scale TFF processing requires 
impractical amounts and volumes of protein to perform process/formulation development 
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experiments. Using this benchtop model TFF setup, the effect of the TFF processing on the 
recovery and aggregation/particle formation was examined with the four Ab molecules during 
processing (as the solution changes from their respective initial buffer/protein concentration and 
to their final formulation buffers/protein concentrations). The lab scale TFF setup was shown to 
mimic reasonably well the previous observations of behavior of the these four Ab molecules during 
large scale TFF processing.   
For the second phase of the work, the ability to better understand and ultimately predict 
this TFF behavior by examining the inherent properties of these four Ab molecules (using minimal 
material and without the need to perform any TFF processing) was examined. First, the inherent 
structural integrity, relative solubility and conformational stability of the four Ab molecules were 
determined and compared to evaluate if correlations could be established with TFF results. This 
evaluation was performed in both PBS buffer (so the four Ab molecules are compared under the 
same conditions) and in their respective TFF processing buffers (so the four Ab molecules are 
compared under the actual solution conditions of TFF processing).  Second, the colloidal properties 
of the four Ab molecules (i.e., the propensity of the molecules to interact with each other and to 
aggregate), in both PBS buffer and in their respective TFF processing buffers, was examined in a 
series of stirring and shaking studies and again comparisons are made with TFF results. Finally, 
the interfacial properties of the four Ab molecules (i.e., the propensity of the four Abs to go to air-
water interfaces), in both PBS buffer and in their respective TFF processing buffers, was examined 
and similar correlations to TFF behavior was performed.  
By examining the impact of various TFF stresses on the recovery and aggregation of the 
four Ab molecules using a laboratory scale TFF setup, and then comparing those results to the 
conformational, colloidal, and interfacial properties of each molecule, we were to gain a better 
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mechanistic understanding of TFF associated instability of molecules. Overall, it was observed 
that evaluating the interfacial properties of these molecules, both in comparison to each other in 
PBS buffer and in their respective TFF processing buffers, is a key step to better understanding 
the propensity of these four Ab molecules to behave “good” or “bad” during TFF processing. To 
this end, with the ultimate goal of being able to identify key analytical tools to perform early stage 
prediction and risk assessment of antibody behavior during TFF using small amounts of protein, 
additional work further exploring the utility of a Langmuir trough method to evaluate the 
interfacial properties of four Ab molecules in various solution conditions is recommended. This 
additional work permit for a better understanding of the predictive ability of the Langmuir trough 
technique in terms of identifying an Ab molecule’s TFF behavior (at both laboratory and large-
scale processing) using minimal amount of protein. 
5.2 Materials and Methods 
5.2.1 Materials 
One IgG1 monoclonal antibody (molecule 2), two IgG4 monoclonal antibodies (molecules 
1 and 8), and a bispecific antibody (molecule 9), were provided by Bristol Myers Squibb (New 
Jersey). Molecules 1 and 2 were provided as 50 mg/mL protein solutions in 20 mM histidine, 8.5% 
sucrose pH 6.0, molecule 8 as an 18.3 mg/mL protein solution in 20 mM histidine, 8.5% sucrose, 
pH 5.5, and molecule 9 as a 50 mg/mL protein solution in 20 mM histidine, 90 mM arginine, 4.0% 
sucrose pH 5.6. The concentrations of the various Abs were measured with an Agilent 8453 UV-
visible spectrophotometer (Palo Alto, California) after dilution.  The extinction coefficients of 1.68 
(molecule 1 and 8), 1.45 (molecule 2), and 1.78 (mg/mL)-1 cm-1 (molecule 9) were used to 
calculate the protein concentration.  
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An XL25 dual channel pH meter, sodium hydroxide, sodium chloride, and potassium 
chloride were obtained from Fisher Scientific (Fair Lawn, New Jersey). Sodium phosphate dibasic 
(anhydrous), histidine, sucrose, mannitol, DTPA, arginine, sodium acetate, potassium phosphate, 
trizma HCl, and trizma base were obtained from Sigma Aldrich (St. Louis, Missouri). Polysorbate 
80 was obtained from Thermo Scientific (Rockford, Illinois). For shaking and stirring studies, 
glass vials used were from West Pharmaceuticals, (3-mLVial, Fiolax Clear, Item#6800-0316), and 




5.2.2.1 Sample Preparation 
Stock solutions of molecule 1, 2, 8, and 9 were diluted into the corresponding buffers to 
achieve a final concentration of 0.2 mg/mL for biophysical assays including UV-Visible, CD, 
intrinsic and extrinsic fluorescence spectroscopy as well as static light scattering.  Stock solutions 
were diluted to 1 mg/mL for biophysical assays including DSC, FTIR, and DLS. One mg/mL 
protein samples were also prepared for the shaking and stirring stability studies and aliquots of 1.1 
mL were placed into 3-mL type 1 borosilicate glass vials and capped with rubber stoppers (West 
Pharmaceutical Services, Exton, PA). Before use, the glass vials were autoclaved. Stock samples 
were diluted to 2 mg/mL for TFF and Langmuir trough studies. All samples were sterile filtered 
with 0.22-µm syringe filters after preparation (Millipore, Billerica, MA). The antibody 
concentration was quantified with an Aglient 8453 UV-Visible spectrophotometer (Palo Alto, CA) 
or with a NanoDrop spectrophotometer (NanoDrop Products, Wilmington, DE) in triplicates at 
A280.  The extinction coefficients of 1.68 (molecule 1 and 8), 1.45 (molecule 2), and 1.78 




   
5.2.2.2 Laboratory Scale Tangential Flow Filtration 
A laboratory tangential flow filtration (TFF) system (Pall) with Minimate TFF capsule was 
used to perform diafiltration and concentration of the four molecules. Molecules 1, 2, and 8 used 
capsules with 50K MWCO and molecule 9 used 30K MWCO capsules. Typically, a starting 
volume of 100 mL was used, with a target final volume of 20 mL. A peristaltic pump was used at 
300 RPM to circulate the sample through the capsule. Valves were manually tightened or loosened 
to obtain a pressure of 20 psi across the capsule. The formulation buffer was added at the same 
rate as the filtrate was removed from the system to keep the concentration constant throughout the 
diafiltration steps. Eight diafiltration steps occurred by exchanging the complete starting volume 
with formulation buffer each time. The sample was then concentrated using the system via 
ultrafiltration to achieve a 5X concentration. During the process, samples were removed for testing 
by UV-Vis spectroscopy and MFI. These samples consisted of the starting and final material along 
with various sample in buffer ratios (initial:formulation) of  5:1, 3:1, 1:1, 1:3, 1:5, and after the 
first  diafiltration, second diafiltration, forth diafiltration, and eighth diafiltration.  
 
5.2.2.3 Microflow Imaging 
The total number and distribution of sub-visible particles in the range of 2 to 100 µm were 
examined using an MFI 5200 with an autosampler (Protein Simple, Santa Clara, CA) with a 100 
µm silane coated flow cell. Measurements were made in duplicate at ambient temperature for all 
samples. Illumination was optimized using deionized water filtered with a 0.22-µm filter prior to 
all measurements.  
5.2.2.4 Differential Scanning Calorimetry 
DSC measurements were performed using a VP-Capillary DSC System (Microcal, 
acquired by Malvern Instruments Ltd). Protein concentrations were adjusted to 1 mg/mL before 
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the measurement. The corresponding formulation buffer was used as a reference for each sample. 
The samples were heated from 10 to 90°C at a rate of 60°C/h. Resulting thermograms were 
corrected by subtraction of buffer-only scans and then normalized to the molar concentration of 
the protein and analyzed using Origin 7.0 software (OriginLab Corporation, Northampton, MA). 
5.2.2.5 Far-UV Circular Dichroism 
Far-UV circular dichroism (CD) spectroscopy of protein samples was performed using a 
Chirascan-plus Circular Dichroism Spectrometer (Applied Photophysics Ltd, Leatherhead UK) 
equipped with a peltier temperature controller and a 4-position cuvette holder.  Quartz cuvettes 
(0.1 cm path length) sealed with a teflon stopper (Starna Cells Inc., Atascadero, CA) were used.  
The spectra were collected from 200-260 nm using 1 nm steps and 0.5 s sampling time. Thermal 
melts were performed over a temperature range of 10 to 90°C. The spectra were collected at 2.5°C 
intervals with a 2 min equilibration time at each temperature. The final protein concentration of 
the sample was 0.2 mg/mL and the measurements were conducted in triplicate. 
5.2.2.6 Fourier Transform Infrared Spectroscopy 
FTIR spectroscopy of Molecules 1, 2, 8 and 9 (at 1.0 mg/mL) was performed (in triplicate) 
at 10°C using a Bruker Tensor-27 FTIR spectrometer (Bruker Optics, Billerica, MA) equipped 
with a KBr beam splitter. The MCT detector was cooled with liquid N2 for at least 20 min prior to 
use and the interferometer was constantly purged with N2 gas. All instrument validation tests were 
performed and passed prior to daily measurements. Two hundred fiftysix scans were recorded from 
4000 to 600 cm-1 with a 4 cm-1 resolution using a Bio-ATR cell. Background measurements were 
acquired with the appropriate buffer alone and subtracted from the sample spectra. Atmospheric 
and baseline corrections were applied using OPUS V6.5 (Bruker Optics, Billerica, MA) software. 
Calculation of the second derivative was also completed using OPUS V6.5 while applying a 9-
point Savitzky-Golay smoothing function. For Fourier self-deconvolution, the deconvolution 
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factor was 2 and the noise reduction filter was 0.5. Following the deconvolution, between 6 and 9 
peaks were fitted to the absorbance spectrum in the Amide I region (1700-1600 cm-1) using a 50% 
Lorentzian and 50% Gaussian function. The areas of the peaks were used to calculate the relative 
percentage of secondary structure components in each Ab sample. 
5.2.2.7 Intrinsic Fluorescence Spectroscopy 
Intrinsic tryptophan fluorescence was measured in triplicate using a Photon Technology 
International (PTI) spectrofluorometer (Lawrenceville, NJ) equipped with a turreted four-position 
Peltier-controlled cell holder and a xenon lamp. Fluorescence emission spectra of samples at 0.2 
mg/mL using 1 cm path length quartz cuvettes were recorded as a function of temperature (10-
90°C). An excitation wavelength of 295 nm was used (>95% Trp emission) with the slit width set 
at 4 nm. Emission spectra were collected from 305-405 nm with a step size of 1 nm and an 
integration time of 1 s. The spectra were collected at 2.5°C intervals with a 2 min equilibration 
time at each temperature. The initial signal was kept at ~800,000 counts per second for 
fluorescence spectra and an emission maximum of ~20,000 counts per second for light scattering 
data. Analysis was performed using in-house software (Middaugh Suite).  The corresponding 
buffer spectrum was subtracted from each protein spectrum prior to data analysis. The emission 
peak position was determined using a mean spectral center of mass method (MSM) executed in 
the Middaugh Suite. Although this calculation method increases the signal to noise ratio for more 
accurate determination of lambda max values, it shifts the apparent peak position by 5-10 nm from 
their actual values. The Tonset values were determined by identifying the point at which the baseline 
deviated from linearity using Origin software. 
5.2.2.8 Extrinsic Fluorescence Spectroscopy 
8-Anilino-1-naphthalene sulfonate (ANS) was used as an extrinsic fluorescence probe in 
the presence of antibody with the same instrument described above. A dye to protein molar ratio 
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of 25:1 was used for sample preparation. ANS was excited at 372 nm, and emission spectra of 
ANS was collected from 400-600 nm every 2 nm as a function of temperature from 10 to 90oC. 
The corresponding buffer spectra were subtracted from protein spectra prior to data analysis. The 
emission peak intensity was determined using a mean spectral center of mass method (MSM) 
executed in the Middaugh Suite. The Tonset values were determined by identifying the point at 
which the baseline deviated from linearity using Origin 8.0 software. 
 
5.2.2.9 Static Light Scattering 
The static light scattering intensity values were collected simultaneously during the 
intrinsic fluorescence experiments using a second photomultiplier located 180° to the 
fluorescence detector and a 0.25 nm slit width. The scattering intensities at 295 nm were 
obtained as a function of temperature (10-90°C). Scattering from the buffer alone was subtracted 
from each protein sample value before data analysis. 
5.2.2.10 Dynamic Light Scattering 
Size analysis by DLS was performed employing the dynamic light scattering mode on a 
ZetaPALS zetasizer (Brookhaven Instruments Corporation, Holtsville, NY) using quartz cuvettes 
that were cleaned of any dust and air-dried.  The hydrodynamic diameters of filtered Molecule 1, 
2, 8 and 9 samples (at 1 mg/mL) were analyzed by generating an auto-correlation decay function 
after centrifugation at 14,000 X g for 5 min. Ten measurements were recorded and averaged for 
30 s each. Number and intensity distributions were fitted using multimodal size distribution (MSD) 
or a cumulant analysis algorithm was employed using the instruments software. All measurements 
were performed in triplicate at 25°C. The viscosity value used for each DLS experiment was 
determined prior to analysis (see section 2.2.11). 
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For determination of the interaction parameter (kD), DLS measurements were instead made 
on a Wyatt DynaPro Plate Reader (Wyatt Technology Corporation, Santa Barbara, CA).  The 
mutual diffusion co-efficients (Dm) of each molecule were determined in the specified buffers at 
1, 3, 5, 8 and 10 mg/mL.  Solvent viscosities used were determined prior to analysis (see section 
on Viscosity), or (in the case of PBS) selected from calculated values in the instrument software.  
A linear plot of 1/Dm as a function of concentration (c) was used to determine the kD values and 
the diffusion coefficient (Ds) for each molecule using the following relation (at low protein 









) c    
 
5.2.2.11 Viscosity 
Solution viscosities were measured at 25°C with an m-VROC viscometer (Rheosense, San 
Ramon, CA). Samples were injected at a rate of 100 mL/min at a shear rate of 1935.6 1/s for a 
duration of 100 s using a 1-mL glass syringe (Hamilton Co, Reno, NV). Measurements were made 
in triplicate. Viscosity values were obtained in units of dynamic viscosity (cP). 
 
5.2.2.12 PEG Solubility Assay 
The experimental protocol was adapted from Gibson et al.6 and Toprani et al.7 Stock 
solutions of PEG-10,000 ranging from 0 to 40% w/v PEG were prepared in each corresponding 
buffer. A volume of 200 μL of each of the PEG-10,000 solutions (from 0% to 40% w/v PEG) was 
added to wells of a 96-well polystyrene filter plate (Corning # 3504, Corning Life Sciences, 
Corning, NY). Fifty microliters of the protein stock solutions (1 mg/mL) were then added to each 
well to achieve a final protein concentration of 0.2 mg/mL. The plates were incubated at room 
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temperature overnight and then were centrifuged at 1233 (× g) for 15 min. The filtrate was 
collected in a clear 96-well collection plate (Greiner Bio-One n # 655001, Greiner Bio-One North 
America Inc., Monroe, NC). The protein concentration was determined by transferring 200 μL of 
filtrate into a 96-well UV Star microplate (Grenier#655801). The filtrate was measured on a 
SpectraMax M5 UV-Visible plate reader at 280 nm to determine the protein concentration The 
concentrations versus %PEG-10,000 data were fit to a standard 4-parameter, modified hill-slope 
sigmoidal curve equation (Eq. 1) using Python (x,y) version 2.7.6.0, an open-source scientific 
software based on Python language. The %PEGmidpt values and apparent solubility value 
parameters were then calculated from the resulting curve fit50 where t = top plateau, b = bottom 
plateau, mid = x-axis midpoint, and s = slope. The %PEGmidpt values were determined by noting 
the x-axis midpoints. 
 




The apparent solubility (thermodynamic activity) values were determined by first plotting 
the same data sets on a logarithmic scale from the transition region and then fitting them using 
Equation 2 to extrapolate the data to zero %PEG concentrations. 
(2) 𝑙𝑜𝑔 𝑆𝑝 = log 𝑎0 − 𝐴12[PEG] 
 
5.2.2.13 SDS-PAGE 
Samples were mixed with 4 NuPAGE LDS sample buffer (Thermo Fisher Scientific, 
Waltham, MA) with and without 5 mM dithiothreitol (Thermo Scientific, Rockford, IL) and 
incubated at 95°C for 5 min. Samples were then treated with 10 mM iodoacetamide (Thermo 
Scientific) at 25°C in the dark for 30 min. Each sample (10 mg) was separated on 10-20% Tris-
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glycine gels using NuPAGE MES SDS Running Buffer (Thermo Fisher Scientific). SeeBlue Plus2 
Pre-stained Protein Standard (Thermo Fisher Scientific) was used as a molecular weight ladder. 
Protein bands were visualized by staining the gels with Bio-safe Coomassie Blue G250 stain 
(BioRad Laboratories, Hercules, CA), followed by destaining in destaining buffer (50% methanol, 
10% acetic acid). 
5.2.2.14 Shaking and Stirring Studies 
Samples were prepared in triplicates at 1 mg/mL. For shaking stress, the antibodies were 
agitated at 300 rpm using an IKA AS260.1 shaking platform with time points every hour over the 
course of 8 hours.  For stirring stress, the molecules were stressed by placing a small pivot-ring-
free stir bar (7 x 2 mm flea micro; Bel-Art-SP Scienceware, Wayne, NJ) inside each 3-mL vial and 
the stir setting was set to 5 at 25°C with time points every hour over the course of 8 hours using a 
Reacti-Therm III (Thermo Scientific). No vortex was observed in the liquid under these stirring 
conditions.  
 
5.2.2.15 Langmuir trough 
Molecules 1, 2, 8, and 9 at 2.0 mg/mL were loaded into a Langmuir trough that was 
controlled at 23 ± 2°C (Biolin Scientific, Inc., Stockholm, Sweden). A paper plate was used to 
measure surface pressure during compression-expansion experiments. The Ab solutions were 
initially allowed to reach a saturation concentration at the interface by allowing the solutions to 
equilibrate for 2 h. After this initial waiting period, the protein samples were exposed to interfacial 
compression-expansion cycles using movable Delrin barriers that touch the air-water interface. 
The available interfacial area changed from 87 to 12 cm2 during each compression-expansion 
cycle. The compression ratio, defined as the ratio of the maximum possible interfacial area and the 
minimum interfacial area of the trough (CR = Amax/Amin), was held constant at 7.25 for this study. 
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A compression-expansion rate was defined as experiments where the protein solution in the trough 
was subjected to 750 cycles in 6 h. 
5.3 Results 
5.3.1 Tangential Flow Filtration 
Four Ab molecules were provided to KU-MVSC by BMS that had known behaviors 
throughout the large scale TFF process. Two Ab molecules (molecules 1 and 2) were deemed 
“good” by showing acceptable protein recovery and low tendency to aggregate. The other two Ab 
molecules (molecules 8 and 9) were deemed “bad” molecules due to lower protein recovery and 
particle formation. These previously recorded results observed during large scale TFF processing, 
along with some of the key properties of the four Ab molecules (as well as their respective buffer 
conditions), are summarized in Table 1.  As an initial evaluation, the four Ab molecules were 
characterized using SDS-PAGE (Figure 1) under both reduced and nonreduced conditions. Based 
on examination the gels, all four Abs appeared to be of high purity and there was no notable 
covalent aggregation and only minor fragmentation detected in each of four protein molecules.  
The first step in determining the causes and mechanisms of protein aggregation and particle 
formation observed by BMS scientists to be induced during large scale TFF of these antibodies 
was to develop a miniaturized lab scale TFF system and evaluate its performance in predicting 
protein stability during large scale TFF processing. Figure 2 denotes the workflow used for these 
small scale TFF experiments and Figure 3 shows a schematic of the small scale TFF process and 
the sample points throughout the processes. The laboratory scale TFF was performed with all four 
Ab molecules using the same processing conditions, but in their respective processing buffers (see 
Table 1), and samples collected throughout the process were analyzed. These samples consisted 
of the starting material in the initial buffer, final concentrate material in the formulation buffer, 
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and intermediate samples collected when buffer ratios of initial:formulation were reached during 
the diafiltration steps (5:1, 3:1, 1:1, 1:3, 1:5, and after the 1st, 2nd, 4th, and 8th diafiltration).  The 
protein concentration of the starting material was 2 mg/mL in the indicated initial buffers with a 
starting volume of 100 mL. The final step in the TFF protocol was a 5X concentration to achieve 
10 mg/mL final material in the formulation buffer (see Table 1). This processes was optimized 
prior to reaching these conditions. Previously, runs were performed with 50 mL of the starting 
material. This was not ideal when the material was concentrated 5X due to the resulting volume 
equaling the dead volume of the filter. It was seen that a larger amount of protein was lost for all 
four molecules (~25-55%). This could be due to loss during the final sample recovery and/or to 
increased aggregation from intensified agitation conditions.   
Using these optimized lab scale TFF process conditions (as described above), the protein 
recovery for each of the four Ab molecules is shown in Figure 4A. Molecules 1 and 2 show greater 
protein recovery than molecules 8 and 9, which is consistent with the “good” and “bad” results 
seen by BMS scientists using the large-scale TFF process. The same Ab samples were then 
analyzed by MFI to observe subvisible particle formation throughout the TFF process (Figure 5A).  
All four Ab molecules showed the presence of subvisible particles in the initial buffer and an 
increase in the subvisible particle concentration during processing into the final formulation buffer 
(ultrafiltration) and at higher protein concentrations (diafiltration).  Molecule 8 had the highest 
levels of subvisible particles in both the initial solution at 2 mg/mL and after TFF processing into 
the final formulation buffer at 10 mg/mL.  
Next, molecule 2 was examined under various conditions such as performing the 
ultrafiltration/diafiltration into a different formulation buffer (Formulation 2). This alternative 
formulation buffer was suggested by BMS scientists.  As shown in Figure 4B, molecule 2  showed 
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lower protein recovery in formulation buffer 2 than formulation 1 buffer (Figure 4B). The third 
condition using molecule 2 was performing a higher fold concentration step of 20X instead of the 
previously examined 5X. In order to reach a 20X concentration, the starting volume of 500 mL 
was used and the targeted final volume was 25 mL.   Increasing the concentration from 5X to 20X, 
led to only a slight decrease, if any, in percent recovery (from ~92% to ~87%, see Figure 4B). The 
last condition examined for molecule 2 was adding 0.01% PS80 to the initial buffer and 
formulation 2 buffer and the TFF process was repeated. Compared to running the TFF process  in 
the absence of PS80,  the addition of 0.01% PS80 produced similar protein recovery results for Ab 
molecule 2 (Figure 4B). MFI was performed to compare the subvisible particles concentration 
under various conditions described above (Figure 5B). Exchanging molecule 2 into formulation 1 
vs formulation 2 showed no difference in particle formation. However, concentrating the Ab 
molecule 2 by 20X compared to 5X showed a 10-fold increase in subvisible particle formation, 
Not surprisingly, the addition of 0.01% PS80 to the initial and formulation buffers significantly 
decreased the subvisible particle formation for molecule 2 (Figure 5B). Due to the large amount 
of material needed for each TFF run, only molecule 2 in formulation 1 buffer was examined in 
duplicate and the errors were extrapolated for all other conditions. The protein recovery amount 
error between the two runs was negligible.  
As a final set of experiments, due to molecule 8 showing the lowest percent recovery and 
a large amount of subvisible particle formation during TFF processing, 0.01% PS80 was added to 
the initial buffer and the formulation buffer and the laboratory scale TFF protocol was performed 
again. When comparing the protein recovery with and without PS80, there was a slight decrease 
observed when PS80 was present (Figure 4C). The addition of 0.01% PS80 to the initial and 
formulation buffers, however, had a major impact on decreasing the subvisible particle formation 
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with molecule 8 as seen by a ~10-fold decrease in particle levels as measured by MFI (Figure 5C). 
This result is not necessarily surprising since it is well known that high levels of subvisible particles 
can form due to aggregation of very low levels of protein.Thus, subvisible particles can form 
without affecting the total protein concentration.8  
In summary, the small scale TFF system at KU showed the same trends seen when 
performing the larger scale procedure at BMS (i.e. Molecule 1&2 are more stable than 8&9). 
This was shown by higher protein recovery of the “good” molecules vs. that of the “bad” 
molecules. The percent recovery was optimized by increasing the starting volume to 100 mL 
instead of the initially tested 50 mL. Molecule 2 was examined using multiple buffer conditions: 
(1) formulation 1; (2) formulation 2; (3) 20X concentration; and (4) the addition of 0.01% PS80. 
The percent recovery was lower for formulation 2 buffer vs. formulation 1. The 20X 
concentration vs. 5X concentration showed a slightly higher percent recovery. The addition of 
0.01% PS80 showed a slightly lower percent recovery than the same formulation buffer without 
it. Molecule 8 was examined with and without 0.01% PS80 and showed a 1% decrease in percent 
recovery. When examining the subvisible particle concentration for samples taken throughout the 
TFF run, there was an increase seen for all four molecules but molecule 8 showed the largest 
amount. There was a comparable amount of subvisible particles observed when comparing 
molecule 2 in formulation 1 to formulation 2. The 20X concentration vs. 5X concentration 
showed higher particle counts, which would be expected.  Both molecule 2 and 8 were stabilized 
by the addition of 0.01% PS80 but significantly less subvisible particles were observed. 
5.3.2 Structural Integrity and Conformational Stability Properties of the Four Antibodies 
in PBS Buffer 
After a small scale TFF method had been established, we sought to correlate the stability 
profile obtained with the four Ab molecules with some inherent properties of these molecules to 
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identify which aspects of the environmental stresses resulting from TFF processing lead to protein 
aggregation.  The first step was to investigate the correlation between TFF stability and key 
structural integrity and conformational stability properties of the  proteins. The four Ab molecules 
were examined in their respective TFF processing buffers (initial buffer, 50/50 mixture of initial 
and formulation buffers, formulation buffer; see Tables 1 and 2) and in PBS buffer (Table 2). 
Molecule 2 was examined in two different formulation buffers (form 1 and form 2) and therefore 
in two 50/50 mixtures (50/50(1) and 50/50(2)). The structural attributes examined include overall 
secondary structure, tertiary structure, conformational stability, size and aggregation behavior, and 
reversible self-association. These were analyzed by a wide variety of analytical techniques (Table 
3).  
The four Ab molecules were examined in PBS buffer to better compare each of the 
molecules inherent properties to one another, prior to analyzing the structural attributes of each 
molecule in their respective TFF processing buffers. Both CD and FTIR spectroscopy were used 
to examine the overall secondary structure of the four Ab molecules (Figures 6 and 7, respectively). 
As expected, both techniques showed each of the four molecules to consist primarily of beta-
sheets, in the case of CD with a min around 218nm (Table 4.) After the initial CD scan at 10ºC, 
a ramp to 90ºC was performed and the Tonset values were determined (Figure 4B). Molecule 2 
showed the highest Tonset value at 60ºC, while molecule 9 had the lowest at ~55ºC (Table 4). Both 
intrinsic and extrinsic fluorescence spectroscopy were used to monitor tertiary structural changes. 
Intrinsic tryptophan fluorescence showed that molecule 2 had the lowest peak maximum at 328 
nm and molecule 1 had the highest at 343 nm (Figure 8A). Molecule 1’s higher peak position may 
be due to a surface exposed tryptophan that was also seen by CD. The samples were then ramped 
from 10 to 90ºC and the thermal data were analyzed using MSM Peak Intensity to determine the 
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Tonset values.  Molecule 2 showed the highest Tonset at 63ºC, followed by molecule 1, and molecule 
8 had the lowest Tonset value at 46ºC (Figure 8B). The data were also analyzed by MSM Peak 
Position and showed molecules 1 and 2 with comparable Tonset values at ~61ºC and molecule 8 
with the lowest at 48ºC (Figure 8C). Next, ANS extrinsic fluorescence analysis was performed 
starting with a scan of each molecule at 10ºC (Figure 9A). A temperature ramp was performed 
from 10 to 90ºC (Figure 9B) and MSM Peak Intensity was used to determine the Tonset values of 
each molecule. This experiment showed molecule 2 with the highest Tonset value at 63ºC followed 
by molecule 1. Molecule 8 had the lowest Tonset value at 53ºC (Table 4).  
UV-Visible spectroscopy showed that the protein concentration range of each of the 
molecules were sufficiently comparable for these experiments (Figure 10A) and the 2nd derivative 
of the spectrum was used to show comparable overall tertiary structures (Figure 10B). Differential 
scanning calorimetry (DSC) ca be used to determine the overall conformational stability of 
molecules and was used to determine Tonset values of the four molecules by performing a 
temperature ramp from 10 to 90 ºC (Figure 11). The Tonset values were selected since the DSC 
thermogram of each molecule displayed distinct profiles and it was thus difficult to compare Tm 
values.  Again, molecule 2 had the highest Tonset value at 64ºC and molecule 9 had the lowest at 
60ºC (Table 4). SLS was used to determine the aggregation propensities over the course of the 
temperature ramp during the intrinsic fluorescence scan (Figure 12). Molecule 2 had the highest 
Tonset by over 10ºC (Tonset = 71ºC) while molecule 8 had the lowest at 56ºC (Table 4). DLS was 
used to determine the particle size for each molecule (Figure 13). Molecule 9 had the highest 
particle size and molecule 1 had the lowest but overall they all were very similar. 
In summary, the molecules were compared in PBS. Both CD and FTIR revealed the 
presence of primarily beta-sheet structure as expected for immunoglobulins. CD also revealed 
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molecule 2 to have the highest Tonset value. Molecule 1 showed a lower than expected Tonset value 
that was comparable to molecule 8. Intrinsic fluorescence showed molecule 2 to have the highest 
Tonset value by peak intensity followed by molecule 1 while molecule 8 had the lowest. For peak 
position, molecule 1 and 2 had comparable Tonset values which were higher than molecule 8 and 
9. Extrinsic fluorescence showed molecule 2 manifesting the highest thermal stability with the 
highest Tonset. Molecule 1 had the second highest, followed closely by molecule 8 and 9. DSC 
and SLS showed the same trend as extrinsic fluorescence. These biophysical techniques showed 
some correlation with the TFF processes (“good” vs. “bad” molecules). Overall, molecule 2 
(“good”) had the highest thermal stability according to the higher Tonset values. Molecule 1 
(“good”) had a trend to either be the second highest stability or comparable to molecules 8 and 9 
(“bad”). Molecule 8 had a trend to be either the least stable or comparable to molecule 9 and/or 
molecule 1. 
5.3.3 Structural Integrity and Conformational Stability Properties of the Four Antibodies 
in TFF Processing Buffer 
After the biophysical properties of the  four Ab molecules were examined in PBS buffer, 
the same methods were repeated for each molecule in its corresponding TFF processing buffers 
including the initial buffer (buffer prior to TFF), 50/50 mixture (50% initial buffer and 50% 
formulation buffer), and formulation buffer (buffer following TFF)(see Table 2). Due to molecule 
2 having two formulation buffers (form 1 and form 2), the 50/50 mix buffers were labeled 50/50(1) 
(50/50 mixture with form 1) and 50/50(2) (50/50 mixture with form 2).  In terms of overall 
secondary structure, FTIR was performed to determine the secondary structure and the percentage 
of alpha-helix, b-sheet, and disorder structures was calculated (Figure 14). When comparing the 
FTIR spectrum, there was no notable change in the secondary structure between buffers for each 
of the four molecules (Supplementary figure S2).   
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Intrinsic tryptophan fluorescence spectroscopy was used to look at the overall tertiary 
structure of each molecule, first by an initial scan at 10ºC (Figure 15). Molecule 1 showed the 
50/50 mix buffer to have lower λmax than the initial and formulation (Figure 15A). Molecule 2 in 
the 50/50 mix (1), formulation 1 (form 1), and formulation 2 (form 2) showed similar λmax, while 
in the initial and 50/50(2) this molecule had slightly higher λmax values (Figure 15B, C). Molecule 
8 and 9 in the 50/50 and formulation buffer had a lower λmax but in the initial buffer these molecules 
had slightly higher λmax values (Figures 15 D, E). These values were compiled and compared in 
Table 5 and Molecule 1 had the highest range of λmax in all 3 buffers (~340-350 nm) compared to 
the other Ab molecules (~325-335 nm). A redshift (increase in wavelength) in the λmax indicates 
an increase in polarity around buried tryptophan residues. Therefore if buried tryptophan residues 
become more exposed, the λmax is higher. The opposite is true for a blueshift, as tryptophan residues 
become more buried in the protein, the λmax will decrease. The changes seen between the different 
buffers can suggest how tightly the protein is folded and can alter the interaction available to 
produce aggregation. A temperature ramp was done from 10 to 90ºC and peak intensity vs 
temperature was used to determine the molecules Tonset values (Figure 16). Molecule 1 showed 
similar Tonset values in all 3 buffers with the initial buffer value trending to be slightly lower. 
Molecule 2 showed the initial buffer with the lowest and formulation 1 with the highest Tonset  
values. Molecule 8 showed that the formulation buffer greatly increased the Tonset compared to the 
initial and 50/50 mix buffer. Molecule 9 showed similar Tonset in all 3 buffers with the 50/50 mix 
buffer being slightly lower. These results were compiled in Table 5 and Molecule 2 had the highest 
and molecule 8 had the lowest Tonset values (Table 5). Peak position vs temperature was also 
examined to determine the Tonset values (Figure 17). Molecule 1, 8, and 9 had the highest Tonset in 
the formulation buffer. Molecule 2 showed the 50/50 mix buffer (1) and form 1 buffer to have an 
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increase in Tonset compared to the initial and 50/50(2), and the formulation 2 buffer had the lowest 
(Table 5).   
Next, a scan at 10 ºC of extrinsic ANS fluorescence was examined (Figure 18). Molecule 
1 and 8 had similar λmax at ~500 nm. The majority of the buffer conditions for molecule 2 had a 
similar λmax at ~500 nm with the exception of 50/50 mix buffer (1) having a lower λmax at 494 nm. 
These results were compiled in Table 5 and Molecule 9 overall showed a slightly lower λmax 
compared to the other three molecules (Table 5). A thermal  scan from 10 to 90ºC was executed 
and the temperature dependent ANS peak intensity was plotted (Figure 19). Molecule 1 showed a 
lower Tonset in the formulation buffer than the initial and 50/50 mix buffer. Molecule 2 showed the 
highest Tonset in 50/50 mix buffer (1) and formulation 1 buffer. The 50/50(2) buffer showed the 
lowest Tonset. Molecule 8 showed the highest Tonset in the 50/50 mix buffer. Molecule 9 in the initial 
and 50/50 mix buffers were comparable, but in the formulation buffer had the lower Tonset. These 
results were compiled in Table 5 and Molecule 2 had the highest Tonset compared to the other three 
molecules (Table 5). 
UV-Visible spectroscopy was used to determine the protein concentrations of all four 
antibodies and they were comparable in range (Figure 20). Using the UV-Visible spectrum, the 2nd 
derivative was determined to compare the tertiary structures of the four molecules. The overall 
tertiary structure of all four antibodies was comparable across all the TFF buffer systems evaluated 
for each the four Ab molecules (Figure 21). DSC was performed in the three different TFF process 
buffers for each molecule (Figure 22). In most cases, Tonset values remained unchanged across all 
three buffer systems. The Tonset value for Molecule 8 is higher in the final formulation. Molecule 
1 had one major transition while all other molecules had at least 2 transitions reflecting the distinct 
domain structure of Igs (See Figure 22 and Table 5).  SLS data was collected concurrently with 
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the intrinsic fluorescence spectrometry temperature ramp (Figure 23) and the Tonset of each 
molecule was determined. Molecule 1 and 8 showed higher Tonset values in the formulation buffer 
than the initial and 50/50 mix buffers. Molecule 2 in the formulation buffers were shown to have 
the highest and in the initial buffer to have the lowest Tonset values. Molecule 9 showed the 50/50 
mix buffer to have the highest Tonset. These results were compiled in Table 5 and Molecule 2 had 
the highest Tonset out of all four molecules (Table 5). DLS was used to determine the particle size 
of each molecule in the different buffers (Figure 24). There was a trend that the 50/50 mix buffer 
showed larger hydrodynamic diameters and percent polydispersities. Overall, there was no 
significant change in diameter or polydispersity of the four molecules in different buffers. 
In summary, many of the same trends were seen in the TFF processing buffers as PBS. 
FTIR revealed the majority were in a beta-sheet structure. Intrinsic florescence peak intensity 
and position showed molecule 2 with the highest Tonset value followed by molecule 1. Molecule 8 
had the lowest Tonset value. Extrinsic florescence again showed molecule 2 with the highest Tonset 
values, molecule 1 and 9 were comparable and molecule 8 had the lowest. DSC showed very 
little change between the different buffer compositions for each molecule. Molecule 2 showed 
the highest Tonset values, followed by molecule 1 then 9 and molecule 8 had the lowest. SLS 
showed molecule 2 with a significantly higher Tonset values and molecule 1, 8, and 9 were 
comparable.  Again, in the TFF processing buffer, the biophysical techniques showed some 
correlation with the TFF processes (“good” vs. “bad” molecules). Overall, molecule 2 (“good”) 
had the highest thermal stability according to the higher Tonset values. Molecule 1 (“good”) had a 
trend to either be the second highest stability or comparable to molecules 8 and 9 (“bad”). 




   
5.3.4 Reversible Self-Association Properties of the Four Antibodies in PBS Buffer and in 
their Respective TFF Processing Buffer 
 A PEG solubility assay was used to determine the % PEG midpoint and apparent relative 
solubility values for each of the four Ab in PBS buffer and in their respective TFF processing 
buffers. In PBS, molecule 1 had the highest PEG midpoint and apparent solubility and molecule 8 
had the lowest overall (Figures 25A and B). When looking at the % PEG midpoint values of the 
four molecules in the TFF processing buffers, a trend was seen that the formulation buffers resulted 
in the highest values, with the exception of molecule 8 where the formulation buffer had the lowest 
value (Figure 26). When looking at the apparent solubility values, a lot of variability was observed 
in the extrapolated data sets, making comparisons difficult across the different buffers and 
molecules (see Supplemental Figure S3).  A summary of the % PEG midpoint and relative apparent 
solubility values for each of the four Ab molecules, and % PEG midpoint values in the TFF 
processing buffers, is shown in Table 6 (PBS) and Table 7 (TFF processing buffers). 
kD2 values were determined by DLS analysis for each molecule in their respective 3 TFF 
process buffers along with PBS buffer to determine its potential for reversible self-association 
(Figure 27). In the initial buffers, the kD2 values were very low (<-0.03) indicating low reversible 
self-association (RSA) and high solubility.  The same trend was observed in PBS buffers, with the 
exception of molecule 8 where the kD2 value was somewhat higher (~-0.05). In buffers containing 
sugars or sugar alcohols (all formulation buffers), the 1/Dm vs. protein concentration plots were 
not linear, preventing kD2 values from being determined by this method (see representative Mol. 2 
inverse Dm plot).  As a final evaluation of RSA, the viscosity of the four Ab solutions in their 
stock solutions was evaluated (Supplementary Figure S3). It was shown that low viscosity values 
(<2 cp) were observed at the protein concentrations of the stock solutions of 50 mg/mL for 
molecule 1, 2, and 9 and 18.3 mg/mL for molecule 8.  
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In summary, the midpoint solubility was highest in the formulation buffers with the 
exception of molecule 8. When comparing all four molecules in PBS, molecule 1 had the highest 
midpoint solubility. When examining the kD2 values, all four molecules had very low potential 
for self-association and the viscosities of the stock solutions were very low. 
5.3.5 Colloidal Stability of the Four Antibody Molecules by Shaking and Stirring in PBS 
and their Respective TFF Processing Buffers 
The colloidal stability of the four Ab molecules were compared through shaking and 
stirring agitation studies. Molecules were stressed by shaking at 300 rpm or stirring on a setting of 
5 over the course of 8 hours with time points examined every hour. The four Ab molecules were 
compared in PBS buffer along with the molecules in their TFF processing buffers (initial, 50/50 
mix, and formulation buffers). Due to molecule 2 having two formulation buffers (form 1 and form 
2), the 50/50 mix buffers were labeled 50/50(1) (50/50 mixture with form 1) and 50/50(2) (50/50 
mixture with form 2). In addition, the four Ab molecules were compared in all three TFF 
processing buffers with the addition of 0.01% PS80. The samples were evaluated by visual 
assessment for turbidity and visible particle formation, and then examined for protein 
concentration and subvisible particle concentration (see Tables 6 and 7 for experimental outline 
and analytical testing plan, respectively). 
For visual assessment of Ab solutions in vials that underwent shaking and stirring, each of 
the four Ab molecules in PBS showed some level of visible aggregation over the 7 hrs of stirring, 
with molecule 2 only showing slight amounts at the last time point (Figure 28). Molecules 8 and 
9 showed the most visible aggregation. When the molecules were under shaking stress, molecules 
1, 8, and 9 showed visible aggregation over the course of 7 hrs. Molecule 2 did not show any 
visible aggregation until 3 days of shaking (Data not shown).  
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When molecule 1 was examined by visual assessment during the stirring agitation in the 
three process buffers without PS80, small amounts of visible aggregation was seen in all cases at 
the later time points of 5 hrs and increased to larger amounts by 8 hrs (Figure 29). When 0.01% 
PS80 was added into the solution, no visible aggregation could be seen up to the last time point of 
8 hrs. Molecule 1 also showed visible aggregation in the three process buffers during shaking 
agitation starting at 3 hrs in the formulation buffer with large amounts seen at 8 hrs (Figure 30). 
Less amounts were seen in the initial and 50/50 mix buffers. When 0.01% PS80 was added into 
the solution, no visible aggregation could be seen up to the last time point of 8 hours. 
When molecule 2 was examined by visual assessment during the stirring agitation in the 
three process buffers without PS80, small amounts of visible aggregation were seen in all cases at 
the time points of 4 hrs which increased to larger amounts by 8 hrs (Figure 31). Formulation 1 
buffer contained the least amount of aggregation out of the 5 different compositions. When 0.01% 
PS80 was added into the solution, no visible aggregation could be seen up to the last time point of 
8 hrs. Molecule 2 showed very little visible aggregation in the process buffers. In the initial and 
formulation 1 buffer, there was no sign of visible aggregation present. In the 50/50(1) buffer, only 
a small amount was seen at 8 hrs. In the 50/50(2) and formulation 2 buffer, visible aggregation 
was seen at 6 and 5 hrs, respectively (Figure 32). When 0.01% PS80 was added into the solution, 
no visible aggregation could be seen up to the last time point of 8 hrs. 
When molecule 8 was examined by visual assessment during the stirring agitation in the 
three TFF process buffers without PS80, small amounts of visible aggregation were seen in all 
cases at the later time points of 5 hrs which increased to larger amounts by 8 hrs (Figure 33). When 
0.01% PS80 was added into the solution, no visible aggregation could be seen up to the last time 
point of 8 hrs. Molecule 8 also showed visible aggregation in the three TFF process buffers during 
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shaking agitation and in greater abundance than seen in stirring (Figure 34). The initial buffer 
showed visible aggregation after the first hour of shaking and the 50/50 mix and formulation buffer 
showed similar amounts after 2 hrs, with large amounts forming after a few hours. When 0.01% 
PS80 was added into the solution, no visible aggregation could be seen up to the last time point of 
8 hrs. 
When molecule 9 was examined by visual assessment during the stirring agitation in the 
three TFF processes buffers without PS80, a small amount of visible aggregation was seen in all 
cases (Figure 35). Both the initial and formulation buffer showed visible aggregation after 2 hrs 
and the 50/50 mix after 4 hrs. Large amounts were seen after just 4 hrs in all process buffers. When 
0.01% PS80 was added into the solution, the visible aggregation was significantly decreased 
greatly but Abs in all three TFF process buffers still showed small amounts of aggregation after 4 
hrs. Molecule 9 showed very little visible aggregation in the three process buffers during shaking 
agitation (Figure 36). Only small amounts were seen in the 50/50 mix (5 hrs) and formulation 
buffer (8 hrs). When 0.01% PS80 was added into the solution, no visible aggregation was observed 
up to the last time point at 8 hrs. 
The protein concentration of each Ab sample in PBS was tested by UV visible spectroscopy 
using the Nanodrop instrument due to volume constraints. A representative absorbance spectrum 
of molecule 2 in PBS shows no change from the starting material (T=0) to 7 hrs of shaking at 300 
rpm (Figure 37A). Figure 37B shows molecule 8 in PBS to represent the absorbance decrease 
when the protein concentration decreases due to aggregation from the stress of shaking from T=0 
7 hrs.  When looking at the concentration of the molecules in PBS, molecules 1 and 2 remained 
stable during the stirring stress over the course of 7 hrs (Figure 38A). Molecule 8 showed a 
decrease in concentration at 7 hrs (~25% loss) while molecule 9 showed a slight downward trend 
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in concentration compared to the other molecules. When shaking the molecules in PBS buffer, the 
concentration of molecules 1, 2, and 9 remained relatively stable after 7 hrs of shaking at 300 rpm 
while molecule 8 showed a significant decrease over time (Figure 38B). 
Next, the protein concentration of each of the four Ab molecule was examined in their 
respective TFF process buffers (both with and without PS80 addition) over the time course of 8 
hrs of stirring (Figure 39). Molecule 1 remained stable in all three buffers conditions (Figure 39A) 
and with PS80 added (Figure 39B). Molecule 2 had a trend showing a slight decrease in the 
different buffer compositions but the two formulation buffers were the most stable overall (Figure 
39C). When PS80 was added to the molecule 2 buffers, there was no loss in concentration observed 
with any of the buffer compositions with the exception of the initial buffer (Figure 39D). Molecule 
8 formulation buffer showed the biggest decrease in concentration over time compared to the initial 
and 50/50 mix buffer, which showed little decrease in concentration (Figure 39E). When PS80 
was added to molecule 8 buffers, the initial buffer showed the largest decrease in concentration, 
and the 50/50 and formulation buffers showed no decrease in concentration with time (Figure 39 
F). Molecule 9 had a large loss of protein concentration over the course of 8 hrs in all three of the 
TFF process buffers (~10-20%), with the initial buffer showing the most loss and the 
formulationthe least (Figure 39G). When PS80 was added to the buffers, the 50/50 and formulation 
buffer showed little to no loss in the protein concentration while the initial buffer showed less loss 
compared to the solution without PS80 (Figure 39H).  
The protein concentration of each of the four Ab molecule was examined in their respective 
TFF process buffers (both with and without PS80 addition) over the time course of 8 hrs of shaking 
(Figure 40). Molecule 1 in the TFF processing buffers showed a steady decrease in concentration 
over the course of 8 hrs in all three buffers (Figure 40A). When PS80 was added to the buffers, 
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the concentration did not show a decrease over the 8 hrs of shaking (Figure 40B). Molecule 2 was 
the most stable in the formulation 1 buffer and the least stable in the formulation 2 buffer 
(Figure40C). The 50/50(1) buffer was relatively stable throughout the stress while the 
concentration in the 50/50(2) buffer decreased over time. PS80 was able to minimize this effect 
and the concentration at all timepoints remained stable compared to the starting material (Figure 
40D). Molecule 8 was the most unstable molecule, showing the highest amount of protein loss 
during the shaking agitation (Figure 40E). All three of the TFF processing buffers showed a large 
decrease over time with the initial buffer having the greatest loss. When PS80 was added into the 
buffers, the concentration of molecule 8 remained constant over the 8 hr stress (Figure 40F). 
Molecule 9 showed little loss of protein during the shaking agitation in all of the TFF processing 
buffers (Figure 40G). When PS80 was added into the solution, no protein loss was observed 
(Figure 40H) 
To better understand the visible aggregation and protein concentration results for each of 
the four Abs in their respective TFF buffers, the subvisible particle concentration was determined 
at each timepoint during stirring agitation for each molecule in each TFF process buffer using MFI. 
Under stirring conditions, Molecule 1 showed the most increase in subvisible particle levels in the 
initial buffer followed by the 50/50 mix buffer and the least amount in the formulation buffer 
(Figure 41A). When 0.01% PS80 was added to the solution, very little increase in subvisible 
particle concentration was observed for the Molecule 1 in the initial and formulation buffer, 
although an increase was seen in the 50/50 mix buffer (Figure 41B).  Molecule 2 showed a large 
increase in subvisible particle concentration in the initial, 50/50 mix (2) and formulation 2 (Figure 
41C). There was a slight increase in subvisible particle levels for Molecule 2 in the 50/50 mix (2) 
buffer and very little increase in the formulation 1 buffer. When PS80 was added to the solution, 
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all the samples were stabilized. Formulation 1 and 2 showed the least amount of particles compared 
to the initial and 50/50 mix buffers.  (Figure 41D).  Molecule 8 showed an increase in subvisible 
particle levels in all of the TFF buffers with the formulation buffer having the highest amount 
(Figure 41E). When 0.01% PS80 was added to the solution, Molecule 8 in the initial buffer showed 
very little increase in subvisible particles, while in the 50/50 and formulation buffers, Molecule 8 
showed a large increase in subvisible particles (Figure 41F). Molecule 9 showed an increase in 
subvisble particle concentration for all TFF buffers (Figure 41G) and the same trend after adding 
PS80 (Figure 41H).   
Similar experiments were then performed under shaking conditions. Molecule 1 showed 
an increase in subvisible particle concentration in the initial and 50/50 mix but very little in the 
formulation buffer (Figure 42A). When 0.01% PS80 was added, the initial buffers particle 
concentration dropped greatly, and the formulation showed little increase in concentration but the 
50/50 mix buffer still showed an increase (Figure 42B). Molecule 2 showed very large increase in 
50/50 mix (2) and formulation 2 buffer, and only a slight increase in initial, 50/50(1), and 
formulation 1 (Figure 42C). When 0.01% PS80 was added, a significant decrease in all the buffers 
was seen with little to no increase in particle number (Figure 42D). Molecule 8 showed a 
comparable increase in particle concentrations in all three buffers (Figure 42E). The PS80 
decreased the amount and increased the time it took for the stress to have an effect, but eventually 
the particle concentration started to increase (Figure 42F). Molecule 9 showed an increase in all 
three buffers with the initial buffer having the least amount and the formulation having the most 
(Figure 42G). After adding PS80, the particle concentration decreased greatly and no significant 
increase was observed compared to time 0 hr (Figure 42H). 
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In summary, when examining the molecules in PBS, molecules 1, 8, and 9 showed some 
visible aggregation after shaking and stirring with molecule 8 showing the most after shaking and 
molecule 9 showing the most after stirring. Molecule 2 showed no signs of visible aggregation 
during shaking up to 3 days and only a slight amount after stirring for 8 hrs. Molecule 8 had the 
largest loss in protein concentration after preforming the shaking agitation. Molecule 9 showed 
protein concentration loss after stirring. Molecules 1 and 2 showed no significant protein 
concentration loss after shaking or stirring.  When examining all four molecules in the TFF 
processing buffers, the same trends were observed as those seen in PBS. Molecule 2 showed the 
lowest amount of visible aggregation by shaking and stirring. Molecule 8 showed the largest 
amount of visible aggregation after shaking and molecule 9 showed the most after stirring. The 
addition of 0.01% PS80 greatly reduced the amount of visible aggregation which was only seen 
after the stirring of molecule 9 and 8 hrs of stirring molecule 1 in the 50/50 mix buffer. The protein 
concentration after stirring produced a gradual decrease with molecule 9 and a slight decrease in 
molecule 8 formulation buffer. When PS80 was added, there was no significant change observed 
in the protein concentration. Under the shaking conditions, molecule 8 showed a large decrease in 
protein concentration. A slight decrease in molecule 1 was also observed. When PS80 was added, 
there was no decrease inprotein concentration observed. MFI showed an increase in subvisible 
particle formation after shaking and stirring with few exceptions. The addition of 0.01% PS80 was 
able to greatly reduce this effect.  
The shaking and stirring showed some correlation with the TFF processes (“good” vs. 
“bad” molecules). Overall, molecule 2 (“good”) had the highest colloidal stability according to 
lower visible aggregation, subvisible particle formation, and less protein concentration loss 
compared to the other 3 molecules. Molecule 1 (“good”) had a trend toward either the second 
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highest stability or comparable to molecules 8 and 9 (“bad”). Molecule 8 had a trend toward be 
either the least stable (shaking) or comparable to molecule 1 (stirring). Molecule 9 was unstable 
under the stirring conditions but was comparable to molecule 1 under shaking conditions. 
5.3.6 Interfacial Properties of the Four Antibody Molecules as Measured by a Langmuir 
Trough 
A Langmuir trough was used to compare interfacial properties of the four Ab molecules. 
First, the system was allowed to reach an equilibrium between molecules exposed to the interface 
and those that remained in the bulk fluid. The surface pressure during this absorption phase was 
recorded over the course of 120 mins. Figure 43 shows representative graphs of molecules 2 and 
8 in their formulation buffers during the absorption phase. Higher surface pressures correlate with 
higher concentrations of molecules at the interface. Molecule 8 appears to have a higher 
concentration of molecules present at the interface compared to molecule 2 as reflected by the 
higher surface pressure observed. Depending on the kinetics, saturation of the molecules at the 
interface can be very different as well. Molecule 2 reaches saturation after ~60 min while molecule 
8 is still increasing after 120 min. This may indicate restructuring or rearrangement of the 
molecules after they reach the interface. The molecules were first compared in PBS. Molecule 8 
had a significantly higher absorption curve at ~17 mN/m (Figure 44). Molecule 1 and 9 produced 
the same surface pressure of ~13 mN/m while molecule 2 had the lowest at ~11 mN/m. Although 
molecule 1 and 9 had the same surface pressure at 120 min, molecule 9 had faster adsorption 
kinetics.  When comparing the molecules in the different process buffers, molecules 1 and 2 have 
lower surface pressure in the formulation compared to the initial and 50/50 mix buffers indicating 
lower amount of protein at the interface (Figure 45A-C). Molecules 8 and 9 show about the same 
or greater amounts of surface pressure in their formulation buffers (Figure 45D-E). Overall, 
molecules 8 and 9 have higher surface pressures than 1 and 2. PS80 was added to each of the TFF 
182 
  
   
processing buffers and the absorption curves were graphed (Figure 46). Overall, the surface 
pressure of each were increased greatly (>30 mN/m). This is presumably due to the PS80 creating 
a layer at the interface.  
After the absorption phase was complete, the liquid at the interface was compressed and 
expanded. The area change vs surface pressure was monitored and the area between the two curves 
was observed. The area between the 2 curves (the hysteresis) is an indication of inter-molecular 
interactions. Therefore, the larger the hysteresis, the greater possibility that inter-molecular 
interactions exist. The more inter-molecular interactions occurring, the greater the tendency to 
aggregate is presumed. Figure 47 shows representative isotherms of molecule 2 and 9. The 
hysteresis observed for molecule 9 was larger than that of molecule 2, indicating that it is more 
likely to display inter-molecular interactions. The area was plotted at the 1st, 2nd, and last cycle 
(cycle 750) and the area lost over time was monitored. The four molecules in PBS showed 
molecule 8 and 9 with the highest hysteresis indicating these two are more likely to be seen at the 
interface and manifest inter-molecular interactions (Figure 48). Molecule 2 showed the lowest 
hysteresis at all cycles. Next, the molecules were examined in the TFF processing buffers (Figure 
49). Molecule 2 showed the lowest hysteresis at cycle 1, indicating it’s less likely to go to the 
interface. Molecule 9 showed the highest hysteresis, indicating it is likely to bind to the interface 
and possess inter-molecular interactions. Molecules 1 and 8 also show large amounts of hysteresis 
at cycle 1. PS80 was added to each of the processing buffers and examined (Figure 50). All 4 
molecules had similar starting surface pressures around 650 mN/m which over the 750 cycles 
decreased to about 300 mN/m. This suggests that the PS80 bound strongly at the air-water interface 
thereby decreasing the ability of the Ab to localize to the surface.  
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The percent of area loss was also examined to compare across the molecules, first in PBS 
(Figure 51). Molecule 1 showed the least amount of loss followed by molecule 8. This reflects the 
Ab’s ability to remain at the interface. When examining the molecules in the TFF processing 
buffer, molecule 8 shows the lowest amount of area loss of the 750 cycles, indicating increased 
stability at the interface and less loss after material to the bulk (Figure 52D). Molecule 2 shows 
the most area lost after 750 cycles, indicating it’s more likely to move into the bulk than stay at 
the interface (Figure 52E). When PS80 was added to the buffers, each molecule was similar with 
a decrease of about 60% the starting surface pressure after 750 cycles (Figure 53).   
MFI was used to examine the subvisible particle concentration after the Ab samples were 
stressed by 750 cycles in the Langmuir trough. In PBS buffer, molecules 8 and 9 showed high 
particle concentration in the starting material that remained constant after the expansion and 
compression runs were completed (Figure 54). In contrast, Molecule 1 and 2 had much lower 
subvisible particle levels in the starting material but showed an increase after the expansion and 
compression cycles. For all four Ab molecules, the interface showed the highest subvisible particle 
counts and the bulk solution the lowest. The Ab molecules were then compared across their 
respective TFF process buffers. Molecules 1, 2, and 9 all showed a slight increase in subvisible 
particle concentration but molecule 8 did not show an increase (Figure 55). The samples were 
examined for visible aggregates, however, molecule 8 showed a large amount of visible 
particulates. While molecules 1 and 9 showed a small amount of visible particles in the initial and 
50/50 mix buffers, none were present in the formulation buffer. Molecule 2 showed no signs of 
visible aggregation. After PS80 was added to each of the TFF processing buffers and the 
compression and expansion cycles were performed on each of the four Ab molecules, the 
subvisible particle concentration did not increase as drastically as they did without the PS80 
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(Figure 56). Molecule 1 showed no significant increase in subvisible particle concentration in any 
of the phases (bulk, interface or remaining) in the three TFF buffer conditions (Figure 56A). 
Molecule 2 showed a slight increase in subvisible particles in the initial buffer as well as 50/50(2) 
and formulation 2, while 50/50(1) and formulation 1 buffer showed little increase in the subvisible 
particle concentration (Figure 56B-C). Molecule 8 did not show any increase in all three buffers 
(Figure 56D). Molecule 9 showed a slight increase in the 50/50 mix buffer but there was no 
increase in the initial and formulation buffer (Figure 56E). All samples with PS80 present in the 
solution did not show any signs of visible aggregation.  
In summary, molecule 2 showed the lowest tendency to be at the air-water interface 
followed by molecule 1 and 9. Molecule 8 showed a significantly larger surface pressure than the 
other 3 molecules in PBS, indicating it is the most likely to be at the interface. When looking at 
the changes of area under the curve, molecule 1 shows the highest percentage remaining at the 
interface after 750 cycles, while molecule 9 shows the least. When the molecules were examined 
in the TFF processing buffers, molecule 8 showed the highest tendency to be at the air-water 
interface and the most visible aggregation. Molecule 2 showed the lowest tendency to be at the 
air-water interface. There was in increase in sub-visible particles with molecules 1, 2, and 9. 
When 0.01% PS80 was added to the samples, the surface pressure greatly increased during the 
absorption phase and were relatively similar across the four molecules and their buffers, 
indicating the PS80 has the tendency to go to the air-water interface and decrease the binding of 
the Abs through a competitive effect. After running the compression and expansion cycles, all 
molecules showed similar decreases in the area under the curve. The Langmuir trough showed 
good correlation with the TFF processes (“good” vs. “bad” molecules). Overall, molecule 2 
(“good”) had the lowest tendency to go to at the air-water interface. Molecule 8 (“bad”) had a 
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tendency to bind to the air-water interface and remain there through compression and expansion. 
Molecule 9 (“bad”) had a tendency to be at the air-water interface when at equilibrium, but 




   
Table 5.1: Summary of molecules examined in this study and their behavior in large scale TFF.  
Molecules 1 and 2 were designated as “good” molecules (highlighted in green) that behaved well 
during large scale TFF. Molecules 8 and 9 were designated as “bad” molecules (highlighted in 
red) because of their tendency to generate aggregates and particles during large scale TFF. The 
initial buffers are the buffers used before the TFF process and the formulation buffers are those 





   
 
Table 5.2: Composition of sample buffers used in biophysical characterization of the four Abs.  
For each molecule, biophysical experiments were carried out in the initial buffer, formulation 





   
 
Table 5.3: Biophysical techniques used to characterize the four Abs grouped by the type of 





   
 
Table 5.4: Summary of biophysical study results with the four Ab molecules in PBS buffer.  
Data shown include each molecule’s λmin at 10°C and Tonset values as measured by CD,  λmax at 
10°C and Tonset values for peak intensity and peak position as measured by intrinsic fluorescence, 
λmax  at 10°C and Tonset values for peak intensity as measured by extrinsic fluorescence, Tonset values 





   
Table 5.5: Summary of biophysical data results with four Ab molecules examined in the different 
TFF buffer compositions (Initial, 50/50, and formulation buffers; See Table 2).  
Data shown include each molecule’s λmin at 10°C and Tonset values as measured by CD,  λmax at 
10°C and Tonset values for peak intensity and peak position as measured by intrinsic fluorescence, 
λmax t 10°C and Tonset values for peak intensity as measured by extrinsic fluorescence, Tonset values 








   
 
Table 5.6: Summary of PEG solubility assay results for all four molecules in PBS.  
The midpoint and the extrapolated apparent solubility were calculated. Errors denote standard 





   
 
Table 5.7: Summary of PEG solubility assay results for all four molecules in TFF processing 
buffers.  
The midpoint and the extrapolated apparent solubility were calculated. Errors denote standard 





   
Table 5.8: Agitation stress experimental outline.  
There were two agitation types, i.e., shaking and stirring, used to stress Ab molecules 1, 2, 8, and 
9 at a concentration of 1 mg/mL. The agitation was done in four different TFF processing buffers 
(see Table 2) with and without 0.01% PS80. The shaking stress was performed at a speed of 300 
rpm and the stirring stress was performed at setting 5. 
 
Table 5.9: Analytical techniques used to examine Ab samples generated before and after shaking 
and stirring agitation.  
The protein concentration was monitored by UV-Visible spectroscopy. The size and 
characterization of aggregates were monitored by visual assessment and MFI.   
Structural attribute 
Analytical techniques for shaking 




UV-Visible Spectroscopy (+/- light 
scattering, +/- centrifugation) 
Characterization of Size and 







   
 
Table 5.10: Langmuir trough study outline. Molecules 1, 2, 8, and 9 were examined at 2 mg/mL 
in the TFF processing buffers (see Table 2) with and without PS80 as well as in PBS buffer.  
The compression and expansion was done at a rate of 150 mm/min for 6 hrs. Samples were taken 













1, 2, 8, & 9 
Initial ± PS80 
50/50 ± PS80 
Formulation± PS80 
PBS 





Table 5.11: Analytical techniques used to examine Ab samples generated by Langmuir trough 
studies. Protein concentration was examined using UV-Visible spectroscopy.  
Characterization of particle size and the presence of visible aggregates were examined using 
visual assessment and MFI. The interfacial properties were examined by the Langmuir trough 
generated data. 
Structural attribute Analytical techniques 
Protein Concentration, covalent 
oligomers/aggregates 
UV-Visible Spectroscopy (+/- light scattering, 
+/- centrifugation) 








   
 
Figure 5.1: Representative SDS-PAGE of molecules 1, 2, 8, and 9.  
Ten g of each sample was separated on a 10-20% Tris-glycine gel using NuPAGE MES SDS 
Running Buffer. The gel was stained using Bio-safe Coomassie Blue G250 stain. Lane 1: SeeBlue 
Plus2 Pre-stained molecular weight standard; Lane 2: molecule 1; Lane 3: molecule 2; Lane 4: 






   
 
 
Figure 5.2: Laboratory scale TFF protocol workflow.  
The stock solution of the Ab molecules is diluted to 2 mg/mL in the initial buffer. The TFF is 
performed and the buffer is exchanged into the formulation buffer followed by removal of buffer 
to reach the desired concentration. Samples are taken throughout the process and analyzed by 
UV-Visible spectroscopy and MFI. 
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Figure 5.3: Laboratory scale TFF scheme.  
One hundred mL of molecules at 2 mg/mL is placed into the sample reservoir. The sample is fed 
into the TFF filter by a peristaltic pump. The sample with the protein is retained and travels back 
to the reservoir while smaller molecular weight materials are removed in the filtrate based on the 
MWCO of the filter.  Samples taken throughout the processes are bolded. These include the 
starting material, final concentrate, samples with buffer ratios (initial:formulation) of 5:1, 3:1, 1:1, 
1:3, and 1:5, and samples after completing the 1st, 2nd, 4th, and 8th diafiltration step. 
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Figure 5.4: TFF protein recovery.  
Panel a is the protein recovered of all four Ab molecules ran under standard conditions described 
in the methods section. Panel b shows the protein recovery for molecule 2 with four different 
conditions, formulation 1 (black); formulation 2 (red); 20-fold concentration step (blue); and 
formulation 2 with 0.01% PS80 (pink). Panel c shows the protein recovery of molecule 8 with and 
without PS80 (black) and with PS80 (red) in formulation buffer. N=1. A duplicate was preformed 




   
 
Figure 5.5: Sub-visible particle concentration of TFF samples as measured by MFI.  
Panel a shows molecules 1, 2, 8, and 9 under standard laboratory scale TFF running conditions. 
Panel b shows molecule 2 in various running conditions; formulation 1, formulation 2, formulation 
2 with a 20X concentration step, and formulation 2 with 0.01% PS80. Panel c show molecule 8 
with and without 0.01% PS80. Data shown is an average of n=2 measurements with error bars 
representing the data range. 
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Figure 5.6: Circular dichroism analysis of Ab molecules 1 (black), 2 (red), 8 (blue), and 9 (pink) 
in PBS buffer.  




   
 
Figure 5.7: FTIR spectroscopy analysis of Ab molecules 1 (black), 2 (red), 8 (blue), and 9 (pink) 
in PBS buffer.  
Panel a represents amide I absorbance. Panel b represents the second derivative spectrum of panel 
a showing characteristic signals of protein secondary structure elements as indicated by arrows. 
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Figure 5.8: Intrinsic fluorescence spectroscopy analysis of Ab molecules 1 (black), 2 (red), 8 
(blue), and 9 (pink) in PBS buffer.  
Panel a represents 10°C spectrum of the four molecules. Panel b represents MSM peak intensity 
vs. temperature from 10-90°C. Panel c represents MSM peak position vs. temperature from 10-
90°C. Error bars represent standard deviation for n=3 replicates. 
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Figure 5.9: ANS Extrinsic fluorescence spectroscopy analysis of Ab molecules 1 (black), 2 (red), 
8 (blue), and 9 (pink) in PBS.  
Panel a represents 10°C spectrum of the four molecules. Panel b represents MSM peak intensity 
vs. temperature (thermal melts) of the four molecules from 10-90°C. Error bars represent standard 
deviation for n=3 replicates. 
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Figure 5.10: UV-Visible spectroscopy and corresponding 2nd Derivative spectra of Ab molecules 
1 (black), 2 (red), 8 (blue), and 9 (pink) in PBS at 0.2 mg/mL.  
Panel a represents absorbance spectra from 250-350 nm. Panel b represents the 2nd derivative of 
the absorbance spectrum from 250-310 nm. N=3 
 
Figure 5.11: DSC analysis of Ab molecules 1 (black), 2 (red), 8 (green), and 9 (blue) in PBS buffer 
scanning from 10-90°C. n=3 replicates. Representative traces shown. 
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Figure 5.12: Static light scattering analysis of Ab molecules 1 (black), 2 (red), 8 (blue), and 9 
(pink) in PBS buffer as a function of temperature.  




   
 
Figure 5.13: Dynamic light scattering analysis of Ab molecules 1 (black), 2 (red), 8 (green) and 9 
(blue) in PBS buffer.  
Panel a represents intensity fitting with multimodal size distribution. Panel b represents intensity 
by lognormal distribution. Panel c represents diameter of the molecules by intensity (blue) and 
number (teal). Panel d represents measured polydispersity values of each of the molecules by 
intensity. Error bars represent standard deviation for n=3 replicates. 
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Figure 5.14: FTIR analysis of Ab molecules 1, 2, 8 and 9 in the TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 in formulation 1. Panel c represents 
molecule 2 in formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Percent 
total α-helix (red), percent total β-sheet/strand/turn (blue), and percent total disordered (yellow) 
are plotted for molecules in their initial, 50/50, and formulation buffers. Error bars represent 
standard deviation for n=3 replicates. 
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Figure 5.15: Intrinsic fluorescence spectra at 10°C of Ab molecules 1, 2, 8 and 9 in TFF process 
buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Molecules 
in their Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. 
Error bars represent standard deviation for n=3 replicates. 
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Figure 5.16: Intrinsic fluorescence spectroscopy (peak intensity) vs temperature analysis of Ab 
molecules 1, 2, 8 and 9 in TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Molecules 
in their Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. 
Error bars represent standard deviation for n=3 replicates. 
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Figure 5.17: Intrinsic fluorescence spectroscopy (peak position) vs temperature analysis of Ab 
molecules 1, 2, 8 and 9 in TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Molecules 
in their Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. 
Error bars represent standard deviation for n=3 replicates. 
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Figure 5.18: Extrinsic ANS fluorescence spectra at 10°C in the presence of Ab molecules 1, 2, 8 
and 9 in TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Results 
from Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. Error 
bars represent standard deviation for n=3 replicates. 
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Figure 5.19: Extrinsic ANS fluorescence spectroscopy (peak intensity) vs. temperature in the 
presence of Ab molecules 1, 2, 8 and 9 in TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Results 
in Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. Error 
bars represent standard deviation for n=3 replicates. 
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Figure 5.20: UV-Visible spectroscopy analysis of Ab molecules 1, 2, 8, and 9 in TFF process 
buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Molecules 
in their Initial buffer (black), 50/50 mix buffer  (red), and formulation buffer (blue) are shown. 
Panel f represents the Ab concentration in the initial, 50/50, and formulation of molecule 1 (black), 
molecule 2 formulation 1 (red), molecule 2 formulation 2 (blue), molecule 8 (pink), and molecule 
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Figure 5.21: 2nd derivative of UV-Visible spectroscopy analysis of Ab molecules 1, 2, 8, and 9 in 
TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Molecules 
in their Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. 
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Figure 5.22: DSC analysis of Ab molecules 1, 2, 8, and 9 in TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Panel f 
represents the Tonset values for each molecule. Molecules in their Initial buffer (red), 50/50 mix 
buffer (blue), and formulation buffer (yellow) are shown. Error bars represent standard deviation 
for n=3 replicates. 
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Figure 5.23: SLS analysis vs temperature of Ab molecules 1, 2, 8, and 9 in TFF process buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 formulation 1. Panel c represents 
molecule 2 formulation 2. Panel d represents molecule 8. Panel e represents molecule 9. Molecules 
in their Initial buffer (black), 50/50 mix buffer (red), and formulation buffer (blue) are shown. 
Error bars represent standard deviation for n=3 replicates. 
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Figure 5.24: Dynamic light scattering analysis of Ab molecules 1, 2, 8, and 9 in TFF process 
buffers.  
Panel a represents intensity with multimodal size distribution fitting. Panel b represents intensity 
by lognormal fitting. Panel c represents number with multimodal size distribution fitting. Panel d 
represents number by lognormal fitting. Panel e represents the diameter of each molecule in initial 
(red), 50/50 (blue), and formulation (yellow) buffers. Panel f represents percent polydispersity 
values of the molecules in each buffer. Error bars represent standard deviation for n=3 replicates. 






























































































 50% Initial Buffer, 50% Final Buffer
 Final Buffer






























   
 
Figure 5.25: PEG solubility assay of the four Ab molecules in PBS.  
Panel a represents the relative apparent solubility of molecules 1 (blue), 2 (red), 8 (pink squares), 
and 9 (pink circles). Panel b represents the PEG solubility assay on a logarithmic scale for 




   
 
Figure 5.26: PEG relative apparent solubility assay of the four Ab molecules in the TFF processing 
buffers.  
Panel a represents molecule 1 in the TFF processing buffers. Panel b represents molecule 2 (Form 
1) in the TFF processing buffers. Panel c represents molecule 2 (Form 2) in the TFF processing 
buffers. Panel d represents molecule 8 in the TFF processing buffers. Panel e represents molecule 
9 in the TFF processing buffers. Molecules in their TFF processing buffers are shown as initial 




   
 
Figure 5.27: Kd2 values determined for Ab molecules 1, 2, 8, and 9 as measured by DLS. 
Panel a molecule 1 (red), molecule 2 (blue), molecule 8 (yellow), and molecule 9 (green) in TFF 
process buffers.  Panel c molecule 1 (red), molecule 2 (blue), molecule 8 (yellow), and molecule 
9 (green) in PBS. Panel d are the kD2 values of each Ab molecule in the TFF process buffers. Panel 




   
 
Figure 5.28: Visual assessment of solutions of Ab molecules 1, 2, 8, and 9 in PBS buffer before 
and after stirring and shaking stress over the course of 7 hrs.  
Stirring agitation is shown on the left side panels and shaking agitation is shown on right side 
panels. “-” represents no visible aggregation seen; “+” represents some visible aggregation seen; 
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Figure 5.29: Visual assessment of solutions of Ab molecule 1 under stirring agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 




   
 
 
Figure 5.30: Visual assessment of solutions of Ab molecule 1 under shaking agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 
aggregation seen; “++” represents large amounts of visible aggregation seen.   
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Figure 5.31: Visual assessment of solutions of Ab molecule 2 under stirring agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 
aggregation seen; “++” represents large amounts of visible aggregation seen.   
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Figure 5.32: Visual assessment of solutions of Ab molecule 2 under shaking agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 
aggregation seen; “++” represents large amounts of visible aggregation seen.   
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Figure 5.33: Visual assessment of solutions of Ab molecule 8 under stirring agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 




   
 
Figure 5.34: Visual assessment of solutions of Ab molecule 8 under shaking agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 




   
 
 
Figure 5.35: Visual assessment of solutions of Ab molecule 9 under stirring agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 
aggregation seen; “++” represents large amounts of visible aggregation seen.   
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Figure 5.36: Visual assessment of solutions of Ab molecule 9 under shaking agitation over the 
course of 8 hrs in the TFF processing buffers.  
Samples without 0.01% PS80 is shown on the left side panels and samples with 0.01% PS80 is 
shown on right side panels. “-” represents no visible aggregation seen; “+” represents some visible 




   
 
 
Figure 5.37: Representative UV-visible absorption spectrum of molecule 2 and 8 in PBS buffer 
before and after agitation stress.  
Panel a represents molecule 2 at T=0 (black) and T=7 hrs (red).  Panel b represents molecule 8 at 




   
 
Figure 5.38: Molecules 1, 2, 8, and 9 Ab concentration after stirring and shaking stress in PBS 
buffer. 
Panel a represents stirring over the course of 7 hrs. Panel b represents shaking over the course of 
7 hrs. Error bars represent standard deviation for n=3 replicates. 
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Figure 5.39: Molecules 1, 2, 8, and 9 Ab concentration after stirring in TFF processing buffers. 
 Panel a represents molecule 1. Panel b represents molecule 1 with PS80. Panel c represents 
molecule 2. Panel d represents molecule 2 with PS80. Panel e represents molecule 8.  Panel f 
represents molecule 8 with PS80. Panel g represents molecule 9. Panel h represents molecule 9 
with PS80. Error bars represent standard deviation for n=3 replicates. 
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Figure 5.40: Molecules 1, 2, 8, and 9 Ab concentration after shaking in TFF processing buffers. 
Panel a represents molecule 1. Panel b represents molecule 1 with PS80. Panel c represents 
molecule 2. Panel d represents molecule 2 with PS80. Panel e represents molecule 8.  Panel f 
represents molecule 8 with PS80. Panel g represents molecule 9. Panel h represents molecule 9 
with PS80. Error bars represent standard deviation for n=3 replicates. 
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Figure 5.41: Subvisible particle concentration of solutions of Ab molecules 1, 2, 8, and 9 before 
and after stirring over 8 hrs in TFF process buffers (with and without PS80) as measured by MFI. 
Panel a represents molecule 1. Panel b represents molecule 1 with PS80. Panel c represents 
molecule 2. Panel d represents molecule 2 with PS80. Panel e represents molecule 8.  Panel f 
represents molecule 8 with PS80. Panel g represents molecule 9. Panel h represents molecule 9 




   
 
Figure 5.42: Subvisible particle concentration of solutions of Ab molecules 1, 2, 8, and 9 before 
and after shaking over 8 hrs in TFF process buffers (with and without PS80) as measured by MFI. 
Panel a represents molecule 1. Panel b represents molecule 1 with PS80. Panel c represents 
molecule 2. Panel d represents molecule 2 with PS80. Panel e represents molecule 8.  Panel f 
represents molecule 8 with PS80. Panel g represents molecule 9. Panel h represents molecule 9 




   
 
 
Figure 5.43: Representative absorption curves from the Langmuir trough study.  
Panel a represents molecule 1 in the formulation 1 buffer. Panel b represents molecule 8 in the 
formulation buffer. Arrows indicate the surface pressure at equilibrium. Data shown is an average 
of n=2 measurements with error bars representing the data range. 
 
Figure 5.44: Absorption curves of Ab molecule 1 (black), molecule 2 (red), molecule 8 (blue), and 
molecule 9 (pink) in PBS buffer from Langmuir trough study.  
n=2 duplicates. Representative traces shown. 




































   
 
Figure 5.45: Absorption phase of Ab molecule 1, 2, 8, and 9 in the TFF processing buffers from 
the Langmuir trough study.  
Panel a represent molecule 1. Panel b represent molecule 2 (Form 1). Panel c represent molecule 
2 (Form 2). Panel d represent molecule 8. Panel e represent molecule 9.  The TFF processing 




   
 
Figure 5.46: Absorption phase of Ab molecule 1, 2, 8, and 9 in the TFF processing buffers with 
0.01% PS80 from Langmuir trough study.  
Panel a represent molecule 1. Panel b represent molecule 2 (Form 1). Panel c represent molecule 
2 (Form 2). Panel d represent molecule 8. Panel e represent molecule 9.  The TFF processing buffer 




   
 
Figure 5.47: Representative Langmuir trough Isotherm from the compression and expansion 
phases with and without PS80.  
Panel a represents molecule 2 in formulation buffer. Panel b represents molecule 9 in formulation 
buffer. Panel c represents molecule 2 in formulation buffer with PS80. Panel d represents molecule 




   


























Figure 5.48: The hysteresis in total area of molecule 1 (blue), molecule 2 (red), molecule 8 (blue), 
and molecule 9 (pink) of the Langmuir trough in PBS at cycle 1, cycle 2 and cycle 750.  
Data shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.49: The hysteresis in total area of molecule 1, 2, 8, and 9 in the TFF processing buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1). Panel c represents molecule 
2 (Form 2). Panel d represents molecule 8. Panel e represents molecule 9. TFF processing buffers 
used are initial (black), 50/50 (red), and formulation (blue) at cycle 1, cycle 2 and cycle 750. Data 
shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.50: The hysteresis in total area of molecule 1, 2, 8, and 9 in the TFF processing buffers 
with 0.01% PS80.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1). Panel c represents molecule 
2 (Form 2). Panel d represents molecule 8. Panel e represents molecule 9. TFF processing buffers 
used are initial (black), 50/50 (red), and formulation (blue) at cycle 1, cycle 2 and cycle 750. Data 
shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.51: The hysteresis in percent area of molecule 1 (blue), molecule 2 (red), molecule 8 
(blue), and molecule 9 (pink) in PBS buffer using the Langmuir trough at cycle 1, cycle 2 and 
cycle 750.  
Data shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.52: The hysteresis in percent area of molecule 1, 2, 8, and 9 in the TFF processing buffers.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1). Panel c represents molecule 
2 (Form 2). Panel d represents molecule 8. Panel e represents molecule 9. TFF processing buffers 
used are initial (black), 50/50 (red), and formulation (blue) at cycle 1, cycle 2 and cycle 750. Data 
shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.53: The hysteresis in percent area of molecule 1, 2, 8, and 9 in the TFF processing buffers 
with 0.01% PS80.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1). Panel c represents molecule 
2 (Form 2). Panel d represents molecule 8. Panel e represents molecule 9.TFF processing buffers 
used are initial (black), 50/50 (red), and formulation (blue) at cycle 1, cycle 2 and cycle 750. Data 
shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.54: Subvisible particle concentration (as measured by MFI) of solutions of Ab molecules 
1 (black), molecule 2 (red), molecule 8 (blue), and molecule 9 (pink) in PBS buffer after 750 cycles 
of compression and expansion using the Langmuir trough.  
Data shown is an average of n=2 measurements with error bars representing the data range. 
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Figure 5.55: Subvisible particle concentration (as measured by MFI) of solutions of Ab molecules 
1, 2, 8, and 9 in TFF processing buffers after 750 cycles of compression and expansion using 
Langmuir trough.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1). Panel c represents molecule 
2 (Form 2). Panel d represents molecule 9. Panel e represents molecule 9.  TFF processing buffers 
used are initial (black), 50/50 (red), and formulation (blue). Data shown is an average of n=2 
measurements with error bars representing the data range. 
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Figure 5.56: Subvisible particle concentration (as measured by MFI) of Ab molecules 1, 2, 8, and 
9 in TFF processing buffers with 0.01% PS80 after 750 cycles of compression and expansion using 
Langmuir trough.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1). Panel c represents molecule 
2 (Form 2). Panel d represents molecule 9. Panel e represents molecule 9.  TFF processing buffers 
used are initial (black), 50/50 (red), and formulation (blue). Data shown is an average of n=2 
measurements with error bars representing the data range. 
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Supplementary Figure 5.1: Viscosity values of Ab molecules 1, 2, 8, and 9 in their stock solution 
(blue) and values of buffers alone (teal).  
Error bars represent standard deviation for n=3 replicates. 
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Supplementary Figure 5.2: Representative deconvoluted second derivative FTIR spectrum of 
molecules 1, 2, 8, and 9 in TFF processing buffers.  
Panel a represent molecule 1. Panel b represent molecule 2 (Form 1). Panel c represent molecule 
2 (Form 2). Panel d represent molecule 8.  Panel e represent molecule 9. Molecules in their TFF 
processing buffers are initial (red), 50/50 (blue), and formulation (green) are shown. 
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Supplementary Figure 5.3: PEG solubility assay on a logarithmic scale for extrapolation of linear 
fit to determine the relative apparent solubility with 0% PEG.  
Panel a represents molecule 1. Panel b represents molecule 2 (Form 1) in the TFF processing 
buffers. Panel c represents molecule 2 (Form 2). Panel d represents molecule. Panel e represents 
molecule. TFF processing buffers are initial (blue), 50/50 (red), and formulation (pink). Error 
bars represent standard deviation for n=3 replicates. 
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6.1. Overview  
6.2. Chapter summaries and future work 
6.2.1. Chapter 2 
In this work, a previously described GroEL-BLI–based method1 was further optimized 
and automated (using an Octet system, 96-well plate format) to bind and detect partially 
structurally altered intermediates (preaggregates) formed in stressed solutions of several different 
therapeutic Ab candidates including IgG1, IgG4, and bispecific antibodies. TEM images of 
stressed Ab samples bound to the GroEL showed the formation of Ab preaggregate GroEL 
complexes. The utility of this approach for use in protein formulation development was explored 
with various mAbs (IgG1 and IgG4) exposed to various stress conditions as well as by using a 
relatively less stable Bis-3. For the latter, significant binding amplitudes were observed with the 
GroEL-BLI biosensor at room temperature at significantly lower protein concentrations (i.e., 
unstressed conditions), compared to the other mAbs, indicating its relatively 
enhanced hydrophobic nature, and by correlation, aggregation propensity. When Bis-3 was 
incubated at 50°C, increases in GroEL-BLI binding amplitude were observed before any 
increases were seen for irreversible aggregate/particle formation as measured by SEC and MFI. 
When examining the more stable mAb-D (IgG4), upon exposure to different stresses including 
elevated temperatures, acidic pH, and addition of Gdn-HCl, the GroEL-BLI biosensor could 
detect preaggregate formation before, or in some cases concomitantly with, irreversible 
aggregate formation as measured by SEC and MFI. Thus, in this case, the GroEL-BLI biosensor 




better detect preaggregate species that may be involved in the formation of longer term 
deleterious protein aggregates. 
The GroEL biosensor technology provides protein-specific information about the presence of 
potentially aggregation-prone species. In some instances, this technology reports the formation 
of preaggregate transient species (GroEL binders) before larger scale aggregation is even 
detected by other analytical tools. The specificity of this GroEL-Ab interaction can be confirmed 
by ATP-induced reversal of Ab binding, and the GroEL-Ab complexes can be easily visualized 
by TEM analysis. This method can rapidly assess solution stability and preaggregate formation 
within the relatively short time window of minutes. This rapid detection of preaggregate species 
using an automated platform can be particularly useful for protein formulation development. 
This early BLI detection method can be used to identify stabilizing conditions and excipients that 
diminish preaggregate formation which may correlate with aggregation profiles during long-term 
stability studies. 
 
6.2.2. Chapter 3 
 The ability to directly compare data gathered for mAb-D in different solutions (containing 
either commonly used pharmaceutical excipients or control additives known to destabilize 
proteins) allowed us to evaluate correlations between HX-MS data and other mAb-D stability data 
sets (e.g., conformational stability using DSC and accelerated stability studies monitoring protein 
aggregation by SEC and MFI using both temperature and agitation as stresses). The effect of 
additives on the relative local flexibility of specific CH2 peptide segments within mAb-D 
correlated well with conformational stability and aggregation propensity under accelerated 




previous work with IgG1 mAbs,2 with this IgG4 mAb. There were, however, no convincing 
correlations between HX-MS data and stirring stress for additive effects on the stability of mAb-
D. These results indicate that potentially useful correlations between HX-MS data (using minimal 
material and a streamlined data analysis approach focusing on key peptide segments) with 
accelerated and real-time stability data to identify stabilizing additives as part of formulation 
development will be dependent on a particular mAbs degradation pathway(s) and the type of 
stresses used for the additive screening studies. To this end, using a variety of different mAbs, 
additional correlations of HX readouts in various formulations with more comprehensive 
accelerated and real-time stability data sets will need to be generated as part of future work. 
6.2.3. Chapter 4 
We have presented here a case study in low-viscosity formulation development of ultra-
high concentration monoclonal antibodies that were previously formulated for maximized 
storage stability but possessed problematically high-solution viscosities. By evaluating a 
relatively large and diverse list of pharmaceutical excipients and additives, we were able to cover 
many of the classes of compounds that have previously been reported to possess viscosity-
reducing effects. Optimized formulations for mAb A (10 mM histidine, 75 mM NaCl, 50 mM 
arginine, 5% sucrose, 0.02% polysorbate 20) and mAb C (10 mM histidine, 75 mM NaCl, 50 
mM lysine, 5% sucrose, 0.02% polysorbate 20) were identified based on these screening studies. 
The best-performing excipients identified in this study to reduce viscosity are consistent with 
previously published results and models with other mAbs where charge interactions are involved 
in the PPI mechanism. Some compounds (like polar solvents), however, did not perform as well 
with mAb A and mAb C as they did in previous studies with other mAbs, reflecting the empirical 




concentration mAb preparations for parenteral injection. Although some viscosity-reducing 
excipients affected the inherent conformational stability of mAb A (but not mAb C), as 
determined by a lower thermal onset temperatures as observed by DSC, the addition of these 
compounds did not affect the storage stability of either mAb (as measured by aggregation 
propensity) at storage temperatures well below the Tonset values. In addition, the solution 
osmolality, although somewhat hypertonic, was in the range used previously for parenteral drug 
products. In the presently described experiments, a systematic approach to developing maximally 
concentrated target formulations with acceptable viscosities and stabilities that can be delivered 
via self-administration by auto-injectors or patch pumps was demonstrated. 
Due to the physicochemical differences inherent to individual monoclonal antibodies, 
high concentration formulation development studies to optimize protein stability and solution 
viscosity require either a detailed, but time-consuming and technically challenging mechanistic 
studies3,4 or a more rapid but empirical approach of excipient screening (or a combination of 
both approaches). The generalized formulation development approach and workflow outlined in 
this work should be applicable to the rapid, empirical approach to the high concentration 
formulation development of many mAbs, especially those of the IgG1 and IgG4 subclasses. In 
addition, once promising additives are identified, more mechanistic studies of structure–activity 
relationships between the mAb and the excipients can be pursued. Thus, it is our hope that this 
case study provides a formulation platform approach that others can use in the future to rapidly 
identify optimized, ultra-high concentration mAb formulations that balance excipient effects on 
protein conformational stability, aggregation propensity, solution viscosity, and solution 
osmolality. 




Molecules 1 and 2 were demonstrated by BMS as being more stable during the large scale 
TFF processing compared to molecules 8 and 9, which were shown to have problems with 
aggregation and particle formation. The first step in probing the cause of this was to duplicate these 
results using a small scale TFF setup in our laboratory. When performing the small scale TFF, 
similar trend was observed in terms of Molecules 1 and 2 showing “good behavior” and Molecules 
8 and 9 showing “bad behavior”, however, these effects were less apparent at small scale. Molecule 
2 showed the best correlation to having “good behavior” and molecule 8 showed the best 
correlation to having “bad behavior”. Based on these results, it is feasible to establish a scale down 
model in the laboratory of the TFF process at large scale which will allow for greater flexibility in 
the future for trouble shooting and analysis of TFF processing conditions and their effects on Ab 
stability. Being able to perform such process development experiments at a small scale will allow 
for better TFF processing conditions to be developed with less material and time than if such work 
was performed at a large scale.   
Next, biophysical properties such as structural integrity and conformational stability were 
examined for each of four Ab molecules in PBS buffer and in their respective TFF processing 
buffers (initial, 50/50 and formulation; see Table 2). Overall, a trend was observed in that each 
“good” molecule (i.e., more stable during TFF) had higher melting onset values as seen by several 
techniques. Several of these techniques showed molecule 8 to be the least stable indicated by the 
lower Tonset values. However in some cases, molecules 1, 8 and 9 appeared to have comparable 
thermal stability profiles and thus inherent conformational stability of the four Ab molecules does 
not consistently explain or predict the instability behavior during TFF processing.    
Out of all four molecules, molecule 8 (“bad”) showed the most negative kD2 value indicting 




good correlation with the “good vs bad behavior”.  In PBS molecule 1 showed the highest midpoint 
solubility and molecule 8 with the lowest, but molecule 9 showed higher solubility than 2. In the 
TFF processing buffers, molecule 2 had a very high midpoint solubility in the formulation 1 buffer 
but the all other molecules and buffers were comparable. Therefore, the reversible self-association 
properties do not consistently explain or predict the instability behavior of the TFF process  
The four Abs’ aggregation propensity was then examined by agitation stress using stirring 
and shaking in PBS buffer and in their respective TFF processing buffers with and without 0.01% 
PS80 present. In PBS, molecule 2 was the most stable and showed little visible aggregation after 
7 hrs of stirring and no aggregation during shaking stress up to 3 days. Molecule 8 showed the 
most visible aggregation during shaking and molecule 9 was observed to form the most during 
stirring stress. When the molecules were examined in the TFF processing buffers, molecule 8 
showed the highest amount of visible aggregation during the shaking stress and molecule 9 showed 
the highest amount during the stirring stress. Molecule 2 showed the least amount of visible 
aggregation with both stirring and shaking. When 0.01% PS80 was added to the buffers, no visible 
aggregation was seen during stirring and shaking in all the molecules with the exception of 
molecule 9 post-stirring. However, the amount of aggregation was decreased compared to the 
amount seen in samples without PS80 present. Overall, molecule 2 was the most stable and 
molecule 8 and 9 were the least depending on the agitation type. Molecule 1 was less stable than 
molecule 2 but was not the most unstable in any case.  Therefore, shaking and stirring studies do 
not consistently explain or predict the instability behavior of the TFF process but gave a trend that 
overall the “good” molecules show less aggregation and the “bad” molecules can show moderate 




Analysis by Langmuir trough was used to examine the molecules tendency to go to the air-
water interface and the likeliness to have inter-molecular interactions. Overall, molecule 8 showed 
the highest propensity to go to the interface and molecule 2 showed the lowest amount. When 
PS80 was added to the solutions, this interaction was blocked and the molecules showed lower 
tendencies to aggregate. In PBS, molecule 2 was the least likely to go to the air-water interface 
and molecule 8 was the most likely. Molecules 1 and 9 were comparable, although molecule 1 
stayed at the interface more readily than molecule 9. Therefore, Langmuir trough was the best tool 
to explain and predict the instability behavior of the TFF process but still did not completely 
correlate.  
Future work will be performed using the Langmuir trough to better understand and 
correlate the interfacial properties of each Ab to the results seen in the TFF process. This work 
includes using different concentrations of each Ab to see if predicting the likelihood of problems 
during the TFF can be seen with lower amounts of material. Different speeds and number of 
cycles during the compression and expansion will also be examined to correlate to the agitation 
seen by the TFF.  This additional work will allow for a better understanding of the predictive 
ability of the Langmuir trough technique in terms of identifying an Ab molecule’s TFF behavior 
(at both laboratory and large-scale processing) using minimal amount of protein. 
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